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ABSTRACT 
 
 
The ubiquitous ɣ-herpesvirus Epstein-Barr virus (EBV) infects B cells and 
modifies their differentiation programme leading to B cell activation and 
immortalization. Although different evidences support a link between EBV 
infection and rheumatoid arthritis (RA) and Sjogren’s syndrome (SS), the exact 
role of EBV in RA and SS pathogenesis remain elusive.  
Recently ectopic lymphoid structures (ELS) have been identified as preferential 
niches for EBV persistence and reactivation in patients with multiple sclerosis 
and myasthenia gravis. Independent studies demonstrated that around 50% of 
RA synovia and 30% of SS salivary glands are characterised by the development 
of functional ELS, capable to promote local differentiation of autoreactive 
plasma cells.  
In this PhD project I explored the potential role of EBV in RA and SS 
pathogenesis by analysing EBV infection in the RA synovium and SS salivary 
glands and its relationship with ELS, in situ autoreactive plasma cell 
differentiation, pathogenic autoantibodies production and cytotoxic immune 
response.  
In this work I demonstrated that: i) markers of EBV latent  and lytic infection 
are consistently associated with the presence of ELS in the RA synovium and SS 
salivary glands; ii) latent EBV proteins are preferentially expressed by B cells, 
while viral reactivation occurs in plasma cells; iii) a large subset of autoreactive 
plasma cells is EBV lytically infected in the RA synovia and SS salivary glands; iv) 
antibodies specific for unmodified and citrullinated EBV peptides, known to 
cross-recognize ACPA, are produced within ectopic lymphoid structures as 
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demonstrated in vivo in human RA/SCID chimeras; v) SS salivary gland grafts 
transplanted into SCID mice release human IgG against  EBV antigens, whose 
production correlates with the level of SS-associated auto-antibodies and vi) 
analysis of CD8+ and CD4+ T-cell localization and granzyme B expression 
indicated that EBV persistence in ELS-containing RA synovia and SS salivary 
glands may be favoured by exclusion of CD8+ T cells from B-cell follicles and 
impaired CD8-mediated cytotoxicity. 
Overall, these results redefine a novel and pathogenically relevant role for EBV 
in B-cell dysregulation and chronic inflammation in RA synovium and SS 
salivary glands. 
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1.1 Epstein - Barr virus 
 
 
1.1.1 Discovery of EBV 
 
Epstein-Barr virus (EBV) was discovered in 1964 by electron microscopy of cells 
cultured from Burkitt’s lymphoma tissue by Epstein, Achong and Barr (1). Four 
years later EBV was proved to be the etiological agent of infection 
mononucleosis (IM). Although primary infection is usually asymptomatic in 
childhood, it causes IM in about one third of the cases if it occurs during 
adolescence or adulthood (2). EBV DNA was detected in 1970 in tissues from 
nasopharyngeal carcinoma (3) and in 1982 it was found to be associated with 
non-Hodgkin’s lymphoma (4). Since then, EBV has been linked to several 
cancers and other diseases (i.e. autoimmune diseases). Today we know that 
EBV is one of the most successful viruses, infecting more than 90% of the world 
population with lifetimepersistence(2).In most cases, EBV establishes an 
asymptomatic latent infection although the clinical outcome of the infection 
depends on the fragile interplay between the virus and the host immune 
response. 
 
 
1.1.2 Classification of EBV 
 
Epstein-Barr virus or human Herpes virus 4 (HHV4) is one of the 8 known 
human herpesviruses. This family, characterized by the capacity to persist 
within their host indefinitely, is divided into three subfamilies on the basis of 
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the virus biological properties and genome homologies; Alphaherpesvirinae, 
Bethaherpesvirinae and Gammaherpesvirinae. Alphaherpesvirinae includes 
herpes simplex virus type 1 and 2 and Varicella-Zoster virus. 
Bethaherpesvirinae includes cytomegalovirus and human herpesvirus 6. 
Gammaherpesvirinae, distinguished for their ability to establish persistence in 
lymphoid cells, includes type 2 (i.e. Kaposi’s sarcoma-associated herpesvirus) 
and type 1 or lymphocryptoviridiae (LCV) (i.e. EBV) viruses. EBV is the only LCV 
with human tropism, whereas the other components of the family only infect 
primates. There are 2 subtypes of EBV, which differ from each other in the 
sequence of some latent antigen genes (i.e. EBNA2, 3A, 3B and 3C) (5). Type 1 
is dominant in the Western hemisphere and Southest Asia, whereas type 1 and 
2 are equally prevalent in Africa (6). There are no proved differences that one 
strain is more “tumorigenic” than the other. 
 
 
1.1.3 EBV genome and structure 
 
EBV is 120-180 nm in diameter and consists of an inner core of protein and 
DNA surrounded by a protein capsid. A protein tegument lies between the 
capsid and the outer envelope that is embedded with glycoproteins important 
for cell tropism, host range and receptor recognition (6). The EBV genome 
consists of 184-Kb linear, double-stranded DNA, encoding for approximately 
100 genes. 
The genomic structure of EBV is characterized by short and long unique 
sequence domains (US and UL, respectively) that contain almost all the 
genome coding capacity, as well as internal (IR) and terminal (TR) tandem and 
reiterated direct repeats (2). After EBV infection, the genome becomes circular 
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by linking the two TR sequences(7). The precise number of TRs is determined 
during viral replication and is maintained identical from the parental to 
progeny cells; consequently, heterogeneity in the number of joined TR 
distinguishes clonal infection events. 
 
 
1.1.4 EBV tropism and cell-entry 
 
EBV preferentially infects B lymphocytes, leading to their immortalization and 
formation of lymphoblastoid cell lines (LCL) in vitro, but it can also infect 
epithelial cells as part of its normal cycle of persistence in the human host. 
Differently from B cells, infection of epithelial cells by EBV in vitro results in 
active replication, with production of new virus and lysis of the cell (8).More 
rarely the virus infects T cells, natural killer (NK) cells, monocytes and smooth 
muscle cells (6, 9, 10). The major envelope glycoprotein gp 350/220 is mainly 
responsible for the high affinity binding of the virus to CD21 (complement 
receptor type 2/CR2) on the B cell. However, in order to entry into a B cell, EBV 
also uses a co-receptor, the glycoprotein gp42, that binds the human leucocyte 
antigen (HLA) class II molecule on the B cell. The entry of EBV in the epithelial 
cell is less well understood but there are evidences that it can be due either to 
the interaction between the viral antigen BMRF2 and integrins on the epithelial 
cell (11) or via two viral glycoproteins gH and gL that bind gHgLR on epithelial 
cells (12). Fusion of the EBV envelope with either B cells or epithelial cells 
require three glycoproteins, gH, gL and gB (13). Once the virus nucleocapsid is 
dissolved, the genome is transported in the nucleus where it is replicated by 
host DNA polymerases and persists as an episome. Viral DNApolymerase 
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accomplishes linear viral replication, which occurs during the lytic phase of the 
viral cycle. 
 
 
1.1.5 EBV Primary infection and persistence 
 
EBV is well-known for its unique ability to transform resting B cells invitro into 
permanent, latently infected lymphoblastoid cell lines in which all the 9 viral 
latent genes are expressed. In contrast toin vitro studies, the understanding of 
the biology of EBV infection in vivo is still rudimentary. Primary infection 
normally takes place in the mucosal tissue of the oropharynx, but the initial 
target cell for the infection is still not clear, being either B cells or epithelial 
cells. One model suggests that EBV first infects oropharyngeal epithelial cells, 
which then undergo lytic cycle to generate virions which can in turn infect B 
cells. Many observations sustain this theory; i.e. the presence of EBV in the 
desquamate oropharyngeal epithelial cells of IM patients (14) and the 
presence of EBV DNA, mRNA and proteins in a small subset of tonsillar 
epithelial cells from healthy EBV+ donors (15), whilst the observed EBV 
replication in normal tongue epithelium suggests that the tongue may be the 
source of EBV secretion into saliva (16). An alternative model suggests that B 
cells may be directly infected by EBV; in fact, the crypt structures in the tonsil, 
formed by invaginations of the tonsillar lymphoepithelium, might allow direct 
access of EBV-containing saliva to the B cells in the underlying lymphoid tissue 
(17).  
Once infection is established, there are 4 different gene programs that EBV-
infected B cells can express which depend on the localization and 
differentiation state on the infected B cells. One of these programs is used to 
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produce infectious virus (lytic program). The other three are all associated with 
the latency state, in which no infectious virus is produced; these are known as: 
1-growth program or latency III which primarily affect tonsillar naïve B cells,  
and in which all 9 known latent genes are expressed; i.e. EBNA1-6, 
LMP1,2A,2B. 
2- default program or latency II,where just EBNA1, LMP1 and LMP2Aare 
expressed, and is present in germinal centre B cells and 
3- latent program or latency I (none or just EBNA1 is expressed) which is typical 
of memory B cells.  
In addition to latent proteins, two small non-translated RNA, EBER1 and 2 are 
expressed during all the phases of EBV latency.  
To explain how this growth-promoting virus achievesits quiescent state in 
memory B cells, it has been suggested  that once EBV has infected naïve B cells, 
it uses the strategy of transforming latently infected B cells into proliferating 
blasts since only in this way it can convert these cells into long-lived memory B 
cells, that enter the peripheral circulation and allow EBV to persist indefinitely 
in protected niches (“The germinal centre model”)  (18-20). 
According to this model, EBV needs such a complex scheme of latent gene 
programs because only by switching from one to the other it can allow the 
naïve B cells to differentiate into memory B cells through the process of the 
germinal-centre (GC) reaction (Fig 1.1). In details, when EBV infects a naïve B 
cell in the lymphoid tissue of the Waldeyer’s ring it uses the growth program to 
activate the cells to become proliferating blasts. This process mimics what 
happen when an antigen contacts a naïve B cell via its surface immunoglobulin 
or B cell receptor (BCR). Usually the naïve B cells will receive survival stimuli 
from both the antigen and antigen-specific helper T cells. EBV, by then 
switching to the default program delivers survival signalsto the germinal centre 
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B cell, independently from the presence of the proper antigen and T cell help. 
At this stage, EBV switches down almost all the genes, so that the new memory 
B cells can enter the circulation invisible to the immune response. In response 
to unknown signals a memory B cell can then differentiate into an antibody 
secreting plasma cell where the virus can reactivate and replicate, although 
this also allows detection by cytotoxic T cells which control the degree of viral 
replication. 
The above model is supported by numerous obervations such as the finding 
that lymphoblasts produced during the growth program resemble antigen-
activated B cells both in their cell surface phenotype and morphologic features 
(21, 22) and the evidence that only naïve B cells express the growth 
programme in the Waldeyer’s ring in healthy carriers(23). However, alternative 
interpretations for the persistence of EBV in the B cell compartments have 
been suggested, such as the model whereby EBV could directly infect memory 
B cells in the oropharinx. This theory is based on the observation that EBV-
infected cells in extrafollicular areas are dominated by clones with stable 
memory IgG genotypes but no ongoing hypermutation (24). It has also been 
suggested that EBV-driven proliferation occurs in extrafollicular areas of the 
tonsil, rather than in germinal centres. This idea comes from the observation 
that transgenic expression of LMP1 under a constitutively active promoter in 
mice resulted in lymphoma and arrested GC development (25). 
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Figure 1.1 
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Figure 1.1 Thegerminal centre model: EBV infects naïve B cells inducing their 
differentiation into memory B cells through the process of the germinal-
centre (GC) reaction  
In the lymphoid tissue of Waldeyer’s ring EBV infects resting naive B cells and 
usingits growth program activate themeinducing their proliferation. This 
process parallels the activation of a naive B cell triggered by the cognate 
antigen. The antigen-activated B-cell blast is rescued through entry into the 
pool of memory B cells when it receives signals from antigen and antigen-
specific T helper cells. EBV switching from the growth to the default program 
delivers these rescue signals to the latently infected blast. Then the memory 
cells exit the cell cycle and enter the peripheral circulation. EBV-infected cells 
enter the peripheral circulation when the virus enters the latent I program, 
where all protein-encoding genes are shutted-down. Memory B cells 
occasionally divide, as part of the homeostatic mechanism for maintaining 
stable numbers of cells. When an infected cell undergoes division, it expresses 
EBNA-1 alone to allow the viral genome to divide along with the cell. Memory 
B cells can response toactivatory signals differentiating into plasma cells and 
therefore secreting antibodies. If such a cell contains the latent virus, it will 
reactivate viral replication producing newinfectious virions. 
 
Source: Thorley-Lawson et al. N Engl J Med. 2004 
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1.1.6 Function of EBV latent antigens 
 
There are 9 different antigens associated with the latent state of EBV, 6 with 
nuclear localization (EBNA-1, -2, -LP, -3A, -3B and -3C) and 3 on the cell 
membrane (LMP-1, -2A and -2B). Additionally 2 short not-polyadenylated and 
therefore not-translated RNAs are expressed during EBV latency, EBER-1 and -
2.  
EBNA1 mainly ensure the maintenance and replication of the episomal EBV 
genome through sequence-specific binding to the plasmid origin of viral 
replication OriP (26). EBNA2 is the first viral protein expressed after B cell 
infection in vitro and is essential for the transformation process. Moreover, 
interacting with the transcription factor RBP-Jk, it transcriptionally activates 
cellular genes, such as CD23 and viral genes such as LMP1 and LMP2A (6). 
EBNALP interacts with EBNA2 and is required for the efficient outgrowth of 
virus-transformed B cells in vitro (27).EBNA3A, 3B and 3C modulates the 
transcriptional activation of EBNA2 mediates by EBNALP (28). 
LMP1 is a classical viral oncogene with a critical role in B cell transformation 
and a strong inhibitor of apoptosis via the up-regulated expression of anti-
apoptotic proteins, i.e. Bcl-2 and A20 (29). Moreover, LMP1 functionally 
resemble CD40 and can provide both grown and survival signals to the B cells 
(25). In details, the cytoplasmic portion of LMP1 contains carboxy terminal 
activator regions (CTARs) that are functionally homologous to the cytoplasmic 
tail of the human CD40 as they are able to interact with the adaptor proteins 
tumor necrosis factors (TRAFF) and TNF receptor-1 associated death domain 
(TRADD) (30). Interactions between TRAFFs/TRADD and CTARs lead to the 
activation of the transcription factor NF-kB. The net result of both LMP1 and 
CD40 signaling consists in rescuing B cells from apoptosis and driving their 
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proliferation. The homology between LMP1 and CD40 further supports the 
hypothesis that EBV, by mimicking the CD40-CD40L interaction, makes a GC-B 
cell independent from T-cell help thus promoting B cell survival(25). 
LMP2A and 2B proteins share a similar structure, consisting of a 
transmembrane domain made of 12 membrane-spanning loops, with a C-
terminal cytoplasmic tail. Additionally, LMP2A has a N-terminal cytoplasmic 
portion that comprises 8 tyrosine residues, two of which form an 
immunoreceptor tyrosine-based activation motif (ITAM) (31). The same ITAM 
sequences are found in the α and β chains of the B cell receptor (BCR). Both 
LMP2A and BCR are in turn associated with Lyn, a protein kinase. The 
phosphorylation of the ITAM by Lyn leads in both cases to the recruitment of 
the Syk tyrosine kinase and the activation of the canonical BCR downstream 
pathway. The main result of this cascade is the delivery of survival signals to 
the B cells.  
In the context of B cell colonization during primary infection in vivo, LMP2A, by 
mimicking the BCR signal, actstogheter with LMP1 surrogate T cell help in 
order to drive infected cells through the GC reaction. Therefore, LMP1 and 
LMP2A have the potential to provide the necessary signals, independent of 
antigen binding and T cell help, to allow latently infected cells to survive and 
eventually differentiate into memory cells. 
Finally, EBER1 and EBER2 encode short non-polyadenylated RNAs expressed in 
all forms of latency. EBERs can bind directly to the ds-RNA–activated protein 
Kinase, PKR, which contributes to the antiviral effects of interferons, 
suggesting that EBER-mediated inhibition of this molecule could promote viral 
resistance (32). In addition, EBERs also interact with the autoantigen La (33) 
and the ribosomal protein L22 (34-36), and have been shown to induce 
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expression of IL-10 in Burkitt’s Lymphoma(37), IL-9 in EBV-infected T cells (38) 
and insulin-like growth factor in epithelial cells (39, 40).  
Table 1.1 summarizes the function, localization and phase cycle expression of 
the most relevant EBV latent proteins. 
 
1.1.7 EBV reactivation: role oflytic proteins 
 
EBV lytic infection occurs in vivo during primary infection and sporadically 
during persistent infection; probably when memory B cells are induced to 
differentiate into plasma cells (41). Conversely, in vitro approximately 5% of 
cells in LCL cultures undergo spontaneous lytic replication. In both cases, lytic 
replication involves a sequential expression of lytic viral antigens. The process 
is initiated by immediate early genes BZLF1 (ZEBRA) and BRLF1 (Rta), which 
transactivate expression of early genes such as BFRF1, BALF2, BHRF1 and 
BMRF1, which products are involved in viral DNA synthesis.Late lytic genes 
mainly encode viral structural proteins. Specifically, the late gene BLLF1 
encodes the envelope glycoproteins gp350 and gp220, BCRF1 encodes a viral 
protein that closely resembles IL-10, and BALF4 encodes the glycoprotein 
gp110 (6). Therefore, production of new virions starts with the synthesis of 
viral DNA and packaging into capsid in the host cell nucleus followed by 
budding through the nuclear membrane resulting in cytoplasmic vesicles 
containing enveloped virions. These vesicles then fuse with the host plasma 
membrane to release the new virus particles by endocytosis (6). This process 
also leads to the death of the host cell. 
Table 1.1 summarizes the function, localization and phase cycle expression of 
the most relevant EBV lytic proteins. 
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Table 1.1EBV latent and lytic proteins 
EBV PROTEIN LOCATION EBV PHASE CYCLE FUNCTION 
EBNA1 nucleus latency I, II, III Gene regulation, extra-chromosomal replication, and 
maintenance of the EBV episomal genome 
EBNA2 nucleus latency III Transcriptional regulator and activator of several 
cellular and viral genes 
EBNA3 nucleus latency III Transcriptional regulator that influences  cellular and 
viral genes 
LMP1 membrane latency II, III Anti-apoptotic protein; mimic CD40-induced 
signalling pathway 
LMP2A membrane latency II, III Mimic BCR and replace survival signal to the B cells 
EBERs nucleus latency I, II, III Induce IL-10 production which can suppress cytotoxic 
T cells and stimulate B-cell growth; inhibit the 
antiviral effect of PKR 
BZLF1 nucleus immediate-early lytic Mediate the switch between the latent and the lytic 
forms of EBV infection 
BFRF1 cytoplasm/perinuclear early lytic Promote fusion of perinuclear virion envelope with 
the outer nuclear membrane 
BMRF1 cytoplasm/perinuclear early lytic Processivity factor for the viral DNA polymerase 
Gp350/220 cytoplasm/membrane late lytic  Major EBV glycoprotein that mediates binding of EBV 
to its B-cell receptor, CD21 
p160 cytoplasm/membrane Late lytic EBV capsid protein 
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1.1.8 Control of EBV infection by the immune system 
 
The innate immune response is an important first line of defense against viral 
infection; viruses early after infection elicit a strong type I INF response by NK 
cells. In fact, NK deficiencies are associated with increasing susceptibility to 
several viral infections, including EBV (42).  The adaptive immune response to 
EBV infection consists both of a humoral and cell-mediated component. 
Antibodies against EBV antigens limit the spread of infection and are critical in 
diagnosing infectious mononucleosis (43), whereas the cytotoxic T cells 
response, eliminating the infected cells that express EBV antigens, are critical 
in controlling viral replication but also contribute to the severe symptoms of 
IM (44).  Both CD4 and CD8 cells make a robust response to EBV antigens but 
CD8+ cells tend to dominate the response to the lytic reactivation. However, 
the immune system is unable to eliminate completely the virus, and as a 
consequence, viral shedding and virus-infected cells persist at a low level, 
approximately 1 in 10.000 to 100.000 memory B cells (45). 
 
 
1.1.9 Viral infections and autoimmune diseases 
 
As a general rule, autoimmune diseases are complex and multifactorial, being 
genetic, epigenetic and environmental factors involved in their pathogenesis. 
Among the latter, viral infections are believed to contribute to the maturation 
of the immune system from the innate to the adaptive phase and therefore 
may also take part in the induction of autoimmune diseases(46).To simplify the 
complex viral-host interactions possibly leading to breach of self tolerance and 
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the onset of autoimmunity, two main sets of events have been strongly 
associated with viral infection and autoimmunity in susceptible individuals. The 
first set includes antigen specific mechanisms, such as molecular mimicry, 
expression of modified or cryptic determinants and superantigens; the other 
set involves non-antigen specific mechanisms such as enhanced processing and 
presentation of self-antigens, immune cell activation, cytokines release and 
apoptosis (47). 
Among the antigen-specific mechanisms, molecular mimicry may develop 
when infecting agent incorporate a viral epitope that has a sequence homology 
with a self-antigen so that the immune response could turn towards the self-
antigen due to cross reactivity, leading to the activation of auto-reactive T and 
B cells specific for the corresponding self-molecule (48). Alternativeantigen-
specific mechanisms through which a virus can activate the immune response 
are due to tissue injury, cell death, oxidative stress and reparative changes that 
happen as a result of the viral infection and that can cause changes in self-
proteins, such as altered expression, post-translational modifications, 
denaturation, misfolding and mutations. These changes could lead proteins 
usually recognized as self to be targeted by the immune system as not-self and 
induce an autoimmune response.  
Among the non-specific immunological mechanisms caused by a virus, the so 
called “epitope spreading” is believed to play a pivotal role and consistsin the 
development of autoimmune responses against endogenous epitopes, 
secondary to the progressive release of self-antigens during a chronic 
infection, which can, in time, induce the expansion of T and B cell mediated 
immune responses towards different self-antigens. Conversely, superantigens 
are proteins produced by virally-infected cells which can bind the T cell 
receptor, without the necessity of antigenic specificity, resulting in a massive 
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activation of T lymphocytes of different specificities eventually leading to an 
autoimmune reaction. Finally, viral infection could also activate the immune 
response through the induction of cell death; in fact, if dying cells are not 
removed for different reasons, i.e. deficient scavenging, the apoptotic process 
could lead to accumulation of nuclear material that can in turn cause 
autoimmunity(49). 
 
 
1.1.10 EBV infections in the pathogenesis of autoimmune diseases 
 
EBV fulfills many general properties which indirectly suggest its involvement in 
the pathogenesis of autoimmune diseases;i) it is ubiquitous and autoimmune 
diseases have a worldwide prevalence; ii) it has life-long persistence in the 
human host with occasional reactivation and autoimmune diseases have a 
chronic evolution with periods of flares; iii) it can alter the host immune 
response leading to various consequences such as the production of 
(auto)antibodies that are specifically associated with certain autoimmune 
diseases (50); iv) EBV has the peculiar ability to inhibit apoptosis, limit anergy 
and tolerance and induce the production of different pro-inflammatory 
cytokines such as TNF-α, IL-1 and IL-6 (51); all these processes are potentially 
related to the pathogenesis of several autoimmune diseases. 
In the literature there is a large body of evidence linking EBV with different 
autoimmune diseases, i.e. multiple sclerosis (MS), rheumatoid arthritis (RA), 
Sjogren’s syndrome(SS), systemic lupus erythematosus (SLE) and myasthenia 
gravis (MG). The evidence in support of its association with RA and SS will be 
reviewed more in details in Sections 1.4 and 1.5 below. However, in general, 
previous studies revealed a higher EBV viral load in the peripheral blood 
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together with exaggerated humoral immune response against EBV in 
autoimmune patients compared to healthy individuals (52-57). Furthermore, 
there is strong evidence that patients with different autoimmune diseases 
display an impaired cytotoxic anti-EBV response (58-61), indicating a lack of 
efficient control of EBV infection. Moreover, there are several examples of 
molecular resemblance between common self-antigens in autoimmune 
diseases and EBV proteins (62-67). Furthermore, there is also direct evidence 
that EBV can infect the target organs in patients with organ-specific 
autoimmune disease(68-74). Finally, meta-analysis of existing epidemiological 
data highlighted a strong connection between EBV infection and MS (75-78). 
However, despite all the above evidence linking EBV with autoimmune 
diseases, the mechanisms by which EBV might contribute to the development 
of such diseases remain elusive.  
Generally the effects of EBV infection in autoimmunity have been based on the 
molecular mimicry, suggesting that autoimmunity may be initiated by EBV 
antigens that cross-react with human proteins (79-81). 
A fascinating hypothesis is also that EBV, due to its unique capacity to infect, 
activate and latently persist in B lymphocytes, would allow survival of 
autoreactive clones which would be normally depleted in the periphery by 
physiological mechanisms of B cell homeostasis such as anergy(82). In details, 
Pender proposed that autoreactive B cells, infected by EBV during primary 
infection, would differentiate through the GC process in latently infected 
autoreactive memory B cells that express some virus-encoded anti-apoptotic 
proteins and become resistant to apoptosis. According to this model, 
autoreactive memory B cells can, in genetically predisposed individuals, lodge 
in organs where their target antigen is expressed and produce in situ 
pathogenic autoantibodies. Subsequently, autoreactive T cells activated in 
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peripheral lymphoid organs would migrate in the target organs where they 
receive co-stimulatory survival signal from the infected B cells. The 
autoreactive T cells would then proliferate and produce cytokines, which in 
turn will recruit other inflammatory cells leading to inflammation and 
destruction of the target organ. 
Additionally, ths same Author also proposed (83) that CD8+ T cellsdysfunction, 
that characterizes many autoimmune diseases, contributes to the 
development of chronic autoimmunity by impairing CD8+ T cells control of EBV 
infection, with the consequent accumulation of EBV infected autoreactive cells 
in the target organs where they produce pathogenic autoantibodies and 
provide costimulatory signal to the autoreactive T cells.  
This hypothesis would also partially explain the recent observationthat ectopic 
B cell follicles in the brain of MS and in the thymus of MG patients are an 
active site of EBV persistence and reactivation (72, 73). Therefore, in this 
scenario, EBV infection in autoreactive B cells would sustain the development 
of ectopic lymphoid follicles in the target organs, a frequent finding in organ-
specific autoimmune diseases and a site for functional autoreactive B cell 
activation and differentiation (84, 85). 
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1.2 Rheumatoid arthritis 
 
 
1.2.1 Definition and classification criteria 
 
RA is a chronic, systemic inflammatory disease, primarily affecting the 
diarthrodial joints leading to joint destruction through inflammatory 
involvement of the synovial membrane, cartilage, and subchondral bone. RA is 
an autoimmune disease since it is characterized by the presence of circulating 
autoantibodies, such as rheumatoid factor (RF) (86)and anti-citrullinated 
protein/peptide antibodies (ACPA) (87-90). 
In 1958 the American Rheumatism Association (ARA) proposed the first 
attempt of diagnostic criteria for RA(91). In 1987 the American College of 
Rheumatology (ACR) published a revised set of seven classification criteria 
(92),that are listed in table 1.2.  
It should be noted that classification criteria are devised to ensure the 
standardization of the diagnosis in patients taking part in clinical studies, and 
to facilitate the analysis of results, but they have significant limitation in 
diagnosis in daily clinical practice. In particular they are less useful in early 
arthritis patients. In fact, joint damage is rarely apparent in the very early 
stages of disease, but rather accumulates consistently over time. Nevertheless 
an early diagnosis would be ideal since an early therapeutic intervention would 
improve the clinical outcome preventing or reducing joint damage and the 
consequent disability. The difficulties to recognize RA patients at early stages 
necessarily hamper the development of new clinical trials for RA treatments. 
Recently, in order to progress a new approach for the RA classification, a joint 
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working group of the ACR and the European League Against Rheumatism 
(EULAR) was created. The main aim of this group was to develop new 
classification criteria for RA that were specifically designed in order to capture 
patients with early RA. In 2010 was therefore developed the ACR/EULAR 
(93)classification criteria for RA, which are listed in table 1.3. 
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Table 1.21987 revised American College of Rheumatology criteria for 
diagnosis of rheumatoid arthritis 
  
 
1 
Morning stiffness in and around joints lasting for at least an hour 
before maximal improvement 
 
2 
Soft tissue swelling (arthritis) of 3 or more joints areas observed by 
physician 
 
3 
Swelling (arthritis) of the proximal interpharingeal, 
matacarpophalangeal, or wrist joints 
 
4 
Symmetrical swellings (arthritis) 
 
 
5 
Rheumatoid nodules 
 
 
6 
Presence of rheumatoid factor 
 
 
7 
Radiographic erosions and/or periarticular osteopenia in hand and/or 
wrist joints 
 
 
 
Criteria 1 through 4 must have been present for at least 6 weeks. Rheumatoid 
arthritis is defined by the presence of 4 or more criteria. 
 
Source adapted from the ACR, 2007, www.rheumatology.org 
(93) 
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Table 1.3The 2010 American College of Rheumatology/European League 
Against Rheumatism classification criteria for Rheumatoid Arthritis 
 
 
 
Score based algorithm: add score of categories A-D; a score of ≥6/10 is needed 
for classification of a patient as having definite RA. 
Source adapted from Aletaha et al. Arthritis Rheum. 2010 
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1.2.2 Clinical aspects 
 
The most common clinical presentation of RA patients consists of symmetrical 
arthritis of the wrists and the metacarpophalangeal and proximal 
interphalangeal joints of the hands. Arthritis of the metatarsophalangeal joints 
of the feet is also common and occasionally, large joints can be affected in 
isolation. The number of swollen joints at baseline is used as an indicator of 
progressive disease and future radiographic progression(94). Early morning 
stiffness, which can last for over 1 hour, is considered a cardinal feature of RA. 
Systemic features including flu-like symptoms, fatigue, malaise and weight loss 
are also common in RA. A more detailed list of extra-articular symptoms is 
listed in table 1.4. The presence of rheumatoid nodules, especially over the 
extensor aspect of the elbows, are a specific feature but occur late in the 
disease and are only seen in a minority of patients.  
Occasionally RA patients present atypical patterns of disease. For example, the 
so-called ‘polymyalgic’ onset of RA, a pattern sporadically observed in patients 
over 65 years old, which present  heavy stiffness and limb girdle pain rather 
than peripheral arthritis. Another atypical manifestation is the ‘palindromic 
rheumatism’, characterised by episodic involvement of one or several joints 
lasting hours to days and occurring at intervals of days to months.  
Notably, there is no single clinical feature or serologic or radiologic exam 
sufficient to diagnose RA. 
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Table 1.4Extra articular manifestations of RA 
 
 
  
ORGAN Clinical presentation 
Skin Vasculitis, nodules 
Cardiac Pericarditis, Myocardial fibrosis/granulomatous 
disease 
Pulmonary Interstitial pneumonitis, Rheumatoid Nodules, 
Serositis 
Neurological Mononeuritis mulptiplex, peripheral neuropathy 
Haematological Anemia, Felty’s syndrome 
Exocrine Secondary Sjogren’s syndrome 
Others Amyloidosis, systemic vasculitis, osteoporosis 
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1.2.3 Epidemiology 
 
RA is the most common form of polyarthritis and affects between 1-2% of the 
adult population worldwide. Its prevalence varies between different countries; 
i.e. there is a lower incidences in parts of China than in Western Europe and 
the USA(95), and lower prevalence rates in Southern than Northern European 
countries (96, 97). Furthermore, prevalence rates of up to 5.3% in Native 
American-Indian population have been reported (98). 
RA is virtually undetectable in parts of Nigeria and rural Africa (99), whereas 
prevalence rates rise to nearly 1% in black populations in urban areas, further 
suggesting an environmental etiology in disease pathogenesis.  
The incidence of RA is typically two to three times higher in women than men, 
a ratio that falls with increasing age. The onset of RA, in both women and men, 
is highest among those in their forty, although the disease can affect people at 
any age. 
 
 
1.2.4 Etiology 
 
Rheumatoid arthritis involves a complex interplay between genetic 
susceptibility and environmental triggers. 
 
 
1.2.4.1 Genetic factors 
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The genetic contribution to the risk of developing RA has a substantial impact 
on conferring susceptibility to RA(100), as estimated through studies of 
monozygotic and dizygotic twin pairs. From studies in Finland and the United 
Kingdom it was found that concordance rates for RA of 12.3% and 15.4% exist 
in monozygotic twins, compared to 3.5% and 3.6% in dizygotic twins. On the 
basis of those observations it was estimated that the heritability of RA is 
approximately 65% (101). 
Multiple loci have been associated with the genetic risk of RA. The HLA locus is 
the most important of these and accounts for 30% to 50% of overall genetic 
susceptibility to RA (100, 101). Within the HLA locus, the strongest association 
is with alleles of HLA-DRB1, encoding a conserved sequence of amino acids in 
the third hypervariable region of the β-chain of the HLA-DR molecule which is 
collectively referred to as the “shared epitope” (102). HLA-DR molecules are 
heterodimers that present antigenic peptides to T lymphocytes. Structural 
analysis demonstrated that the shared epitope can influence peptide binding 
as well as contact between HLA-DR and the T cell receptor(103, 104). 
Therefore, the products of shared epitope HLA-DRB1 alleles may predispose to 
RA as a consequence of an impaired antigen presenting to T cells. Proposed 
models include failure to generate appropriate Treg cells, the presentation of 
arthritogenic peptides to class II-restricted peripheral-effector T cells and the 
selection of pathogenic T cells during thymic selection (105). Interestingly the 
HLA-DRB1 shared epitope appears to confer genetic susceptibility for the 
development of the subgroup of RA that is characterized by ACPA production 
(106). 
Beside HLA-DRB1 shared epitope, other single nucleotide polymorphisms 
(SNPs) in candidate genes have been linked to RA; i.e. loci involved in T-APC 
interactions (i.e. CTLA-4), in the regulation of the T cell activation threshold 
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(i.e. PTPN22), signal transducer and activator of transcription (i.e. STAT4) or 
the homeostatic chemokine CCL21 (107). Several novel SNPs have been 
identified using genome-wide association studies (108, 109); however, despite 
this increasing list of gene associated to RA, the overall susceptibility to RA 
conferred by the non-HLA genes identified so far is estimated to be below 5%. 
 
 
1.2.4.2 Environmental factors 
 
Among environmental factors, infectious agents, most notably intracellular 
pathogens and viruses, have long been suspected to promote the development 
of RA.  Different studies proposed a number of candidate pathogens as a 
trigger of RA, such as mycoplasma (110), mycobacterium tuberculosis(111), 
human retrovirus 5 (112), alpha virus (113)EBV (114), cytomegalovirus (115), 
rubella virus(116) and parvovirus B19(117). Among those, EBV has been one of 
the most studied and has been linked to RA on the basis of different 
observations, as discussed in section 1.4. At present there appears to be no 
consistent data suggesting that a single infectious agent is responsible for RA 
development, although many avenues of research are investigating such a 
possibility. 
Others (i.e. non-infectious) environmental factors that have been proposed to 
contribute to RA are smoking(118), obesity and diet (119, 120). Smoking is 
extremely interesting as it has been shown that cigarette smoking is an 
independent risk factor for RA among person with the shared epitope HLA-
DRB1 (121), a link possibly explained by the induction of protein citrullination 
in the lung upon activation of airway macrophages and which might trigger 
breach of self- tolerance towards citrullinated antigens (122).  
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Based on the above observations, it is evident that multiple environmental 
factors may interact in various ways and in different genetically determined 
individuals in order to trigger the development of RA.  
 
 
1.2.5 Immunopathogenesis of RA synovitis 
 
Together with activation of the resident stromal cells (i.e. fibroblast-like 
synoviocytes), one of the features that histologically characterize the inflamed 
RA synovium is the infiltration of different immune cell subsets, including T 
cells, B cells, plasma cells, macrophages and DCs. Infiltrating immune cells can 
follow three main patterns of infiltration; i) diffuse synovitis, which is present 
in ~50% of the cases and is characterized by predominant macrophage 
activation and diffuse T cell infiltration; ii)  follicular synovitis, whereby  T and B 
cells form compact lymphoid aggregates without a clear GC reaction (~25% of 
the cases) and iii) in the resting ~25% of the patients synovial tissue presents 
organized ectopic GC-like structureswhereby B/T cell follicles are further 
characterized by the differentiation of CD21+ follicular dendritic cells networks 
(FDCs)(123, 124).The latter two patterns can be defined as ectopic lymphoid 
neogenesis or tertiary lymphoid structure (TLS) formation as they display 
features typical of secondary lymphoid organs (SLOs) such as T/B cell 
segregation, differentiation of HEVs and expression of lymphoid chemokine 
CXCL13 and CCL21, which respectively segregate in the B and T cell areas of the 
aggregates. This phenomenon has been described in diverse chronic 
inflammatory conditions of autoimmune, infectious or cancer-related origin 
(listed in table 1.5) and, in the case of autoimmunity, it has been associated 
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with the development of autoantibodies and in some cases a more severe 
disease outcome. 
The possibility that during chronic inflammation the same pathways implicated 
in the physiological development of lymphoid organs could be aberrantly re-
activated and lead to the formation of TLS gave rise to a growing interest in the 
dissection of the pathways and regulatory systems normally involved in 
physiological lymphoid organogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Table 1.5Human chronic inflammatory diseases with lymphoid neogenesis 
 
 
 
 
Source: Aloisi et al. Nature Reviews Imm. 2006. 
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1.2.5.1 Microarchitecture of TLS 
 
Secondary lymphoid organs (SLOs) are characterized by the presence of B cell 
(follicle) and T cell (paracortex) areas, and specialized vascular and canalicular 
systems. Their complex structure is essential for regulating leukocyte traffic 
and compartmentalization. Specifically SLOs provide the proper environment 
that allows the encounter between the antigen (via antigen presenting cells 
migrating from the periphery through afferent lymphatics) and naïve 
lymphocytes (entering from the peripheral blood), which in turn cause the 
activation and differentiation of antigen-responsive T and B cells (Fig 1.2 A). 
The process of lymphoid neogenesis is highly dynamic since it allows sparse 
lymphocytes to aggregate and eventually organize in GCs surrounded by a T-
cell area where also DCs and HEVs are located (Fig 1.2 B)(125-127). Ectopic GCs 
are made by proliferating B cells and a network of CD21+ FDCs, which allow 
the B cell maturation by presenting the cognate antigen in the form of 
immunological complexes, stimulate proliferation and prevent apoptosis of GC 
B cells (128, 129). Ectopic GC are characterized by the presence of naïve B cells 
centroblasts, centrocytes, memory B cells and plasma cells, indicating that the 
complete process of B cell maturation occurs in those structures. Also T-cells 
are found in ectopic GC, most probably acting as cognate T-cell help and 
therefore contributing to the development of the GC B cell response (130).  
The basic cellular constituent of B and T cell areas in TLS are similar to the one 
found in SLOs, but the general structure of the TLS markedly differs from that 
of conventional SLOs (Fig 1.2). In fact, differently from SLOs, TLS lack the 
surrounding capsule, which implies that they are directly exposed to external 
signals such as the stimulated antigens or cytokines produced in the inflamed 
environment. Moreover, TLS also lack of the afferent lymph vessels that 
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normally represent the way through which antigens and DC enter the SLOs. 
This incomplete development of TLS can therefore cause an irregular access of 
DCs, lymphocytes and macromolecules in TLS, causing abnormal B and T cell 
activation. 
Various members of the tumor necrosis factor (TNF) family play a crucial role in 
regulating the development of ectopic lymphoid structures in chronic 
inflammatory conditions. One of the most important is the heterotrimeric 
lymphotoxin α1β2 (LT-β), which is mainly produced by B cells during chronic 
inflammation. This molecule plays a pivotal role in the cellular organization of 
ectopic lymphoid structures by inducing PNAd+ high endothelial venules (HEV) 
(131), the ectopic expression of CXCL13, CCL21 and CCL19, which are 
responsible for the segregation of B and T cells into different areas (132) and 
follicular dendritic cell network differentiation (133). Notably, ectopic 
expression of CXCL13 and CCL21 within the inflammatory aggregates in RA 
synovia is observed both in the context of highly organized GC-like structures, 
where there are distinct B/T cell areas and the presence of FDC networks, as 
well as in minor organizational stages, devoid of FDC networks (126). 
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Figure 1.2 
 
 
 
 
 
 
Figure 1.2 Basic structure of secondary and tertiary lymphoid organs 
A. Lymph node (secondary lymphoid organ, SLO) architecture. An external capsule 
mainly made of collagen surrounds and protects the whole lymph node. The inner 
cortex is composed by the B cell area, which can form primary follicles or, after 
encounter the antigen, secondary follicles with an ongoing GC-reaction, and the 
paracortex where T-cells but also DCs and HEVs reside. B and T lymphocytes enter 
the lymph node via HEVs, whereas DCs and antigens are carried there via afferent 
vessels. The medulla, formed by numerous lymph-draining sinuses separated by 
medullary cords, mainly contains macrophages, plasma cells and memory T cell. 
B. Tertiary lymphoid organs (TLOs) architecture. Similarly to SLO, TLOs present a 
segregated B and T cell area. B cells can form primary follicles or well-structured 
secondary follicles. In the last case there is the formation of a polarized GC 
containing a dark and light zone respectively composed by proliferating centroblasts 
or smaller centrocytres. HEVs, DCs and sparse plasma cells reside in the mantle zone, 
which is the T-cell area. Differently from SLOs, TLOs lack the surrounding capsule and 
afferent vessels. 
 
Source: Aloisi at al. Nature Review Imm. 2006 
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1.2.5.2 Functionality of TLS 
 
GC within lymphoid tissues are the main sites where antigen-driven antibody 
response takes place, leading to B cells affinity maturation and differentiation 
into memory B and plasma cells via the processes of somatic hypermutation 
(SHM) and class-switch recombination (CSR) of the igG genes (134, 135). It is 
now clear that AID is the enzyme responsible to initiate and control both SHM 
and CSR (136). Although the exact mechanisms are still not entirely 
understood, SHM is initiated by AID by introducing single point mutations in 
WRC (W = A/T, R = A/G) motifs which are mutational “hot spots” within the Ig 
variable genes, which encode for the antigen-binding region of the antibody 
(137, 138). This process results in affinity maturation occurring through cycles 
of antigen-dependent selection within the GC whereby a B cell acquire one 
new mutation at each proliferation cycle. In addition, AID regulates CSR via its 
carboxy-terminal region (139)by introducing double-strand breaks which 
allows recombination of Ig switch regions of DNA followed by excision of 
switch circles within the constant heavy-chain region. Ig class switch from IgM 
and IgD to IgG, IgE or IgA is an important mechanism that has a strong impact 
on the biological functions of antibodies enhancing their effector capacity 
(140). 
In the mid-90s, several groups, by performing analysis of the V-gene repertoire 
from total RA synovial RNA extracts or from follicular structures microdissected 
from the RA synovium, clearly demonstred that a significant fraction of B 
lymphocytes accumulating within the synovial membrane of RA patients have 
an oligoclonal repertoire with highly mutated V regions, compatible with a 
local antigen-driven GC reaction (141, 142).These data provided strong indirect 
evidence that RA synovium can support in situ diversification and expansion of 
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B-cell clones. The direct demonstration was recently provided by our group, 
reporting that in the RA synovium lymphoid aggregates characterized by FDC 
network formation invariably express AID(85). Importantly, AID can also be 
expressed in the absence of full compartmentalization of the GC into dark and 
light zones, a morphological feature that distinguish RA synovium TLS from 
secondary lymphoid organ GC (141). Humby et al also demonstrated that AID 
expression is almost exclusively observed within FDC network, which are 
detectable in around half of the RA samples with Grade 3 lymphocyte cluster, 
i.e. where radial number of lymphocytes aggregates is >10 (126, 143). 
Moreover, it was also demonstrated that a further 20% of patients with RA 
synovitis histologically characterized by T/B cell segregation but without 
expression of FDC networks, expressed AID mRNA in the presence of 
detectable mRNA encoding CD21 long isoform (85), a specific isoform of the 
complement receptor 2, which is selectively expressed by FDCs but not B 
lymphocytes. Thus, the majority of RA synovia with T/B-cell lymphoid 
aggregates appears to present GC-related immunological activity, even in 
absence of histologically detectable FDC networks.  
In SLO, both naïve B cells, which accumulate in the mantle zone surrounding 
GCs, and memory B cells can enter or re-enter the GC and undergo de novo or 
new rounds, respectively, of selection and affinity maturation (135). According 
the presence of both antigen-inexperienced IgD+CD27- B cell as well as 
IgD+CD27+ unswitched and IgD-CD27+ switched memory B cells have been 
detected in the RA synovia. Thus both naïve and memory B-cell subsets could 
possibly undergo affinity maturation in ectopic lymphoid structures. Berek et al 
(141, 144)by analyzing the Ig V gene repertoire of B-cell clusters 
microdissected from RA synovia, have demonstrated that both scenarios are 
likely to take place. They observed that in some synovial aggregates B cells 
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display identical rearrangements and only differ by single nucleotide 
mutations, indicating that the entire diversification of the Ig V region 
repertoire of some clones occurs within the synovial membrane. They also 
suggested that already mutated memory B cells undergo further rounds of 
SHM within the synovial membrane with the acquisition of a highly mutated 
and diversified repertoire. Another possibility is that hypermutated memory B 
cells proliferate without further diversification.  
There are many evidences proving that B cells also actively undergo CSR within 
the RA synovium. Humby et(85) analyzing the expression of circular transcripts, 
which are specific transcribed by CSR, demonstrated that CSR invariably occurs 
in the RA synovium characterized by AID+/CD21L+ lymphoid structures, which 
thus support the production of high affinity IgG (auto)antibodies. In the same 
study it was demonstrated that locally differentiated plasma cells produce RA 
associated autoantibodies such as those directed against citrullinated proteins. 
These findings strongly suggest that ectopic lymphoid structures within RA 
synovium not only sustain in situ Ig V repertoire diversification and class 
switching but also allow the in situ differentiation of autoreactive plasma cells. 
 
 
1.2.6 Autoantibodies in RA 
 
RF was the first autoantibody demonstrated to be linked to the RA 
pathogenesis in 1940 by Emil Waaler (145). After that, many other 
autoantibodies have been found associated with RA pathogenesis. The pool of 
autoantibodies found in RA patients is extremely heterogeneous; in fact, they 
can target collagen, cartilage proteins, heat shock proteins, enzymes, nuclear 
proteins and, most importantly, citrullinated proteins such as fibrin or 
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vimentin. Notably, anti-citrullinated protein antibodies (ACPA) have a high 
degree ofspecificity for RA, while all other antibodies including RF may also 
occur in other diseases and even in healthy individuals. Although it lacks 
specificity, RF is still the most widely used serological marker of RA and 
represents one of the seven classification criteria of the American College of 
Rheumatology for the disease. 
ACPA and RF are strongly associated with a more severe and erosive disease, 
suggesting that auto-antibodies, possibly also including those not routinely 
used for diagnostic purposes, may contribute to the pathological processes 
characteristic of RA such as chronic synovitis and erosiveness; however, a 
formal demonstration of the pathogenicity of autoantibodies is still 
missing.(146). 
 
 
1.2.6.1 Rheumatoid factors 
 
RFs are autoantibodies directed against the Fc portion of IgG. IgM is the main 
isotopic form of RF found in serum and synovial fluid of RA patients. It should 
be noted that transiently increased levels of IgM-RF are also found during 
normal immune response and during infections, probably in reaction to 
immune complexes containing microbial antigens (147, 148). Thus, low-affinity 
IgM-RF can be found in a small percentage (<15%) of healthy individuals (149, 
150). In contrast, RA is characterised by chronic persistence of high-titre IgM-
RF (as well as the presence of IgG and IgA subtypes). Around 60-80% of RA 
patients with established disease are positive for IgM-RF, whereas the 
prevalence of the same antibody in patients with early RA is significantly lower. 
High titres of IgM-RF can also be detected in patients with primary Sjögren's 
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syndrome or mixed cryoglobulinaemia, wherease low titres are found in other 
rheumatic diseases(151, 152). Both IgG, IgA and IgM-RF can be detected in the 
earliest stages of the disease and can even precede the onset of RA by several 
years (153).  
 
 
1.2.6.2 Anti-citrullinated protein antibodies (ACPA) 
 
Anti-citrullinated protein antibodies (ACPA) are autoantibodies directed 
against epitopes containing the unusual amino acid citrulline that is generated 
by post-translational deimination of arginyl residues by the enzyme peptidyl 
arginine deiminase. ACPA are the only autoantibodies specifically found in 
serum of RA patients. Although citrullination of proteins occurs in normal 
epidermis and elsewhere (154), the physiological role of citrullination remain 
uncertain.  
Filaggrin was the first protein whose citrullinated epitopes were demonstrated 
to be specific in RA. Filaggrin is a protein that binds keratin fibres in epithelial 
cells and is exclusively expressed in squamous epithelial cells.Notably, filaggrin 
is also the target of anti-keratin antibodies that had been reported to be highly 
specific for RA (155). Considering that filaggrin is not expressed in the joint, it is 
reasonable to think that it is not the primary target structure of ACPA but most 
probably represents a cross-reacting antigen. Beside citrullinated filaggrin, 
other established antigens that bind ACPAs are citrullinated type II collagen 
(CII), α-enolase, fibrinogen and vimentin (156, 157). 
All the different citrullinated antigens can be measured by ELISA, although in 
the clinical setting,ACPA are the most used and are mainly detected using the 
anti-cyclic citrullinated peptide (anti-CCP) test. In facts, ACPA not only 
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represent the most specific serological marker antibodies for RA but also, 
similarly to RF, can be detected in RA serum even before the clinical onset 
(156, 158). Moreover, presence of ACPA in RA patients has been associated 
with radiographic disease progression (i.e bone damage) and with the 
presence of RA associated HLA-DR alleles ("the shared epitope"). 
Thus, ACPA are currently the most used and reliable diagnostic marker for RA, 
whose determination is particularly useful in patients with early arthritis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Sjögren Syndrome 
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1.3.1 Definition and classification criteria 
 
Sjogren’s syndrome (SS) is a chronic autoimmune disease characterized by 
immune cell infiltration of the exocrine glands leading to glandular 
dysfunction, aberrant autoantibody production and extra glandular systemic 
features, including arthritis, fatigue and diverse organ involvement (159). This 
syndrome may present as a primary disease (pSS) or in association with other 
autoimmune rheumatic disease such as rheumatoid arthritis, systemic lupus 
erythematous and systemic sclerosis defining as secondary Sjogren’s syndrome 
(sSS) (160). 
The main targets of the inflammatory process in SS are the exocrine glands 
(minor and major salivary glands, lacrimal glands etc), determining the 
hallmark clinical feature: the sicca syndrome (159). Moreover, common 
feature of SS is the presence of a large number of autoantibodies suggested to 
be involved in the pathogenesis of the disease. The strict correlation between 
the presence of some of these antibodies (anti 52-kDa SSA/Ro, 60-kD SSA/Ro, 
and SS-B/La) and the development of the disease has prompted their inclusion 
as a critical criterion for the diagnosis of SS. The most accepted and better 
validated criteria for the classification of the disease are listed in the 2002 
revised version of the 1993 European criteria proposed by the American-
European Consensus Group (160)(table 1.6). As discussed above for RA, 
classification criteria are not strictly designed for use in diagnostic in daily 
clinical practice. In fact, only when sensitivity and specificity of classification 
criteria are both close to 100% they can be used as diagnostic criteria. The 
reported specificity and sensitivity of the revised criteria for SS, are 
respectively 97% and 90% (160). 
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Table 1.6 Classification criteria for Sjögren’s syndrome 
 
I. Ocular symptoms 
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II. Oral symptoms 
 
III. Ocular signs: positive result for at least one of the following two tests: 
    1. Schirmer’s I test 
    2. Rose Bengal score or other ocular dye score  
 
IV. Histopathology: In minor salivary glands focal lymphocytic sialoadenitis with a focus score >1 
defined as a number of lymphocytic foci (more than 50 lymphocytes) per 4 mm2 of glandular tissue  
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive 
result for at least one of the following diagnostic tests: 
    1. Unstimulated whole salivary flow (<1.5 ml in 15 minutes) 
    2. Parotid sialography  
    3. Salivary scintigraphy  
 
VI. Autoantibodies in the serum to Ro(SSA) or La(SSB) antigens, or both 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive 
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI) 
c. The classification tree procedure represents a valid alternative method for classification, although 
it should be more properly used in clinical-epidemiological survey 
 
For secondary SS 
In patients with a potentially associated disease (for instance, another well defined connective tissue 
disease), the presence of item I or item II plus any 2 from among items III, IV, and V may be 
considered as indicative of secondary SS 
Exclusion criteria: 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency disease (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft versus host disease 
Use of anticholinergic drugs  
 
 
Source: Vitali et al. Ann Rheum Dis. 2002 
 
1.3.2 Epidemiology 
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SS is considered one of the commonest autoimmune diseases, affecting 
between 0.1% to 4.8% of the population. The great variability in the prevalence 
of the disease is found not only in different area of the world but also in the 
same country (161). This discrepancy can be due to methodological differences 
such as in the definition and application of SS diagnostic criteria or different 
reporting systems (i.e., community vs. hospital-based reports). On the other 
hand, genetic and environmental factors, which play a crucial role in the 
pathogenesis of autoimmune diseases, may clarify some of these geographic 
and ethnic differences. 
The highest prevalence of SS has been documented in northern Europe, while 
the lowest rates are observed in some parts of Asia and comparable rates have 
been reported in North America and mainland Europe. Anyway, it should be 
noted that there is little epidemiological data for SS in region outside Europe 
and North America(162). 
Sjogren's syndrome occurs in patients of all ages but it generally manifests 
during the fourth and fifth decades of life with a female to male ratio of 9:1 
(163, 164). 
Recently, Lin DF et al. (165) documented different clinical manifestations of SS 
in their cohort of 573 Chinese patients. In this area of the world, the age of 
disease onset was much younger compared with western cohorts and up to 
30% of patients were diagnosed before the age of 30 years. Furthermore, their 
reported different symptoms, and fever, pericardial effusion, pulmonary and 
renal manifestations were relatively common. 
 
1.3.3 Clinicalaspects 
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SS exocrine glands are typically characterized by a chronic autoimmune 
process leading to severe tissue damage and glandular dysfunction. The ductal 
epithelium represent the main target of this process and therefore SS is 
currently defined as “autoimmune epithelitis” (166).  
Dry mouth and dry eyes (sicca syndrome) together with problems in 
swallowing, taste alterations and a broad range of ocular problems represent 
the main symptoms of this disease. Hallmark of the ocular involvement in SS is 
the development of a keratoconjunctivitis sicca, considered the main 
consequence of qualitative and quantitative alterations in the ocular tear flow. 
As a consequences of the lack of saliva, SS patients often report symptoms like 
dental caries, mucositis and oral candidiasis (167). However, it is still debated 
whether the loss in the secretory component of the glands represents the only 
cause of the glandular dysfunction. It is strongly believed that serum 
autoantibodies might contribute to this process by interfering with 
neurological stimuli that regulate glandular secretion (167). 
According to its definition of autoimmune disease, SS might affect diverse 
organs: joints, gut, respiratory tract, skin, neurological system can all be 
involved during the disease course, diversely influencing disease morbidity and 
prognosis.  
From 42% to 83% of SS patients report muscoloskeletal symptoms, more often 
in the female population. The spectrum of articular manifestations is large and 
in one third of the patients articular manifestations develop before the onset 
of the sicca syndrome (167). SS articular involvement is often polyarticular and 
symmetric with morning stiffness and arthralgia; mono-oligoarticular 
involvement is described in the early phases of the disease. More rarely, SS 
patients can develop a frank inflammatory arthritis, although commonly non-
erosive (168). Development of myalgia represents another frequent 
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musculoskeletal manifestation of SS, often associated with fibromyalgic-like 
symptoms and severe fatigue (167). 
Haematological abnormalities are commonly reported in SS patients: anaemia, 
lymphopenia, polyclonal and monoclonal gammopathies and 
lymphoproliferative disorders have been described with various prevalence in 
different populations (169). Often SS patients present skin manifestation like 
skin xerosis which is found in between 23 to 67% of SS patients and most 
probably related to an impaired sebaceous and sweet glands glandular 
secretion (170). Less common cutaneous manifestations include vasculitis, 
urticaria vasculitis and annular lesions (171, 172). One third of SS patients 
presents with Raynaud’s phenomenon often in association with articular 
involvement (173). 
Neurological involvement includes the development of peripheral 
neuropathies and, less frequently, central-nervous-system involvement (167).  
Between 2 to 75% of SS patients can be affected by a broad range of 
respiratory involvement (174-176). Nasal cavity involvement with bleeding and 
hyposmia, xerotrachea and bronchial hyper reactivity has been described(167, 
174). Furthermore, interstitial lung disease is not uncommon in SS patients, 
although frequently this is not symptomatic but easily detectable at CT scans. 
As a consequence of the diffuse distribution of exocrine glands in the gut, the 
whole gastrointestinal tract might be involved in SS with the most common 
manifestation being dysphagia, occasionally associated with oesophageal 
dysmotility (177).  
A significant association between SS and primary biliary cirrhosis has been 
described being sicca syndrome more frequent in patients with primary biliary 
cirrhosis, with anti-hepatocytes and anti-mitochondrial antibodies (AMA) not 
infrequently found in SS patients (178).  
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Histologically chronic active hepatitis with prevalent periductal involvement 
and portal fibrosis has been detected in the liver of SS patients (178). 
Moreover, the development of sicca syndrome has been associated with liver 
involvement during Hepatitis C virus (HCV) infection (159). Interestingly, in SS 
patients the prevalence of anti HCV antibodies is higher compared to the 
healthy population (4 to 19% of the patients) (179). However, given the 
tropism of HCV for salivary glands, HCV infection is currently an exclusion 
criterium in the classification of SS. 
SS patients might also suffer of acute pancreatitis, malabsorption and 
calcification, since the exocrine components of the pancreas are seldom a 
target of the disease (180). 
Renal involvement has been described in SS patients with renal tubular 
acidosis being the most common manifestation. Glomerulonephritis is rare 
while a mild proteinuria is present in 44% of the patients. Defects in urine 
concentration have been described in 22 to 44% of SS patients. Rarely renal 
failure has been described. Renal involvement in SS has been related to the 
aberrant production of anti-tubular antibodies or to cell-mediated tissue 
damage by antigen specific lymphocytes (167). 
Interstitial cystitis is commonly found in SS patients. Also autonomic bladder 
dysfunction has been reported in association with anti-muscarinic receptors 
antibody production. 
Gynaecological symptoms are often referred and in particular dryness and 
development of gynaecological infection related to impaired gland secretion 
(167). 
Among other autoimmune disease, Hashimoto thyroiditis and coeliac disease 
have been reported to be frequently associated to SS (181). 
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Finally, the most serious complication of SS is the evolution towards 
haematological malignancies, in particular lymphoma development which 
involves approximately 5% of primary SS patients. Lymphomas in SS are most 
commonly non-Hodgkin B cell lymphomas which usually arise within the major 
salivary glands, most often the parotids, with the histopathologic pattern of a 
low-grade marginal zone lymphoma of the mucosa-associated lymphoid tissue 
(MALT-L). The development of lymphoma is the main factor influencing 
morbidity and mortality in SS patients(182). 
 
 
1.3.4 Etiology 
 
The etiology of SS is still unknown. However it is considered a multifactorial 
disease where a combination of genetic background, gender, immunological 
abnormalities, environmental factors and infectious antigens play a role in 
development of the disease(159). 
 
 
1.3.4.1 Genetic factors 
 
Patients affected by primary SS compared with normal subjects display a 
higher frequency of selected histocompatibility antigens, in particular HLA B8, 
DR3 and DRw52 (183). In particular, the HLA DRB1*03-DQB1*02 haplotype has 
been strongly associated with the production of anti-Ro and anti-La antibodies 
in patients affected by SS and by SLE, suggesting an overlap in the genetic 
background of these two diseases (184). Moreover, several cytokine and pro-
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inflammatory gene polymorphisms have been suggested to play a role in the 
SS pathogenesis(185, 186). 
 
 
1.3.4.2 Role of pathogens 
 
The role of infectious agents in the mosaic of autoimmunity is probably the 
best-established one, although no strict correlation has been found between 
SS and any particular virus.  
Cytomegalovirus, Hepatitis viruses C (HCV), Human Immunodeficiency virus 
(HIV) and Human T Cell Leukemia Virus type 1 (HTLV-1) have been often 
associated with the development of  sialoadenitis and the occurrence of a SS-
like syndrome in humans and in mouse models. Similarly, Epstein-Barr virus 
has been demonstrated to elicit, in humans, latent infection of salivary glands 
and, upon reactivation, to generate a T cell-dependent B-cell activation 
together with cytokine production typical of SS (IL-12 and IL-18)(159). HTLV-1 
has also been associated with SS; evidences came from both in vivo studies 
using HTLV-1 transgenic mice that develop a SS-like syndrome, and from 
evidence of a higher prevalence of SS in areas endemic for HTLV-1 infection 
(187). 
Upon HIV infection between 2 and 5% of patients develops a salivary gland 
infiltrates similar to primary SS, although no autoantibody production has been 
detected in these patients compatible with SS. 
HCV infection in mice and humans can mimic several SS clinical aspects and 
despite HCV infected patients are excluded from the diagnosis of SS, some 
authors suggest HCV as etiological factor for SS (188). 
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Recent evidence demonstrated a cross reaction between a linear B cell epitope 
of Ro60-kd autoantigen and a protein of the Coxsackie virus 2B, strongly 
suggesting a role for Coxakie virus infection in SS pathogenesis(189) although 
this was not confirmed in subsequent studies (190). 
Diverse mechanisms can explain the relationship between viral infection and 
SS development. It is strongly believed that molecular mimicry between viral 
antigens and self-epitopes in SS can play an important role in the pathogenesis 
of the disease (191). In addition it has long been suggested that cryptic 
antigens displayed on the cellular surface of the glandular epithelium upon 
virus-mediated infection in association with an aberrant class II MHC 
expression by the same epithelial cells play a key role favouring the activation 
of self-reacting lymphocytes and maintaining the inflammatory process (192). 
 
 
1.3.5 Immunopathogenesis of salivary gland involvement in Sjogren’s 
syndrome 
 
 
1.3.5.1 The inflammatory infiltrates 
 
The majority of the data describing the formation of the typical inflammatory 
aggregates (inflammatory foci) in SS glands derives from studies on minor and 
major salivary glands. This is due not only to the fact that salivary glands and in 
particular minor salivary glands are commonly involved in the disease course, 
but also because they can be easily taken with minor surgical procedures (i.e. 
labial salivary gland biopsies). 
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Salivary glands are divided in major (parotid, submandibular and sublingual) 
and minor glands (labial, buccal and palatine). The acini and the ducts 
represent the gland secretory component; a stromal component is also present 
with nerves, blood and lymphatic vessels. The ducts are classified in 
intercalated (surrounded by myoephithelial cells), striated and excretory. 
Typically SS lymphomonocytoid inflammatory infiltrate is organized around the 
excretory ducts. Histologically the diagnosis of SS is based on the Chisholm and 
Mason score and refers to the presence of at least 1 focus score (a focus is 
defined by the presence of 50 periductal lymphocytes) in 4mm2 of tissue area 
(187).  The immune cells that constitute these follicular structures, which share 
similar features with lymphoid follicles in SLOs as described in the previous 
chapter, are predominantly lymphomonocytic cells. In particular, 
CD4+/CD45RO+ memory T cells represent the major cellular component of 
these aggregates. Cytotoxic CD8+ T cells are less abundant and usually localise 
around acinar structures where they could contribute to acinar loss via 
production of perforin/granzymes (193). B lymphocytes are the second main 
lymphocytyc subset, constituting 20-30% of the infiltrating cellular component, 
particularly at later stages of salivary gland involvement (194). Typically, the 
number of recruited B cells increases during the expansion and organization of 
the periductal inflammatory focus. 
In a subset of SS patients, B and T lymphocytes can become organized in 
discrete areas, with T/B cell compartmentalization, and in around 30-40% of SS 
minor salivary glands it is possible to observe the presence of ectopic GCs 
characterized by CD21+ follicular dendritic cells networks (194). Therefore, also 
Sjogren’s syndrome, as previously discussed for Rheumatoid Arthritis, is a 
chronic inflammatory condition characterized by ectopic lymphoid structures 
formation.  
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Different evidences have demonstrated that ectopic expression of 
lymphotoxins (LT) and homeostatic chemokines play a crucial role in regulating 
the development of ecopic lymphoid structures in SS salivary glands. Similarly 
to the mechanism of SLO organogenesis, CXCL13, CCL21 and CCL19 are up-
regulated in the SS salivary glands and their expression correlate with the 
gradual acquisition of lymphoid features and FDC networks formation (195-
197). Lymphoid chemokines are differentially expressed by different cell types 
in discrete anatomical structures within ELS in SS salivary glands, allowing the 
formation of separate T and B cell zone. In particular, CXCL13 is capable of 
selectively recruit leukocytes expressing the specific receptors CXCR5, while 
CCL21 selectively recruit CXCR7+ cells. Consequently CXCL13 is found in the B 
cell-rich areas of the aggregates and CCL21 localise in close contact with HEVs 
in the surrounding T cell area (195, 198, 199). Therefore both CXCL13 and 
CCL21 play a fundamental role in regulating the progressive organization and 
maintenance of periductal foci in SS salivary glands. 
Ectopic lymphoid structures have been suggested to be functional in SS salivary 
glands, promoting Ag-driven B cell activation, selection and proliferation with 
the in situ production of autoantibodies (123). In support of this hypothesis, B 
cells with highly organized foci in SS salivary glands express somatically 
hypermutated Ig genes (200) and can produce autoantibodies such as anti-
Ro/SSA and anti-LA/SSB (201, 202). Recently, it has been demonstrated that 
ectopic GCs in SS salivary glands are functional, since they invariably express 
AID in periductal inflammatory foci characterized by features of secondary 
lymphoid organs such as T/B cell segregation and FDC networks (203). Since 
AID expression has been demonstrated to be sufficient for, and exclusively 
expressed in, B cells undergoing CSR and/or SHM (204), its detection in SS 
salivary glands indicate that B cells activate their molecular machinery 
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responsible for hypermutation of Ig genes in ectopic lymphoid tissue. Together 
with the finding that autoreactive B cells are detected in situ in SS salivary 
glands and correlates with serum detection of the same autoantibodies (202), 
this discovery reinforce the notion the ectopic lymphoid neogenesis in SS is 
accompanied by local selection and proliferation of autoreactive B cells and 
that circulating autoantibodies may, at least in part, reflect local production in 
the salivary glands. 
 
 
1.3.5.2 The ductal epithelium 
 
The ductal epithelium plays an important role in the SS pathogenesis since it is 
involved in the immune cell recruitment within the glands, in the process of 
antigen presentation and in the direct stimulation of the immune cells(205). 
Epithelial cells derived from the SS salivary glands are capable to secrete 
molecules involved in immune cells recruitment and organization (196). This 
suggests that, upon antigen stimulation the ductal epithelium provides the first 
signals for leukocyte migration. 
SS ductal epithelial cells have also been suggested to actively participate to the 
organization of the immune response by presenting the antigen/s and 
providing the costimulatory molecules capable to activate the infiltrating 
lymphocytes. In fact has been demonstrated that primary cultures of SS ductal 
epithelial cells retain the expression of costimulatory molecules such as HLA-
DR/DP/DQ (206), CD80/CD86 (207) and CD40 (208) as well as adhesion 
molecules such as VCAM-1 and ELAM-1, suggesting an active role of the ducts 
in the antigen presentation process in vivo. Ductal epithelial cells can also 
release proinflammatory cytokines (IL-1, IL-6, and TNF-a) and 
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metalloproteinase (209), that can in turn stimulate the infiltrating immune 
cells. Finally the ductal epithelium show an increased apoptosis rate in SS 
salivary glands, as demonstrated by the aberrant expression of Fas and Fas 
ligand (210), suggesting that it can play a role in the break of tolerance towards 
autoantigens and in the perpetuation of the autoimmune process by releasing 
apoptotic blebs containing autoantigens. 
However, it is still not clear whether the activation of the ductal epithelium is a 
constitutive feature of SS salivary glands or merely reflects a secondary event 
due to pathogen infection. 
In the most severe cases of SS, the ductal epithelium can be infiltrated by the 
immune cells forming areas of lymphoepithelial proliferation or 
lymphoepithelial sialoadenitis (LESA). The presence of this hystopathological 
lesion has been specifically associated with the development of the mucosa 
associated lymphoid tissue (MALT) type B-cell lymphomas. 
 
 
1.3.5.3 Apoptotic mechanisms involved in tissue damage in SS salivary 
glands 
 
The major mechanisms believed to play a pivotal role in determining abnormal 
apoptotic rate in SS salivary glands are discussed beloved. It is important to 
note that the increased apoptosis of epithelial cells in SS salivary glands may 
not only explain, at least in part, the exocrine dysfunction observed in SS, but 
also contribute to clarify the mechanism underling the breach of tolerance and 
generation of autoantibodies. In fact, some autoantigens in SS are typically 
associated with apoptotic process. In particular Ro/SSA and Ro/SSB are 
expressed within apoptotic “blebs”(211, 212) while the 120Kd antigenic form 
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of α-fodrin is generated during apoptosis upon cleavage by caspases and 
calpains (213). 
Together with the Fas/Fas-L pathways, cytotoxic lymphocytes, the key players 
in cell-mediated immunity, may induce apoptosis through exocytosis of 
cytolytic granules. This mechanism depends on the synergy of a calcium-
dependent pore-forming protein (perforin) and a battery of proteases 
(granzymes), and results in penetration of the target cell by effector molecules. 
This machinery is believed to be partly responsible for epithelial cell apoptosis. 
Of particular interest, CD8+ T lymphocytes producing perforin and granzyme B 
are localized around acinar structures in SS salivary glands. In addition it has 
been observed that acinar cells surrounded by CD8+ cytotoxic T cells displayed 
an increase apoptotic ratio (193), supporting the hypothesis that direct 
cytotoxic mechanism also mediate epithelial cell injury via aberrant apoptosis. 
 
 
1.3.6 Autoantibodies in Sjogren’s syndrome 
 
Autoantibody production in SS seems to reflect a breakage in the immune 
tolerance towards autoantigens, often cryptic. In this regard, the development 
and maturation of autoreactive B cells encoding for these autoantibodies has 
been largely investigated. It is believed that at glandular level the aberrant 
presentation of antigens/autoantigens can favour the development of 
autoreactive B cells, whose survival and spreading is supported by the excess 
of antigens presented by local APC and by the aberrant expression of B cell 
survival factors within the glands. 
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The main self-proteins implicated in SS pathogenesis are Ro/La 
ribonucleoproteins and fodrin whilst the main target for potentially pathogenic 
antibodies has been suggested to be the acetylcholine muscarinic receptor M3. 
 
 
1.3.6.1 Anti Ro/SSA and anti La/SSB 
 
Autoantibodies to the ribonucleoprotein particles Ro/SSA and La/SSB are 
commonly found in sera of patients with SS but are also generally detected in 
sera of patients with SLE. Their presence in SS patients is associated with 
longer disease duration, increased frequency of non-exocrine manifestations 
and the presence of lymphocytic infiltrates in the minor salivary glands(214, 
215). 
The Ro/La ribonucleoprotein complex is composed of the Ro 60 kDa, Ro 52 kDa 
and La 48 kDa proteins that are associated with one small cytoplasmic RNA (Y-
RNA). 
The Ro/SSA antigen is a ribonucleoprotein particle composed of hY-RNAs and 
two protein components (60 kDa and 52 kDa) conforming a ribonucleoprotein 
complex.  
The La/SSB antigen is also a ribonucleoprotein particle associated with RNA 
polymerase III transcripts, including the hY-RNAs. 
It is not clear what trigger tolerance breakdown and autoantibody response to 
Ro/SSA and La/SSB in SS. It has been suggested that stresses, such as 
ultraviolet radiation, viral infections and apoptosis can lead to undesirable cell 
surface exposure of autoantigens to the immune system (216).  
Although there is not much genetic information explaining SS pathogenesis, it 
is known that a single nucleotide polymorphism in intron 3 of the Ro52 gene is 
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strongly associated with the presence of anti-Ro52 autoantibodies in primary 
SS (217). 
 
 
1.3.6.2 Anti-α-fodrin 
 
Fodrin is the main component of the cortical cytoskeleton of most eukaryotic 
cells, composed of α and β subunits. Many studies have associated fodrin with 
apoptotic mechanisms. It was reported an abnormal location of α-fodrin on 
the surface of apoptotic-induced cells (218). Moreover, it was demonstrated 
that α-fodrin is specifically cleaved by granzyme B during cytotoxic lymphocyte 
granule-induced cell death (219). Also, it was found that Epstein–Barr virus 
(EBV) reactivation induces an increase in apoptotic protease activities leading 
to progression of α-fodrin proteolysis (220). More recently, Maruyama et al. 
(221) described a 150 kDa cleaved product of α-fodrin that is exposed as a 
neoepitope to the immune system. These studies indicate that an abnormal 
proteolysis of α-fodrin may lead to an altered location of this autoantigen in 
the external surface of apoptotic epithelial cells, triggering the autoimmune 
process in the salivary glands. 
Although several authors have further investigated the prevalence and clinical 
significance of anti-α-fodrin antibodies in SS describing prevalence of 
antibodies in 55–64% of adult patients with primary SS and in 40–86% of those 
with secondary SS (depending on the Ig isotype study)  (222)and in 
child/juvenile SS patients (223, 224), there is evidence that these antibodies do 
not have significant additional diagnostic value (225). 
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1.4 Link between EBV and Rheumatoid arthritis: evidences and 
controversies 
 
 
The evidences linking EBV to RA include serological data, a higher EBV viral 
load in RA patients, cross-reactivity between EBV proteins and RA self-
antigens, the expression of EBV DNA/RNA/antigens in the RA synovial 
membrane and a cell-mediated response against EBV systemically and within 
the RA joints (68). 
Among all the above aspects, both positive and negative findings have been 
reported. Here, I shall review the main relevant observations. 
 
 
1.4.1 Humoral response to EBV antigens in rheumatoid arthritis 
 
EBV was first implicated in the pathogenesis of RA by Alspaugh and Tan (226), 
who reported that sera from patients with RA were reactive against a nuclear 
antigen in EBV-transformed lymphocytes. This “RA nuclear antigen” (RANA) 
was identified as a glycin/alanine-rich repeat in EBNA1. Since then, there has 
been a general consensus in several reports to conclude that RA patients, 
compared to healthy controls, have higher titers of antibodies specific for both 
latent and lytic EBV antigens, not only in the serum but also in the synovial 
fluid (56, 227-231). However, EBV titres in RA serum were found usually equal 
to, or greater than, those in the synovial fluid, an observation which led to the 
controversial suggestion that the synovial fluid titres may merely reflect the 
serum anti-EBV antibodies levels and not local production (228, 232, 233). 
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1.4.2 Cell-mediated immune response to EBV in rheumatoid arthritis 
 
Several groups reported that cytotoxic CD8+ T cells directed against EBV 
antigens are altered in frequency (61, 231, 234)and are functionally impaired in 
RA patients(61, 235). In a recent study CD8+ T cells, with a decreased ability to 
produce INF-γ, were demonstrated to be directed predominantly against lytic 
EBV peptides in RA patients(61). 
In keeping with these reports, there is strong evidence to suggest that the 
impairment of T cells from RA patients does not allow an adequate control of 
EBV-induced B cell proliferation(235, 236). Accordingly, B cells from RA 
patients undergo lymphoblastoidtransformation in vitro more often compared 
to controls and the time needed to transform lines is shorter (237). 
Interestingly, the deficiency in the CD8+ T-cell function seems not to be 
present in the early stages of RA and has been therefore related to an acquired 
phenotype possibly due to chronic inflammation rather than to genetic factors. 
In any case, the net result of functional defects in the EBV-specific CD8+ T cell 
compartment is a reduced control of EBV infection. 
 
 
1.4.3 Molecular mimicry between EBV antigens and self-proteins in RA 
 
In the molecular mimicry hypothesis, cross reactivity is assumed to occur 
between viral and human proteins. Different findings suggest a role for 
molecular mimicry between EBV and self-antigens in RA patients. 
Significant homology has been descried among several sequences of both 
EBNA-6 and HLA DQB1*0302 (238). 
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Glycine/alanine repeats identical to those found in EBNA-1 are also present in 
cytoskeleton proteins including cytokeratin and type 2 collagen(63) which are 
putative autoantigens in RA. Interestingly, an antibody to these glycine/alanine 
repeats strongly reacted with a 62-kDa protein expressed by synovial lining 
cells in RA patients (239)while reduced reactivity with synovium from patients 
who had other joint diseases (osteoarthritis, psoriatic arthritis, lupus, and 
villonodular synovitis) was noted. Although the target protein has not been 
fully characterized, it seems to be located on lining macrophage synovial cells.  
The RA susceptibility sequence QKRAA located in HLA-DRB1*0401 shares 
homology with a sequence in the gp110 EBV glycoprotein (240), which is a lytic 
cycle antigen expressed by the endoplasmic reticulum and on the surface of 
EBV-transformed lymphoblastoid cells (241). The gp110 protein is among the 
herpes virus gB proteins, which are targets of the immune response to 
infection (242). Both B cells and T cells cross react to the QKRAA sequences in 
gp110 and HLA-DRB1*0401 (240). Therefore, EBV infection may lead to an 
immune response against HLA-DR molecules containing the shared epitope. 
The humoral response to purified EBV gp110 and EBNA-1 varied with the 
expression of the shared epitope, being strongest in patients carrying RA 
susceptibility alleles (243). 
 
 
1.4.4 Cell-mediated response to EBV antigens within the joint 
 
CD8+ T-cell clones directed against BZLF1 and BMLF1 proteins were identified 
in the joint fluid from RA patients. Both BZLF1 and BMLF1 are transactivators 
produced during the EBV lytic cycle (244). This T-cell response was stronger in 
the joint than in peripheral blood, suggesting accumulation of EBV-specific T 
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cells within joints. However, a similar T-cell response was also found in the 
synovium from patients with other joint diseases (psoriatic arthritis, 
spondyloarthropathy, and reactive arthritis), as well as against cytomegalovirus 
proteins (244). 
More recently, another study demonstrated the presence of T cells directed 
against gp110 in the synovium of both RA patients and patients with other 
inflammatory joint diseases (spondyloarthropathies, connective tissue 
diseases, and chondrocalcinosis) (234). Remarkably the strength of the 
response, as assessed using the limit dilution method, was greater in the RA 
patients compared to controls. Further, the response in the RA patients was 
stronger in joint fluid than in peripheral blood(234). 
These data strongly suggest that within the RA joints there is an ongoing cell-
mediated response to lytic-cycle EBV antigens. The stronger response in the 
synovial fluid compared to the peripheral blood is probably due to the 
preferential migration of EBV-reactive cytotoxic T cells from the bloodstream 
to the joints. 
 
 
1.4.5 EBV load in RA patients 
 
The percentage of EBV-infected B cells is higher in RA than in healthy subjects. 
The EBV-burden in RA patients was investigated in different studies showing an 
EBV load 10-time higher in RA patients than in controls (56, 245). In particular, 
Balandraud et al observed that the higher EBV burden remained stable over 1-
year follow-up period (56). More recently, it was observed that the increased 
EBV load is not associated with any particular HLA-DR alleles (114).  
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1.4.6 EBV and anti-citrullinated proteins antibodies in RA  
 
EBV antigens can undergo post-translation citrullination, thus becoming 
targets for anti-CCP, highly specific in RA. 
Antibodies towards a citrullinated EBV peptide derived from EBNA1 (VCP1) 
have been identified in 50% of sera from RA patients compared to only 5% of 
controls(66). The VCP1 antibody titres correlated with anti-CCP titres and were 
more common among patients with rheumatoid factors. The same group 
demonstrated that anti-VCP1 antibodies from RA sera cross-reacted with 
citrullinated EBNA1 and citrullinated peptides that are autoantigens in RA, such 
as fibrinogen and filaggrin (66).  
Recently, another viral citrullinated peptide, VCP2, derived from EBNA2 was 
suggested to be a substrate for ACPA (246). Accordingly, pre-incubation of RA 
sera (positive for CCP and VCP2) with VCP2 inhibited the binding to anti-CCP by 
as much as 60%. VCP2 has been demonstrated to be a good and sensitive tool 
in the diagnosis of RA, being detected almost exclusively in RA patients with 
respect to control subject and patients with other autoimmune diseases (247). 
Moreover, it was demonstrated that anti-VCP2 antibodies have a similar 
sensitivity and sensibility of anti-CCP in predicting RA (248). 
 
 
1.4.7 Presence of EBV nucleic acids and proteins in the RA synovia 
 
The investigation of EBV within the synovial tissues of RA patients has proved 
by far the most controversial aspect of EBV involvement in RA.  
Although EBV presence in the RA synovial membrane has been investigated 
using different techniques, such as immunohistochemistry (IHC), in situ 
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hybridization (ISH) and PCR techniques, these have never been performed in 
parallel on the same cohort of patients.  
In some PCR and RT-PCR studies, RA patients were significantly more likely to 
have EBV DNA or RNA in synovial fluid or membrane compared to controls 
(245, 249). In addition, EBV DNA was identified in the synovial membrane also 
by Southern blot analysis (69). 
Other studies detected EBV in the RA synovium mainly by ISH and IHC. Takey et 
al (70) demonstrated the expression of EBER and LMP1 in synovial lining cells 
from about 25% of the RA cases analysed, but not in OA controls. They also 
found that the incidence of EBV-positive synovial lining cells was higher in RA 
synovial samples with high lymphocyte infiltration than in the moderately 
infiltrated ones. Takeda et al (69) also found evidence of EBV DNA, EBER and 
EBV-lytic antigens in a high proportion (about 50%) of synovial tissues from RA 
patients but no evidence of EBV infection in synovial tissues from OA patients.  
Despite these evidences, there have been also conflicting reports, especially in 
the analysis made by ISH and IHC. For example, Alspaugh et al (71)studying the 
pannus extracted from RA patients, investigated the presence of RA-associated 
nuclear antigen (RANA), anti-RANA, EBV specific antigens, and EBV genomes. 
Although they detected rarely some RANA and commonly anti-RANA, they did 
not detect any EBV-specific antigens or genes. They therefore concluded that 
EBV is not the primary event causing RA through direct infection.  Brousset et 
al (250) did not detect any transcripts associated with the latent and early-lytic 
phase of EBV in RA synovial membranes using ISH technique. Niedobitek et 
al(251) failed to detect LMP1 or BZLF1 positive cells in RA synovial tissue, 
although they found EBER-positive lymphocytes. 
In summary, even though converging evidence indicates that EBV infection and 
both humoral and cellular immunity toward the virus are dysregulated in 
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patients with RA, evidence that EBV infection is altered in the RA synovium 
remains controversial and the exact role played by the virus in the 
pathogenesis of RA is yet to be clarified. 
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1.5 Link between EBV and Sjogren’s syndrome: evidences and 
controversies 
 
 
EBV is an excellent putative candidate to be involved in the pathogenesis of SS. 
In fact, EBV replicates in the oropharynx during primary infection and it has is 
normal site of latency in salivary and lacrimal glands. Since EBV can induce a 
strong T-cell and B-cell response, the immune recognition of the virus at its site 
of latency or activation might contribute to exocrine gland damage. 
Several observations support a link between EBV and SS both in the peripheral 
and exocrine gland compartment 
 
 
1.5.1 Peripheral compartment 
 
Firstly, in comparison with healthy controls, SS patients show an increased 
humoral response towards the virus. Independent investigations revealed 
higher titres of anti-EBV antibodies (especially anti-EBNA1, -2 and -3) in serum 
of SS patients compared to controls (252, 253). Secondly, there are different 
examples of molecular resemblance between self-antigens in SS and EBV 
proteins. For instance anti-La/SSB antibodies from SS patients precipitate a 
cytoplasmic protein, which is complexed with EBER-1 and EBER-2 (33). 
Recently Navone et al (254), trying to identify novel autoantigens in SS, 
screened a random peptide library with pooled IgG derived from SS patients. 
They found a single peptide recognized by the majority of patients’ sera, but 
not by the control sera. This peptide shows homology with an EBV-derived 
protein, with tear lipocalin (a protein highly expressed in tears and saliva) and 
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with alpha-fodrin (a cytoskeleton protein considered an important autoantigen 
in SS). Anti-peptide antibodies affinity purified from SS sera recognized both 
the viral protein and tear lipocalin and alpha-fodrin. Moreover, Inoue et al 
(220)demonstrated that EBV reactivation can increase the apoptotic protease 
activity sustaining alpha-fodrin proteolysis and therefore causing the 
production of a cleavage product of alpha-fodrin that represent a key organ-
specific autoantigen in the SS pathogenesis.  
Furthermore, in vivo evidences of a link between EBV and SS come from a work 
from Miysaka et al (255), where they demonstrated that transferring B cells 
from SS patients to SCID mice induces a monoclonal lymphoproliferative 
disorder that resembles those arising in SS.  
 
 
1.5.2 Exocrine compartment 
 
As in the RA synovium, it is still highly controversial whether an increased 
expression of EBV nucleic acids and proteins are still expressed in SS salivary 
and lacrimal glands.   
It was recently demonstrated that the saliva of patients with SS can activate 
EBV (256). In this study the influence of saliva was examined on an EBV-
negative cell line transfected with BZLF1, a trans-activating EBV gene 
promoter. The results showed that saliva of SS patients exerts a significant 
effect on the EBV gene promoter. 
Using ISH, IHC and dot blot hybridization Wen et alobserved that two different 
forms of EBV infection may exist in SS salivary glands(74). One is EBER1-
negative latency in epithelial cells and the other is EBER1-positive latency in 
lymphocytes. They did not detect any EBV lytic protein in the samples 
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analysed. Conversely Fox et al (257) using IHC observed that more than 50% of 
the SS salivary glands analysed were positive for the EBV early lytic antigen 
(EA) although only in epithelial cells. They did not detect any EBV+ 
lymphocytes. Differently, Pfugfelder et al (258), using IHC, PCR and ISH, found 
that lacrimal glands from SS patients express high level of EBV DNA and latent 
antigens both in epithelial cells and in lymphocytes. Early and late lytic 
antigens were the only EBV antigens expressed exclusively in epithelial cells of 
SS lacrimal glands. They also detected a significantly reduced or no EBV 
DNA/proteins expression in the control lacrimal glands, where only epithelial 
cells were infected. Few other works confirmed a higher expression of EBV 
DNA in SS salivary glands compared to the control, only in epithelial cells (259). 
Conversely, there are other studies which failed to observe an increased EBV 
expression in SS compared to control salivary glands. Venables et al (260) 
found no differences between SS patients and normal controls analysing the 
presence of EBV in the salivary glands either by ISH or IHC. Using IHC 
Schuumrman et al (261) did not detect any EBV antigen expression neither in 
SS or control salivary glands. Using ISH for EBV DNA the same group detected 
reactivity in around 50% of the SS salivary glands analysed, only in epithelial 
cells. Merne et al (262) using IHC, found instead similar level of expression of 
EBV latent antigen in SS and control salivary glands. 
 
Thus, although there is a general consensus that dysregulated EBV infection 
and aberrant T/B cell EBV-reactivity are present in the RA and SS patients, 
significant controversies exist regarding the expression and the pathogenic role 
of this virus in the target tissues of both disease, namely the RA synovium and 
the SS salivary glands. 
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Common limitations of previous studies have been i) the use of a limited 
number of techniques to detect the virus; ii) generally small cohorts of patients 
analysed and, most importantly, iii)  the absence of immunophenotypical 
characterization of the inflammatory infiltrates, in particular regarding the 
presence of ectopic B cell follicles and GC-like structures. 
These are fundamental limitations as the virus may express different programs 
of gene expression at different stages and in different cell types which can only 
be assessed via a comprehensive approach with the parallel use of diverse 
techniques among the same tissues.  
Furthermore, the evidence that EBV has preferential tropism for B cells and the 
recent observation that ectopic B cell follicles are preferential niches for EBV 
latency and reactivation, highlight a fundamental deficiency of previous 
studies, mainly the characterization of tissue for the presence/absence of 
ectopic lymphoid structures. 
With these limitations in mind, I set up the goal of overcoming previous pitfalls 
in the investigation of EBV in the RA synovium and in SS salivary glands as 
described in the next sections of this PhD thesis. 
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CHAPTER 2  
RATIONALE OF THE THESIS AND AIMS 
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2.1 Rationale of the thesis and aims 
 
 
Epstein-Barr virus (EBV) infects B cells and modifies their differentiation 
programme leading to B cell activation and immortalization. Increasing 
evidences support a link between EBV and common B cell-related autoimmune 
diseases, such as multiple sclerosis (MS) and myasthenia gravis (MG) where 
ectopic lymphoid structures (ELS), in the brain and the thymus respectively, are 
preferential sites of EBV persistence and reactivation. Since a subset of RA and 
SS patients are also characterised by such ELS formation in target organs, in 
the first instance I investigated whether EBV infection is deregulated and 
preferentially associated to ELS also in the RA synovia and SS salivary glands. 
Furthermore, in this PhD thesis I investigated whether a deregulated EBV 
infection in RA synovia and SS salivary glands play a pathological role in these 
conditions either via contribution to local autoimmunity through the in situ 
differentiation of autoreactive plasma cells and/or the activation of a local 
cytotoxic immune response.  
 
In details the main aims of my PhD were: 
 
1) To set the long outstanding issue of whether EBV proteins/RNA are 
expressed in the RA synovia and SS salivary glands and if their expression is 
related to the presence of ELS. In order to clarify this aspect, I used a 
comprehensive array of techniques (i.e. IHC, IF, ISH, RT-PCR) on a large number 
of RA synovial and SS salivary gland biopsies fully characterised for the level of 
inflammation and the presence of GC-like structures. Different experimental 
approaches to investigate EBV expression were employed since previous 
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discrepancies in EBV RNA/protein detection could have been due not only to 
tissue heterogeneity but also variability of the specific sensibility of different 
techniques. 
 
2) To investigate whether there is a relation between the cytotoxic T cells 
infiltration and function and EBV reactivation in SS salivary glands and RA 
synovia. This aim will test whether EBV reactivation contributes to elicit a T cell 
response in the target organ promoting local inflammation and tissue 
destruction. 
 
3) To clarify whether anti-EBV antibodies are directly manufactured in situ in 
the RA synovium and SS salivary glands. For this purpose I first detected anti-
EBV antibodies (anti-EBNA1, anti-VCA and anti-EA) in matching RA sera vs 
synovial fluids, and then investigated local production in the synovial and 
salivary gland compartments using the RA/SCID and SS/SCID chimeric models. 
For this purpose, mice were engrafted with ELS+/EBV+ RA synovia or SS 
salivary glands and the production of human IgG antibodies directed against 
EBV antigens assessed in the mouse circulation. 
 
4) To assess whether antibodies against citrullinated EBV antigens are actively 
manufactured by GC-like structures in the RA synovium, possibly contributing 
to the development and persistence of local autoimmunity in the RA joints. 
 
5) To test the hypothesis that EBV infection favours B cell survival and 
proliferation, and their differentiation into autoantibody-producing plasma 
cells in RA synovia or SS salivary glands. In order to address this question, I 
aimed to investigate whether anti-citrullinated fibrinogen antibody-producing 
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plasma cells in RA synovia and anti-Ro52/SSA and anti-La/SSB antibody-
producing plasma cells in SS salivary glands were affected by EBV 
infection/reactivation. 
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CHAPTER 3  
MATERIALS AND METHODS 
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3.1 Samples used in this study 
 
 
3.1.1 Synovial tissue from RA and OA patients 
 
Synovial tissue was collected from 43 RA patients (30 females, 13 males, mean 
age (range) 64.2 years (28-82), mean disease duration 4.5 years (1-16), mean 
CRP 38.7mg/l (5-132), mean ESR 34 (5-71), 72% RF+, 58.1% ACPA+) fulfilling 
the revised 1987 ACR criteria for RA (92). All patients attended the 
Rheumatology Department at Barts & The London School of Medicine and 
Dentistry, Queen Mary University of London and were treated with 
conventional DMARDs in monotherapy or in combination. Synovial tissue was 
collected after informed consent (LREC07/Q0605/29 granted by the East 
London &The City Research Ethics Committee 3) either by ultrasound-guided 
joint biopsy or total joint replacement or following synoviectomy. 
As negative control population, 11 cases with OA (8 females and 3 males; 
mean age 72.8, range 68-82) undergoing total joint replacement were included 
in the study. 
Freshly collected synovial tissue was part embedded in paraffin or frozen in 
OCT (optimal cutting temperature) for immunohistochemical studies and part 
dissected in multiple pieces and stored in a 10:1 v/v of RNA Later (Ambion) at- 
80°C forRT-PCRanalysis.  
A summary of of histological, immunohistochemical, ISH and RT-PCR findings in 
RA synovial samples is reported in Table 3.1. 
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Table 3.1 Summary of histological, immunohistochemical, ISH and RT-PCR findings in RA synovial samples 
 
 
RA sample Histopathological characterization Real time RT-PCR In situ hybridization Immunohistochemistry 
Synovitis 
score 
Inflammation 
score CD20 CD3 CD138 CD68 
 
CD21 Grade 
 
EBER1 
 
LMP2A 
 
EBER1/2 
 
GAPDH LMP2A LMP1 BFRF1 
gp350/ 
220 p160 
                  
Aggregate 
synovitis 
with FDC       
 
 
  
       
5409 8 16 4 3 2 2 + G3 n.p. n.p  + +   +  +    + n.p.  - 
5409N 7 17 4 4 3 3 + G3 n.p. n.p n.p. n.p.  + n.p.  +   n.p. n.p. 
0210R1 7 19 4 4 4 3 + G3 + + + +  +  n.p.  +  n.p. n.p. 
3009 9 18,5 3,5 4 4 3 + G3 - + +  +   +   +  +   - n.p. 
3009+ 9 18,5 3,5 4 4 3 + G3 n.p. n.p. n.p. n.p.  +  n.p.  +  -  + 
3008A 9 15 3 3 4 3 + G3 n.p. n.p.  +    +/-  + +  +   +  -   
4208 8 15 3 3 2 4 + G3 n.p. n.p.  +  +   + +  + n.p. n.p. 
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4408med 9 16 3 4 2 4 + G3 + -  + +   +   n.p.   + n.p.  - 
16609 7 15 2 3 3 4 + G3 - +  -  +/-  + n.p.  + n.p. n.p. 
1108 7 15 2 3 2 4 + G2 n.p. n.p.  -  -  + n.p. n.p.  - n.p. 
7209 7 15 3 2 2 4 + G3 + + n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
13009 7 14 2 2 2 4 + G3 + + n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
                  
Aggregate 
synovitis 
w/o FDC 
                 
2508 7 9 2,5 2 1,5 2 - G3 n.p. n.p. n.p. n.p.  + n.p.  +  n.p. n.p. 
1308 6 7 2 1 2 1 - G3 n.p. n.p. -  -  + n.p.  - n.p. n.p. 
3408 6 9,5 2 2,5 1 2 - G3 n.p. n.p. n.p. n.p.  +  n.p.  - n.p. n.p. 
3608-1 7 5 1,5 0 2 0,5 - G3 n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
3608new 5 14 2 2 4 4 - G2 n.p. n.p. +  +  - n.p.  + n.p. n.p. 
4908 8 9,5 2 2 0,5 3 - G3 n.p. n.p. n.p. n.p.  +  n.p.  +  n.p. n.p. 
4908 mid 8 12 2 2 2 3 - G3 n.p. n.p. +  + n.p. n.p. n.p. n.p. n.p. 
4908 new 5 12 2 2 3 2 - G2 n.p. n.p. n.p. n.p.  +  n.p.  -  n.p. n.p. 
6608 7 13,5 2 3 1,5 3 - G3 + +  +   +   + n.p.  - n.p. n.p. 
4009lat 6 14 2 3 2 4 - G3 n.p. n.p. n.p. n.p.  -  n.p. - n.p. n.p. 
5402c 4 5,5 2 0,5 1,5 1 - G2 n.p. n.p. - +  - n.p.  -  n.p. n.p. 
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7108 4 5,5 1 0,5 1 1 - G2 n.p. n.p. n.p. n.p.  - n.p.  + n.p. n.p. 
209 4 5 1 0,5 1,5 1 - G1 n.p. n.p. n.p. n.p.  -  n.p. -  n.p. n.p. 
208 6 3,5 0,5 0,5 0,5 1 - G3 n.p. n.p. n.p. n.p.  +   n.p. + n.p. n.p. 
1409 7 9 1 1 4 2 - G1 n.p. n.p.  n.p. n.p.  - n.p. n.p.  n.p. n.p. 
12609wrist 3 10 1 1 3 2 - G2 n.p. n.p. -  - n.p. n.p.  - n.p. n.p. 
3508 6 7 1 2 1 1 - G2 + + +  + n.p. n.p. n.p. n.p. n.p. 
2408 3 4 1 0,5 0.5 1 - G1 + + n.p.  n.p.  n.p. n.p. n.p. n.p. n.p. 
                  
Diffuse 
synovitis       
 
 
  
       
1909a 3 6 0 0,5 0,5 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
3208 3 7 0 2 0 2 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
4708 7 13 2 3 2 3 - diffuse n.p. n.p. n.p. n.p.  - n.p. n.p. n.p. n.p. 
4608lat 3 7,5 0,5 0 0 3 - diffuse n.p. n.p. -  +  - n.p.  - n.p. n.p. 
4608mid 5 5 1,5 0,5 0,5 1 - diffuse n.p. n.p. -  - n.p. n.p. n.p. n.p. n.p. 
20307 5 6 1 1 2 1 - diffuse n.p. n.p. n.p. n.p.  n.p. n.p. n.p. n.p. n.p. 
108 5 1 0 0 0 0,5 - diffuse n.p. n.p.  -  +  - n.p.  - n.p. n.p. 
1808b 3 2 0 0 0 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
2408 3 2,5 0 0,5 0 1 - diffuse n.p. n.p. -  +  - n.p.  - n.p. n.p. 
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3808   4 0 0 0 3 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
4108a 2 1,5 0 0 0 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
909 5 1 0 0 0 0,5 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
2009c 3 3,5 0 0 0,5 2 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
3109c 3 4 0 0,5 0,5 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
4609 med 3 5 0 1 0 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
5509lat 3 2 0 0 0,5 1 - diffuse n.p. n.p. n.p. n.p.  - n.p.  - n.p. n.p. 
1908b 3 3.5 1 0 0.5 1 - diffuse - + n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
7809 2 6 2 1 1 1 - diffuse - - n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
0808 3 4 0.5 0.5 0 1 - diffuse - + n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
3709 3 3 0 0.5 0.5 1 - diffuse - - n.p. n.p. n.p. n.p. n.p. n.p. n.p. 
 
n.p. = not performed 
+ = present 
- = absent 
+/-= present only in some areas 
 
 
99 
 
 
3.1.2 Minor Salivary glands from SS and NSCS patients 
 
Minor salivary gland samples were obtained from patients attending the 
Rheumatology/Oral Medicine Combined Sjogren’s Clinic at Barts and The 
London NHS Trust. Samples were stored at the EMR Sjogren’s tissue bank. 
Biopsy samples were obtained from 29 patients (25 women and 4men) with a 
mean age of 48.3 years (range 27-65 years) and mean disease duration of 5.9 
years (range 1-14).  All patients fulfilled the American–European Consensus 
Group. Sixteen of 29 (55%) were positive for anti-Ro/SSA and/or anti-La/SSB. 
As negative control population, 7 patients with non-specific chronic sialodenitis 
(NSCS) (6 women and 1 man) were chosen as a control group. Their mean age 
was 48.7 years (range 16-73 years), and their mean disease duration was 3.14 
years (range 1-10 years). Salivary gland biopsies were performed for routine 
diagnostic purposes after obtaining the patient’s consent (LREC 05/Q0702/1). 
Freshly collected salivary glands were part embedded in paraffin for 
immunohistochemical studies and part dissected in multiple pieces and stored 
in a 10:1 v/v of RNA Later (Ambion) at -80°C for RT-PCR analysis.  
A summary of histological, immunohistochemical and ISH finding in SS salivary 
glands as well as and clinical data of those SS patients is summarized in table 
3.2. 
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Table 3.2 Summary of histological, immunohistochemical and ISH findings in SS salivary glands and clinical data of the 
relatedSS patients 
 
 
e.c. = epithelial cells; + = present; - = absent; F= female; M= male
  Histopathological  characterization IHC ISH Clinical data 
SS samples Diagnosis CD20 CD3 CD138 CD21 LMP2A BFRF1 EBER Gender Age at presentation anti-ANA anti-Ro anti-La 
ELS+FDC+              
CC6 1° SS 2 1.5 3 + + + + F 47 + + + 
CC20 1° SS 3 2 2.5 + + + + M 50 + + + 
CC30 1° SS 3 3 3 + + + + F 55 + + - 
CC69 2° SS 3 3 3 + + + + F 62 + + - 
CC79 1° SS 2 2 2 + + + + F 28 + - - 
CC96 1° SS 3 2 2 + + + + F 61 + - - 
ELS+FDC-              
CC23 1° SS 1.5 2 2 - + <5 cells+ + F 65 + + + 
CC31 2° SS 2 1 2 - + - + F 51 + + + 
CC84 2° SS 2 2 1.5 - + <5 cells+  F 55 + - - 
CC87 2° SS 1 2 2 - + <5 cells+  F 39 + + + 
CC94 2° SS 2 2 1 - + <5 cells+ + F 61 + - - 
Diffuse              
CC88 1° SS 1 1.5 0.5 - + (e.c) - - F 39 + + - 
CC92 1° SS 1 1.5 0.5 - + (e.c) -  F 62 - + - 
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3.1.3 Collection of human tonsils 
 
Normal human tonsils were obtained from patients undergoing tonsillectomy. 
Freshly collected tonsils were embedded in paraffin for immunohistochemical 
studies or stored in a 10:1 v/v of RNA Later (Ambion) at -80°C for RT-PCR 
analysis. 
 
 
3.1.4 Tonsil from an IM patient 
 
Paraffin-embedded sections from a patient with IM were kindly provided by 
Dr. Francesca Aloisi at ISS, Rome, Italy. 
 
 
3.1.5 RA and OA serum and synovial fluid 
 
Paired sera and synovial fluid were obtained from 7 RA patients (6 females and 
1 male with mean age 54, range 42-67; mean disease duration 10.5 years, 
range 5-16). All patients attended the Rheumatology Department at Barts & 
The London School of Medicine and Dentistry, Queen Mary University of 
London and were treated with conventional DMARDs in monotherapy or in 
combination. 
As negative control population, paired sera and synovial fluid from 10 OA 
patients (5 females and 5 males with mean age 64.2, range 61-77), were kindly 
provided by Dr. Cristiano Alessandri (Policlinico Umberto I, Rome, Italy). 
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Sera from blood and synovial fluid from each patient were collected at -20°C 
until tested. 
 
 
3.1.6 Serum from SCID mice transplanted with RA synovia 
 
In this study I used the serum collected from 30 Beige SCID mice double 
transplanted with a total of 60 samples of human synovial tissue from 4 RA 
patients undergoing arthroplasty (2 with diffuse and 2 with CD21+ aggregate 
synovitis) (263). Each mouse was double-transplanted with tissue obtained 
from adjacent pieces of synovium from the same patient, thus minimizing 
variability of transplants within each mouse. Sixteen mice were transplanted 
with diffuse RA synovia EBV negative and 14 with ELS+/CD21+/EBV+RA 
synovia. 
In this model full engraftment of human tissue is reached after 7 days, and 
significant levels of circulating human ACPA antibodies are detectable from 
week 2 onwards (264). Four weeks post-transplantation animals were 
sacrificed and underwent a terminal bleed; serum was collected and stored at -
20oC for subsequent analysis of human ACPA and anti-EBV antibodies. All 
procedures were performed according to the Home Office regulations (PPL 
70/7001). 
 
 
3.1.7 Serum from SCID mice transplanted with SS salivary glands 
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In this study I used the serum collected from 8 Beige SCID mice double 
transplanted with a total of 4 salivary glands from 2 different SS patients anti-
SSA/Ro and anti-SSB/La positive. Each mouse was double-transplanted with 
tissue obtained from adjacent pieces of salivary gland from the same patient. 
Serum from mice were collected at week 1, 2, 3 and 4 and stored at -20oC until 
used. All procedures were performed according to the Home Office regulations 
(PPL 70/7001). 
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3.2 Immunohistochemistry 
 
 
3.2.1 Sample fixation and embedding 
 
Fixatives preserve cells and tissues, make the antigen insoluble and therefore 
detectable and protect the tissue against the detrimental effects of 
subsequent processing and staining procedures.  
Paraffin samples were fixed with formalin or paraformaldehyde (aldehyde-
based fixatives) for 28-48 hours prior the embedding. 
Frozen samples were fixed before the staining with cold acetone (-20°C for 10 
minutes). 
Acetone fixes the tissue by coagulating the proteins and inducing their 
denaturation. Paraformaldehyde and formalin determine the formation of 
cross links between the proteins, making them insoluble. 
 
 
3.2.1.1 Paraffin embedding 
 
Formalin fixed followed by paraffin embedding allow to fix and store material 
with good preservation of the tissue architecture and cell morphology. 
Fresh tissue was trimmed and immediately fixed in 4% paraformaldehyde 
(Appendix 1) for 24 hours at room temperature. The tissue was then fitted into 
the embedding cassettes and processed as follows: 
1) 70% Ethanol, two changes, 1 hour each 
2) 80% Ethanol, two changes, 1 hour each 
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3) 95% Ethanol, two changes, 1 hour each 
4) 100% Ethanol, two changes, 1 hour each 
5) Xylen, three changes, 1 hour each 
6) Paraffin wax (56-58 °C), two changes, 1 hour and half each. 
Finally the tissue sample was embedded into paraffin blocks and placed in a 
cold plate to set for at least 2 hours. 
Paraffin embedded samples were stored in boxes at room temperature until 
used. 
 
 
3.2.1.2 Frozen sample embedding 
 
OCT was placed on the top of a labelled small piece of cork, and the sample, 
previously trimmed, was arranged on the OCT. More OCTwas placed on the 
sample to cover completely the tissue. The cork with the embedded sample 
was then immersed within ice-cold isopentane, previously bought at its 
freezing point (-160°C), until completely frozen. The sample was then wrapped 
in aluminium foil and transferred within a falcon tube in the liquid nitrogen for 
transportation. Embedded samples were stored in -80°C freezer until used. 
 
 
3.2.2 Samples cutting 
 
 
3.2.2.1 Paraffin-embedded samples 
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Paraffin samples were placed in ice filled boxes to cold down 20 min before 
cutting. Three µm thick sequential sections were cut in a Leica Microtome 
(knowlhill, UK). The sections were then floated on a warm bath (45 °C), before 
being picked up onto microscope Superfrost Plus slides (previously labelled 
with sequential numbers) and allowed to drain on a hot plate set at 60°C. After 
30 min the slides were removed from the hot plate and stored in boxes at 
room temperature until used. 
 
 
3.2.2.2 Frozen samples 
 
Six microns sequential sections were obtained by cutting the specimens in a 
cryostat (Leyka), which is essentially a microtome inside a freezer. Each section 
was then mounted on a glass slide (superFrost Plus). Slides were allowed to dry 
overnight at room temperature and then individually wrapped in aluminium 
foil, placed in boxes and stored at -80°C until use. Each slide was allowed to 
adjust at room temperature before being unwrapped and used for 
immunohistochemistry/immunofluorescence. 
 
 
3.2.3 Slides deparaffinization and rehydration 
 
Before proceeding with the staining protocol, the slides must be first 
deparaffinized and then rehydratated in order to permeabilize the tissue 
before the staining. Notably incomplete paraffin removal can cause poor 
staining of the section.  
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Before each immunohistochemical procedure (including Haematoxylin and 
Eosin staining) the slides were treated according to the following protocol. 
Slides with paraffin sections were immerse in xylene (2 changes, 5 minutes 
each), followed by passages in 100% absolute ethanol (2 changes, 5 minutes 
each) and 70% ethanol (2 changes, 5 minutes each). Slides were then rinsed 
with distilled water for 5 minutes and placed in a jar containing Tris buffer 
saline (TBS) (Appendix 1) until used. 
Frozen slides do not need to be rehydrated before use. 
 
 
3.2.4 Haematoxylin and Eosin (H&E) staining 
 
Haematoxylin and Eosin (H&E) staining was performed in order to visualize 
cells and tissue components of the samples.  
The H&E staining, by using two different dyes, allows the visualization and 
differentiation of the cellular nuclei and cytoplasm under light microscopy. 
Haematoxylin stains the chromatin within the nucleus, with a deep blue colour, 
while Eosin stains the cytoplasmic material, connective tissue and collagen 
with a pink colour. 
Frozen or paraffin sections were immersed in Mayer’s Haematoxylin for 5 
minutes. Slides were then rinsed in tap water and placed few seconds in 1% 
Acid Alcohol (Appendix 1) to remove the excess of Haematoxylin from the 
cytoplasm, allowing Haematoxylin to stain only the nuclei. The slides were then 
washed in running tap water and immersed in Eosin for 5 minutes. Finally, the 
slides were washed in tap water, dehydrated and mounted in organic solvent 
soluble mounting medium (DePeX). 
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3.2.5 Antigen retrieving 
 
Formalin-fixed tissues requires an antigen retrieval step in order to remove 
methylene bridges (inter- and intra- molecular bridges), which cross link 
proteins and therefore mask antigenic sites. 
Generally two different methods of antigen retrieval are used; the proteolytic-
induced antigen retrieval and the heat-induced antigen retrieval. Some 
antigens prefer enzymatic to heat mediated antigen retrieval and vice versa. 
 
 
3.2.5.1 Proteolytic-induced Antigen retrieval 
 
Different enzymes can be used to break the protein cross-links formed during 
the fixation of formalin-fixed paraffin embedded samples, such as Trypsin, 
Proteinase K, Pepsin and Pronase. However, the use of enzyme digestion 
method may destroy some epitopes and tissue morphology. Therefore the 
optimal enzyme concentration and incubation time need to be tested. 
In this study I used proteinase K. Proteinase K was warmed up at 37°C (in order 
to achieve the optimal enzymatic activity) and placed on the slides for 5 
minutes. After incubation, slides were rinsed in TBS and placed in TBS until 
staining. 
 
 
3.2.5.2 Heat induced Antigen retrieval 
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Heat treatment at temperatures of 95°C in appropriate buffer solutions (citrate 
buffer pH 6 or EDTA buffer pH 9) can reconstitute the antigenicity of many 
proteins that have been rendered non-reactive during the fixation and paraffin 
embedding process.Although citrate buffers at pH 6 is historically been the 
most widely used retrieval solutions, high pH buffers have started being 
implemented for many cases showing improved end results. In this study I 
used both solutions at pH6 and pH9 (Target Retrieval Solution, DAKO, UK). 
Plastic jars with sufficient quantity of Target Retrieval Solution were placed in 
heat water bath at 95°C. After deparaffinization and rehydration, the slides 
were immersed into preheated Target Retrieval Solutions and placed either in 
the water bath at 95°C for 45 minutes or subjected to 3 cycles of 3 minutes at 
750 Watt in a microwave oven. After incubation, jars with slides were removed 
from water bath/microwave and allowed to cool down for 20 minutes at room 
temperature. After retrieving slides were rinsed in TBS and left in TBS until 
stained. 
 
 
3.2.6 Endogenous peroxidase and protein block 
 
Some cells or tissues contain endogenous peroxidase. Using HRP conjugated 
antibody may result in high, non-specific background staining. This non-specific 
background can be significantly reduced by pre-treatment of tissues with 
hydrogen peroxide prior to incubation with HRP conjugated antibody. In every 
staining procedure that required the use of 3, 3’-diaminobenzidine (DAB) as 
substrate for colour development, a peroxidase block was performed by 
incubating each slide for 20 minutes with 0.3% of hydrogen peroxidase. After 
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the blocking, slides were rinsed in TBS and left in TBS until used in following 
steps.  
Another common cause of non-specific background staining is non-
immunological binding of the specific immune sera by hydrophobic and 
electrostatic forces to certain sites within tissue sections. This form of 
background staining is usually uniform and can be reduced by blocking those 
sites with normal serum or specific solution. In this study I performed the 
protein block either incubating the slide with 20% normal serum in TBS for 30 
minutes or 10 minutes with a ready to use Protein Block Solution (DAKO, UK). 
 
 
3.2.7 Immunohistochemical detection of the antigens 
 
Immunohistochemistry allows the localization of specific antigen/s on tissue 
sections. This system is based on the recognition of a specific antigen/s by a 
conjugated (direct method) or unconjugated (indirect method) primary 
antibody. The direct method is a one-step staining method and involves a 
labelled antibody (i.e. a fluorescence dye or an enzyme such as horseradish 
peroxidase HRP or alkaline phosphatase AP) reacting directly with the antigen 
in tissue sections. This technique, using just one antibody is simple and rapid, 
but the sensitivity is low due to little signal amplification. The indirect method 
involves an unlabelled primary antibody (first layer) that binds to the target 
antigen in the tissue and a labelled secondary antibody (second layer) that 
reacts with the primary antibody. The secondary antibody can be linked to an 
enzyme or a fluorescent dye. Further amplification can be achieved if the 
secondary antibody is conjugated to several biotin molecules, which can 
recruit enzyme-linked Avidin complexes.  
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While a fluorescent dye can be detected directly using a specific fluorescence 
microscopy, the use of an enzyme-linked-antibody needs a substrate solution 
and a chromogen, that reacting with the used enzymes allows the precipitation 
of the colour (colorimetric methods) on the site of antibody-antigen binding. 
 
 
3.2.7.1 Colorimetric methods: horseradish peroxidase and alkaline 
phosphatase 
 
Colorimetric reactions most often use antibodies chemically conjugated to the 
enzymes horseradish peroxidase (HRP) or alkaline phosphatase (AP). The HRP 
reacts with diverse chromogen substrate, i.e. DAB and AEC. The DAB results in 
a brown precipitate insoluble in alcohol and other organic solvents, while AEC 
develops in an intense red product that is soluble in alcohol and therefore 
must be used with an aqueous counterstain and mounting media. 
The AP catalyses the hydrolysis of phosphate groups from a substrate molecule 
resulting in a pink or blue product.AP has optimal enzymatic activity at a basic 
pH (pH 8 - 10). Since endogenous alkaline phosphatase is diffusely expressed in 
human tissue, in order to avoid unspecific staining in the section, it is necessary 
inhibit the endogenous enzyme. In this study Vector Red (Vector Lab) was used 
as chromagen and Levamisole was used to inhibit the endogenouse activity of 
the alkaline-phosphatase. 
 
 
3.2.7.2 Staining procedures: the Avidin-Biotin complex (ABC) Methods 
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The avidin-Biotin (ABC) method is a widely used technique for 
immunhistochemical staining and is based on the strong affinity that Biotin (a 
small molecular weight vitamin) displays for Avidin (a large glycoprotein of 68 
Kd). Avidin has four binding sites for biotin providing the backbone of a 
macromolecular amplificatory complex. Avidin can be labelled with enzymes 
(HRP or AP) or fluorochromes, allowing diverse methods of detection to be 
used. A DAKO Avidin-Biotin Complex (ABC) (Appendix I) linked to HRP or AP 
was used in this study. The technique involves three layers: the first layer is 
unlabelled primary antibody, the second layer is the biotinylated secondary 
antibody and the third layer is the enzymatic HRP or AP-Avidin conjugated. The 
used enzyme is then visualised by the use of the appropriate chromogen and 
substrate. 
Since endogenous biotin is found in many tissues, it is necessary to pre-treat 
tissues with unconjugated avidin saturated with biotin, in order to inhibit the 
endogenous enzyme. For this purpose a commercially available Biotin Blocking 
System (DAKO, UK) was used. After 10 minutes of incubation with the avidin 
solution, slides were rinsed in TBS and incubated with the biotin solution for 10 
minutes. Then slides were washed and left in TBS. 
 
 
3.2.7.3 Staining procedures: Dako EnVision System Polymeric Method 
 
This system uses a secondary antibody directly linked to a dextran polymer 
binding a large number of HRP molecules. The advantages of this method are 
many including higher sensitivity as compared with the ABC method, and 
reduced number of staining layers. In details, after the first layer of 
unconjugated primary antibody, the EnVision secondary is applied on the slides 
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and after washing and application of the substrate chromogen, the colour is 
developed.  
 
 
3.2.7.4 Immunofluorescence 
 
Immunofluorescence is an antigen-antibody reaction where the antibodies are 
labelled with a fluorescent dye and the antigen-antibody complex is visualized 
using ultra-violet (fluorescent) microscope. Fluorochromes are dyes that 
absorb ultra-violet rays and emit visible light. This process is called 
fluorescence. Commonly used fluorochromes are fluorescein isothiocyanate 
(FITC) and tetramethyl rhodamine isothiocyanate (TRITC). When those 
molecules with luminescent properties absorb light, they emit light of a 
different wavelength. Fluorescent materials give off light because of their 
atomic structure. Electrons are arranged in discrete energy levels surrounding 
the atom’s nucleus with each level having a predetermined amount of energy. 
When an electron absorbs energy from a photon of light it becomes “excited” 
and jumps to a higher, less stable energy level. The excited state does not last 
long. The half-life of the excited state is generally less than 10 seconds. The 
electron loses a small amount of energy as heat and the remainder of the extra 
energy is given off in the form of a photon. The emitted fluorescence has a 
lower energy than the absorbed light, so the wavelength of the emitted light is 
longer than that of the excitation light. A range of wavelengths of light can 
excite the electrons of a fluorochrome. For example, fluorescein will fluoresce 
when hit by light with any wavelength between 450 nm and 520 nm. However, 
the closer the excitation wavelength is to 495 nm, the more fluorescence will 
be produced. This optimal wavelength is called the excitation peak. Similarly, 
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the light produced by fluorochromes has a range of wavelengths. The emission 
of light from fluorescein ranges from 490 nm to 630 nm, and the emission peak 
is approximately 515 nm (visualised in green). In this study I used secondary 
antibodies conjugated with red-emitting TRITC, green-emitting FITC, green-
emitting alexa 488 and red-emitting alexa 555. In some experiment a double 
staining was performed, using a mixture of primary antibodies raised in 
different species followed by secondary antibodies conjugated with 
fluorescent dye with a well separated emission spectra (i.e. TRITC/FITC or alexa 
488/alexa 555). The use of two different dyes permits unequivocal 
demonstration of colocalization or not of two antigens.  
In all immunofluorescence experiment nuclei were stained using DAPI (4',6 
diamidino-2-phenylindole), a fluorescentdye that strongly bind to A-T rich 
regions in DNA. When bound to double-stranded DNA DAPI has an absorption 
maximum at a wavelength of 358 nm (ultraviolet) and its emission maximum is 
at 461 nm (blue). Therefore the nuclei of tissue incubated with DAPI are 
visualised in blue. 
 
All the incubation steps were performed in a humid chamber at room 
temperature. All the washes were performed in TBS. All primary antibodies 
were unlabelled, diluted in the antibody diluent and incubated for 1h or 1h and 
half at room temperature or overnight at 4°C. All secondary antibodies, either 
biotinylated or fluorochrome-conjugated, were diluted in the DAKO antibody 
diluent (DAKO, UK) and incubated for 1 hour at room temperature. Single 
stainings were performed using either the ABC method or the Envision System 
or fluorescence dye. Double staining were performed using two different 
fluorescent dyes.  
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The protein block was performed before each immunofluorescence staining 
and additional peroxidase or biotin block was performed when using the 
Envision or ABC methods, respectively. 
Once slides had been stained, they were either mounted with aqueous 
mounting medium (when using AEC or fluorescence) or dehydrated through 
passages in alcohol and xylene and mounted in xylene soluble mounting 
medium (DePex, VWR, UK, when using peroxidase). 
 
 
3.2.7.5 Antibodies and titration experiments 
 
For primary and secondary antibodies, pilot titrations were run to determine 
the optimal working dilution and duration of incubation on positive controls. 
The optimal conditions were then used in subsequent experiments. A 
complete list of primary antibodies and secondary antibodies used in this study 
are listed in Table 3.3. 
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Table 3.3 Primary and secondary antibodies used for immunohistochemistry 
and indirect immunofluorescence 
 
-Primary antibodies- 
 
ANTIGEN 
 
 
SPECIFICITY 
 
CLONE 
 
HOST 
 
SOURCE 
 
DILUTION 
CD20 B lymphocytes L-26 Mouse Dako 1:20 
CD79a B lymphocytes Polyclonal Rabbit Abcam 1:100 
CD138 Plasma cells M115 Mouse Dako 1:50 
CD3 T lymphocytes F.7.2.38 Mouse Dako 1:50 
CD4 Helper T cell subset 4B12 Mouse Dako 1:50 
CD8 Cytotoxic/suppressor  T cell 
subset 
C8/144B Mouse Dako 1:50 
CD68 Macrophages KP1 Mouse Dako 1:50 
CD21 Follicular dendritic cells 1F8 Mouse Dako 1:30 
Granzyme B Granzyme B GB7 Mouse AbD Serotec 1:50 
CD56 Natural Killer 123-C3 Mouse AbD Serotec 1:80 
cytokeratin Epithelial cells C-11 Mouse Biolegend 1:150 
EBNA1 EBV latent protein 1H4 Mouse Kind gift of Prof. G. Niedobitek 1:20 
LMP1 EBV latent protein CS. 1-4 Mouse Dako 1:300 
LMP2A 
 
EBV latent protein 
 
15F9 Rat AbD Serotec 1:150 
4E11 Rat Ascenion, Germany 1:150 
BFRF1 EBV early lytic protein Polyclonal Rabbit Kind gift of Prof. A. Faggioni 1:700 
BMRF1 EBV early lytic protein OT14E2 Mouse Kind gift of prof. Middeldrop 
JM 
1:700 
p160 160 kDa protein of the EBV 
capsid 
OT10 Mouse Bioworld Consulting 
Laboratories, Mt. Airy, MD 
1:100 
gp350/220 350/220 kDa EBV membrane 
capsid 
72A1 Mouse Bioworld Consulting 
Laboratories 
1:100 
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-Secondary antibodies- 
 
NAME 
 
DILUTION 
 
SOURCE 
Goat anti-mouse igG (H+L)  ALEXA 488 1:300 Invitrogen 
Goat anti-mouse igG1 ALEXA 488 1:300 Invitrogen 
Goat anti-mouse igG1 ALEXA 555 1:300 Invitrogen 
Goat anti-mouse igG2a ALEXA 488 1:300 Invitrogen 
Goat anti-mouse igG2a ALEXA 555 1:300 Invitrogen 
Goat anti-mouse igG2b ALEXA 488 1:300 Invitrogen 
Goat anti-rabbit ALEXA 555 1:300 Invitrogen 
Goat anti-rat ALEXA 555 1:300 Invitrogen 
Goat anti-rat TRITC 1:150 Jackson ImmunoResearch 
Goat anti-mouse FITC 1:350 Jackson ImmunoResearch 
Goat anti-mouse biotin 1:200 Dako 
Goat anti-rat biotin 1:200 Dako 
Goat anti-rabbit biotin 1:200 Dako 
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3.2.7.6 Image capture 
 
Images from IHC and IF were captured and visualised using CellP imaging 
software on an Olympus BX61 motorised microscope with ColorView II and F 
View II digital cameras  (Olympus Microscopy, UK). Fluorescence signals were 
viewed using the U Plan APO objectives (4x/0.16na, 10x/0.40na, 20x/0.70na, 
40x/0.85na) and FITC (HQ480/40 - HQ535/50m - 510-560nm), TRITC 
(HQ535/50 - HQ610/75m - 572.5-647.5nm) and DAPI (EXD360/40 - 
EMD460/50m - 435-485nm) filter sets. Captured images were exported as TIFF 
files and adjusted using Photoshop software (Version 7.0) (Adobe Systems 
Incorporated, USA). 
 
 
3.2.8 Evaluation of the Synovitis Score and presence of lymphocytic 
aggregates in RA synovia 
 
Each RA synovia was evaluated for the synovitis score and for the presence of 
lymphocytic aggregates (table 3.1). 
To evaluate the synovitis score I followed the method described by Krenn et al 
(265).  Each paraffin-embedded 3 µm thin RA synovia section was stained with 
haematoxylin and eosin and then semi-quantitatively evaluated according to 
the synovial lining cell layer, stroma cell density and inflammatory infiltrate. 
Each parameter was evaluated on a semiquantitative scale from 0 to 3 and the 
sum was interpreted as follow: 0-1 (no synovitis); 2-4 (low grade synovitis); 5-9 
(high grade synovitis).   
To grade lymphocytic aggregates I referred to the method devised in our group 
and previously described by Manzo et al (126). In details, the number of radial 
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cells was counted in lymphocytic aggregates: between 2 and 5 cells (G1); 
between 6 and 10 cells (G2); more than 10 cells (G3). 
 
 
3.2.9 Characterization of the inflammatory infiltrates in RA synovia 
 
The histological grading of RA synovial tissues and the level of inflammation 
were assessed by immunohistochemical staining on 3 µm thick paraffin-
embedded, serial sections. Each sample was single stained for CD20 (B cells), 
CD138 (plasma cells), CD3 (T cells), CD68 (macrophages) and CD21 (FDC 
network). In details, each section was dewaxed in xylene, rehydrated through 
graded alcohol solutions and washed in TBS. For CD20, CD3, CD138 and CD68 
staining, the antigen retrieval was performed incubating each slides in Citrate 
Buffer (pH 6) for 30 minutes at 95°C and the primary antibody was incubated 
at the appropriate dilution for 1 hour at RT. For CD21 proteolytic digestion with 
Proteinase K (DAKO, UK) was used as antigen retrieval method followed by 
overnight incubation with the primary antibody at appropriate dilution.  
After exposure to the primary antibody, sections were incubated for 30 
minutes at RT with the Dako HRP-conjugated polymer (Dako, UK). After 3 
washes with TBS, colour reaction was developed using DAB substrate-
chromogen and slides were counterstained with Meyer’s haematoxylin (Sigma, 
UK) and dehydrated through graded ethanol solutions and xylene and 
mounted in DePex (BHD, UK). Negative controls included either the omission of 
the primary antibodies or isotype controls. A tonsil was routinely used as 
positive control. 
The presence of CD20, CD3, CD138 and CD68 was scored from 0 (representing 
no infiltration) to 4 (representing intense infiltration) as described by Tak et al 
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(266, 267). CD68 was scored both for the number of positive cells in the 
synovial lining layer and in the sub-lining space. CD21 was analysed in each 
sample in order to identify the presence/absence of FDC networks. 
Samples were divided in 3 different groups according to the synovial pathotype 
(table 3.1): 1) diffuse synovitis, mainly characterised by macrophage infiltration 
and by none or just few and spread B/T and plasma cells, 2) aggregate synovitis 
without FDC networks, characterised by inflammatory aggregates of B/T cells, 
variable number of plasma cells but without clear FDC networks and 3) 
aggregate synovitis with FDC networks identifying GC-like structures. 
From 9 RA patients, snap frozen synovial tissue was also available for 
immunohistochemical studies. Six-µm acetone-fixed sections were 
immunostained for CD20, CD3 and CD138 as described above without antigen 
retrieval. Samples were classified as ELS+ or ELS-/diffuse on the basis of the 
presence/absence of B cell aggregates. 
 
 
3.2.10 Characterization of the inflammatory infiltrates in SS and NSCS 
salivary glands 
 
The histological grading of the tissue and the evaluation of level of 
inflammation was assessed by immunohistochemical staining on sequentially 
cut sections from paraffin-embedded SS and NSCS salivary glands. Each sample 
was stained for CD20, CD3, CD138 and every antigen was scored from 0 to 4 by 
adapting the synovial score described above. On the basis of these stainings 
samples were classified as ELS+ or ELS- (table 3.2). All ELS+ samples were 
further stained for CD21 in order to classify samples as ELS+/FDC+ or 
ELS+/FDC- (table 3.2). 
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CD20, CD3, CD138 and CD21 staining were performed ad described in the 
previous paragraph. 
Negative controls included the omission of the primary antibodies or the use of 
Ig isotype controls.  
 
 
3.2.11 Analysis of EBV antigens expression 
 
Analysis of latent and lytic EBV proteins expression was performed on 3 µm-
thick paraffin-embedded biopsies (RA and OA synovia, SS and NSCS salivary 
glands). In details after deparaffinised, sections were placed in citrate buffer 
(pH 6.0) or EDTA buffer pH 9 and subjected to 3 cycles of 3 minutes in a 
microwave oven for antigen retrieval. Endogenous peroxidase activity was 
blocked by incubating tissues for 20 minutes in 0.3% H2O2 in TBS. To block non-
specific binding, sections were incubated with 10% normal serum matched to 
the host species of the secondary antibodies. Samples were then 
immunostained with antibodies against EBV latent (LMP1, LMP2A, EBNA1), 
early lytic (BFRF1 and BMFRF1) and late lytic (p160 and gp350/220) proteins. 
Primary antibodies were incubated overnight at +4°C (BFRF1, BMRF1 and 
EBNA1), for 1 hour (LMP1, p160 and gp350/220) or 90 min (LMP2A) at room 
temperature. For EBNA1 immunostaining, sections were permeabilized with 
0.1% Triton X100 for 10 min and 0.05% Triton X100 was added to the primary 
antibody-containing medium.  
Sections were then incubated with biotinylated secondary antibodies and 
avidin-biotin peroxidase complex (Elite Vectastain ABC kit, Vector Laboratories, 
Burlingame, CA). The final reaction was visualized with diaminobenzidine and 
sections were counterstained with Mayer’s haematoxylin. Negative controls 
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include omission of primary antibody and the use of IgG isotypes. Tonsil from a 
patient with mononucleosis was used as positive control. 
From 9 RA patients, snap frozen synovial tissue was also available for 
immunohistochemical studies. Three-µm acetone-fixed sections were 
immunostained for LMP1, LMP2A and BFRF1 as described above without 
antigen retrieval. 
 
 
3.2.12 Identification of EBV+ cells 
 
Three µm-thick, deparaffinised tissue sections (from RA and OA synovia, SS and 
NSCS salivary glands) underwent antigen retrieval with buffer citrate and 
protein block with 10% normal serum matched to the host species of the 
secondary antibodies. Sections were then incubated with the unconjugated 
primary antibodies overnight + 4°C (anti-EBV lytic antigens BMRF1 and BFRF1) 
or 1 h at room temperature (anti-B cells CD20 and CD79a; anti-plasma cells 
CD138 and anti-EBV latent antigens LMP2A and LMP1),  alone or in different 
combinations for double staining (i.e. CD20/LMP2A, CD79a/LMP1, 
CD138/BFRF1, CD138/BMRF1). Slides were then incubated with the 
corresponding fluorochrome-conjugated secondary antibodies for 1 hour and 
sealed in DAPI-containing medium (Invitrogen). Negative controls include 
omission of the primary antibodies and the use of IgG isotype control. Tonsil 
from a patient with IM was used as positive control for EBV stainings. 
From 9 RA patients, snap frozen synovial tissue was also available for 
immunofluorescence studies. Three-µm acetone-fixed sections were double 
stained for CD138/BFRF1 and CD20/LMP2A as described above without 
antigen retrieval. 
123 
 
3.2.13 Cytotoxic T cells localization and relationship with EBV+ cells 
 
The relationship between cytotoxic T cells, B cells and EBV infected cells was 
investigated by immunofluorescence using 3 µm-thick paraffin-embedded 
biopsies (from RA synovia, SS and NSCS salivary glands). Deparaffinised tissue 
sections underwent antigen retrieval with buffer citrate incubated for 30 
minutes at 95°C and protein block with Dako Protein Block Solution. Double 
stainings CD20/CD8 were performed to analyse the localization of CD8+ T cells 
respect to B cell follicles. Double stainings CD8/Granzyme B (the last a serine 
protease whose expression is restricted to cytotoxic lymphocytes), 
CD56/GranzymeB or CD4/Granzyme B were performed to identify the subset 
of cytotoxic T cells. Double staining CD8/BFRF1 or Granzyme B/BFRF1 were 
performed to identify the localization of cytotoxic T cells respect to the EBV 
lytically infected cells. Each unconjugated primary antibody was incubated 1 
hour RT, a part of BFRF1 that was incubated overnight +4°C. 
Slides were then incubated with the corresponding fluorochrome-conjugated 
secondary antibodies for 1 hour and sealed in DAPI-containing medium 
(Invitrogen). Negative controls include omission of the primary antibodies and 
the use of IgG isotype control. Tonsil from healthy donor was used as positive 
control. 
 
 
3.2.14 Quantitative cell counts 
 
Cell counts were performed in five 40X microscopic fields per section (RA 
synovia and SS and NSCS salivary glands).  
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The percentages of CD20+ B cells expressing LMP2A and of CD138+ plasma 
cells expressing BFRF1 were assessed by counting the number of double 
positive CD20+/LMP2A+ cells versus total CD20+ cells and the number of 
double positive CD138+/BFRF1+ versus total CD138+ cells.  
The absolute numbers of CD8+, CD4+ and Granzyme B+ cells were assessed by 
counting the medium number of positive cells in 5 random 40X microscopic 
fields per section. The percentages of CD8+, CD56+ and CD4+ cells co-
expressing Granzyme B were assessed by counting the number of double 
positive CD8+/Granzyme B+, CD56+/Granzyme B+ and CD4+/Granzyme B+ 
versus the total CD8+, CD56+ or CD4+ cells respectively. The percentage of 
Granzyme B+ cells co-expressing CD8, CD56 or CD4 was assessed respectively 
by counting the number of double positive CD8+/Granzyme B+, 
CD56+/Granzyme B+ and CD4+/Granzyme B+ versus the total Granzyme B+ 
cells. 
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3.3 EBER in situ hybridization (ISH) on RA, OA, NSCS and SS tissues 
 
 
3.3.1 EBER ISH 
 
In situ hybridization was performed on paraffin-embedded synovial tissue 
sections from RA and OA patients and salivary glands from SS and NSCS 
patients using the Epstein-Barr virus (EBER) PNA Probe/Fluorescein and PNA 
ISH detection Kit (DAKO), as described below. Sequential cut sections were 
stained for CD20, CD138 and CD3 in order to analyse in which lymphocytic area 
EBER+ cells localise. IHC stainings were performed as described below. 
RNA ISH is used to measure and localize transcripts within tissue sections, 
using a labelled RNA strand complementary to the target region (i.e. probe). 
Probes that hybridize to the target sequence are generally labelled with either 
radio-, fluorescent- or antigen-labelled bases (i.e. biotin, alkaline phosphatase) 
and are respectively localized and quantified in the tissue using either 
autoradiography, fluorescence microscopy or immunohistochemistry.  
To localised EBER in tissue sections of RA and SS, the PNA ISH Detection Kit 
(Dako, UK) was used. All the experimental steps were performed using RNAse-
free conditions in order to avoid RNA degradation and all the reagents used 
were contained in the kit. Briefly, 3µm thick paraffin-embedded sections were 
dewaxed in xylene, rehydrated through graded alcohol solutions and washed 
in TBS. Slides were then placed in a humid chamber and incubated for 20 
minutes with 1:10 diluted in Baxter-treated Water Proteinase K. Slides were 
then washed in RNAse-free water. In order to eliminate water, slides were 
immersed in 96% ethanol for 5 sec and then were allowed to dry at room 
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temperaturefor 5 min. The hybridization was performed adding the 
fluorescein-conjugated PNA probe and incubation was performed at 55°C for 
1½ hour. For each experiment an irrelevant probe and a probe for GAPDH 
(both from Dako) were used as internal negative and positive controls, 
respectively. 
After hybridization slides were immersed in a preheated stringent wash 
solution and incubated for 25 minutes at 55 °C with shaking. The low salt 
concentration of the stringent solution and high temperature incubation 
facilitate to remove imperfectly matched sequences and therefore increase the 
sensibility of the technique. Slides were then placed at room temperature for 
10 min allowing the cool down and washed in TBS. Slides were then incubated 
with an anti-FITC AP-conjugated antibody for 30 min at RT in a humid chamber. 
Slides were then washed in TBS, rinsed in pure water and then incubated with 
a substrate solution (5-bromo-4chloro-3indolyphosphate (BCIP)) and nitroblu 
tetrazolium (NBT) for 30 minutes or until the colour was properly developed 
(max 1 hour). The reaction develop a blue colour, in fact BCIP is oxidized by 
NBT, forming an insoluble dark blue diformazan precipitate after reduction. 
Slides were then washed in tap water for 5 min, and sealed with an aqueous 
mounting medium (Dako). 
 
 
3.3.2 EBER ISH combined to CD20 or CD138 immunohistochemistry 
 
In order to identify which cells were EBER+, paraffin-embedded samples, after 
EBER ISH, underwent the CD20 or CD138 IHC. In brief, all the ISH procedure 
described above was first performed on the tissue slides until blocking of the 
substrate with tap water. Afterwards slides were washed in TBS for 5 min and 
127 
 
incubated with TBS/0.3% H2O2 to block the endogenous peroxidase. After the 
protein block (Dako), sections were incubated with the primary antibody (CD20 
or CD138) for 1 hour at RT, then washed in TBS and incubated with a 
secondary biotinylated antibody. Sections were then incubated with the 
avidin-biotin peroxidase complex (Elite Vectastain ABC kit, Vector Laboratories, 
Burlingame, CA) and the final reaction was visualized with AEC (Dako). After 
washing in dH2O slides were sealed with the aqueous mounting medium.   
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3.4 Quantitative Taqman real-time PCR 
 
 
3.4.1 Extraction of total RNA from RA and OA synovia and SS and NSCS 
salivary glands 
 
RNA was extracted using the Quiagen RNAesy mini kit according to 
manufacturer’s instructions. Tissues stored at -80°C in RNA Later were defrost 
on ice, weighted and then cut in order to obtain approximately 20 mg of 
starting material (30 mg of tissue is the maximum amount suggested in the 
protocol to avoid reduction in RNA yield and purity).  
Tissues were placed in a sterile, RNAase-free tube and 600 µl of buffer RLT 
(containing denaturing guanidine thiocyanate and with the addition of 10 µl of 
fresh β-Mercaptoethanol/ml of RLT buffer) were added. Tissues were 
homogenised using a rotor-stator homogenizer until the sample was uniformly 
homogeneous (usually 20-40 sec). Tissue lysate were centrifuged for 3 minutes 
at maximum speed (13000 rpm) in a microcentrifuge tube. An equal volume of 
70% ethanol was added to the lysate and immediately mixed by pipetting in 
order to precipitate RNA, which remains in the aqueous phase. An aliquot (700 
µl) of the sample were added to the RNeasy mini column placed in a 2 ml 
collection tube and centrifuged for 15 s at ≥8000 x g (≥10.000 rpm) to allow the 
RNA to bind to the silica column. The flow-through was discarded and the 
remaining sample (approximately 500 µl) added to the RNeasy mini column 
and centrifuged as above. 
To avoid any possible DNA contamination, a DNase step was included 
according to manufacturer’s instruction. 350 µl of Buffer RW1 was added to 
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the column, centrifuged for 15 s at ≥8000 x g and the flow-through discarded. 
10 µl of DNAse I stock solution (previously prepared by dissolving solid DNase I 
(1500 Kunitz units) in 550 µl of RNAase-free water) were added to 70 µl of 
Buffer RDD, gently mixed and added to the RNeasy mini column silica-gel 
membrane. Following 15 min incubation at RT, 350 µl of buffer RW1 were 
added to the column, centrifuged for 15 s at ≥8000 x g and the flow-through 
discarded. 
The RNeasy columns were transferred into a new 2 ml RNAs free collection 
tube. In order to wash away contaminants (residual DNA and proteins) in the 
organic phase, 500 µl of Buffer RPE were pipetted onto the RNeasy column and 
centrifuged for 15 s at ≥8000 x g to wash the column. The flow-through was 
then discarded and another 500 µl Buffer RPE carryover the tube was 
centrifuged again for 1 min at full speed (13.000 rpm). 
For elution the RNeasy column was transferred to a new RNAase free 1.5 ml 
collection tube, and 30 µl of RNAase-free water was pipetted directly onto the 
RNeasy silica-gel membrane and the tube centrifuged for 1 min at ≥8000 x g. 
The elution was immediately frozen at -80°C until required. 
 
 
3.4.2 Quantification of total RNA 
 
Nucleic acids are traditionally quantified using UV absorption using a  
spectrophotometer. In its simplest form the absorbance is measured at 260 
and 280 nm. The concentration of nucleic acid can be determined using the 
Beer-Lambert law, which predicts a linear change in absorbance with 
concentration. An absorbance of 1 unit at 260 nm is equivalent to about 40 
µg/ml of RNA. RNA has its absorption maximum at 260 nm and the ratio of the 
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absorbance at 260 and 280 nm is used to assess the RNA purity of an RNA 
preparation. Pure RNA has an A260/A280 of 1.8-2.0. 
In this study the concentration of total RNA isolated with RNeasy Kit was 
determined by using the Nanodrop Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE). This instrument allows an exact quantification with 
the use of 1 µl of eluted RNA. 
 
 
3.4.3 Determination of RNA quality and integrity 
 
RNA integrity was assessed by resolving total RNA on a 0.8% agarose gel. 
Agarose powder, in 1x Tris Acid EDTA (TAE) buffer (Appendix II), was boiled in a 
microwave for 2 minutes, then the ethidium bromide (fluorescent dye that 
binds to nuclei acids) was added and the solution poured into a minigel tray 
where a well-comb was inserted. After polymerization, the comb was removed 
and the gel was placed in the minitank and covered with 1x TAE running buffer. 
Samples were mixed with blue loading buffer dye to monitor migration, loaded 
into the gel wells and run at 80 V (voltage) for 30 minutes. RNAs were 
visualised by fluorescence of the incorporated ethidium bromide using a UV 
light transilluminator and examined for RNA degradation and DNA 
contamination. 
RNA should demonstrate 2 bands on electrophoresis (corresponding to the 28S 
and 18S of eukaryotic ribosomal RNA), with the intensity of the 28S band being 
approximately double that of the 18S band. If the 18S band appears more 
intense than the 28S band, or a smear is present, RNA degradation is likely. 
Extra bands at high molecular weight normally indicate genomic DNA carry-
over. 
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3.4.4 Reverse Transcription PCR 
 
In Reverse-Transcription PCR (RT-PCR), mRNA is converted to complementary 
DNA (cDNA) using a reverse transcriptase before being amplified. RNA was 
reverse transcribed to cDNA using the Thermoscript RT-PCR System for First-
Strand cDNA Syntesis (Invitrogen). One µg of extracted total RNA from each 
sample was mixed with 1 µl of Oligo(dT)20 Primers (50 µM) or Random 
Hexamers (50 ng/mL) and 2 µl of 10 mM dNTP mix and brought to a 12 µl 
volume reaction with DEPC-treated water in a 0.5 ml PCR tube. After brief 
spinning down in a microcentrifuge, samples were incubated for 5 min at 65°C 
to denature RNA tertiary structure and samples were immediately cooled on 
ice to allow RNA and oligos to anneal. For the final reaction, 8 µl of a master 
mix containing 1 µl of ThermoscriptTM RT (15 U/µl), 1 µl of 0.1 M DTT, 1 µl of 
RNAsiOUTTM Ribonuclease Inhibitor (40 U/µl), 1 µl of DEPC-treated water and 4 
µl of 5X cDNA synthesis buffer were added. After mixing and a brief spin down 
of the tubes, the reverse transcription to cDNA was run in a PCR machine 
(Applied Biosystems 9700) for 1 hour at 50°C and the reverse transcriptase was 
inactivated at 85°C for 5 min. In order to remove the original RNA that could 
interfere with the quantitative real-time PCR analysis, RNA digestion was 
performed using 1 µl of E. coli RNasi H (2 units/µl) at 37 °C for 20 min. Finally, 
the completed cDNA strand was diluted to a final concentration of 10 ng/µl 
with DEPC-treated water and stored until used. 
 
 
3.4.5 Quantitative Taqman real-time PCR 
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PCR involves amplification of a specific DNA sequence, which spans between 
two sequences of primers. Real-time PCR monitors the fluorescence emitted 
during the reaction as an indicator of amplicon production during each cycle 
(in real time) as opposed to the endpoint detection by conventional 
quantitative PCR methods: it is based on the detection and quantitation of a 
fluorescent reporter whose signal increases in direct proportion to the amount 
of PCR product in reaction. 
For quantitative Taqman real-time evaluation of mRNA expression levels of 
genes, sequence-specific primers and probes from Applied Biosystems were 
used. Each gene expression assay contains, together with the forward and 
reverse primers, a Taqman MGB probe with a FAM reporter dye at the 5’ end. 
Within the probe, the dye is linked to a non-fluorescent quencher; during the 
polymerase reaction, the probe is detached from the cDNA and the quencher 
is released allowing fluorescence emission from the reporter dye. 
The real-time PCR were run in triplicate on 384-well PCR plates (Applied 
Biosystem) with an equal loading of 10 ng of cDNA/well and detected using the 
ABI PRISM 7900HT Instrument. The thermal cycling condition used comprised a 
2 min UNG activation step at 50°C, a 95°C Taq polymerase enzyme activation 
step for 10 min and cycles of 95°C denaturation for 15 sec and 60°C 
annealing/extension for 1 min. Results were then analysed after 40 cycles of 
amplification using the ABI PRISM 7900HT Sequence Detection System Version 
2.3 (SDS 2.3). cDNA from normal human lymph nodes was used as calibrator. 
Relative quantification was measured using the comparative Ct (Threshold 
Cycle) method. As endogenous control, 18S was used to normalise for the 
cDNA of each sample. The ΔCt for each of the triplicates were calculated. 
When a single value within each triplicate differed substantially from the other 
two values the skewed value was excluded from the analysis. To calculate 
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ΔΔCt, the ΔCt of each sample was subtracted to the chosen reference sample 
(usually a synovia from an OA patient or a salivary gland from a NSCS patient). 
The relative quantity was then calculated following the equation RQ=2˄- ΔΔCt 
where 2 represents doubling of the amount of the product of amplification 
after each PCR cycle. In order to assess the efficiency of the real-time PCR for 
each gene, a standard curve was prepared by serial 2˄5 dilutions (i.e. 1:1, 1:32 
and 1:1024) of the cDNA from a positive control tissue (tonsil). Optimal PCR 
efficiency must have a difference of 5 Ct between each dilution.  
 
 
3.4.6 Quantitative Taqman real-time evaluation of gene expression in SS 
salivary glands and RA synovia 
 
Total RNA was extracted from RA and OA synovia and SS and NSCS salivary 
glands using the Quiagen RNeasy Mini Kit (Quiagen) and reverse transcribed to 
cDNA using Thermoscript Kit (Invitrogen) as described above. 
The following target genes were evaluated: CXCL13, AID and Blimp-1 in the 
salivary glands and CXCR13 and AID in the synovial tissue. CXCL13 was chosen 
as previous work from my group demonstrated that the expression of this 
lymphoid chemokine in the target tissue closely segregates with the presence 
of ELS. Similarly, AID was shown to be a sensitive and specific marker of 
functional ectopic GC-like structures. Finally, Blimp-1 is a transcription factor 
specifically expressed in plasma cells and was thus used as a marker of plasma 
cell infiltration within the tissues.  
All primers and probes were obtained from Applied Biosystem and the 
complete list is reported in table 3.4. Samples were run in triplicate at 10 ng of 
cDNA/well, detected using the ABI PRISM 7900HT Instrument and results 
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analysed using the ABI PRISM 7900HT Sequence Detection System Version 2.1. 
Relative quantification was assessed using the Comparative Ct Method 
calculated as described above. Mammalian 18S or human β-actin were used as 
endogenous control to normalize for the cDNA of each sample. cDNA from a 
tonsil was used as a positive control. 
 
 
3.4.7 Pre-amplification of specific genes and quantitative PCR 
 
Analysis of EBV genes (EBER, LMP2A, and EBNA1) was performed by 
quantitative real-time RT-PCR after the selective pre-amplification of target 
genes. In addition to viral genes, GAPDH as housekeeping gene and CD19 as 
control for the presence of infiltrating B cells were also analysed after selective 
pre-amplification. 
The pre-amplification step increase the quantity of the desired cDNA targets 
for gene expression, helping to avoid false negative results while analysing low 
expressed genes. Since EBV-infected B cells likely represent a small fraction of 
the total RNA extracted from the resident and inflammatory cell populations 
within synovia/salivary glands, it should be suspected that detectability of viral 
nucleic acids in whole synovia/salivary glands tissue might be well below the 
sensitivity of conventional real-time PCR techniques. Thus, cDNAs were pre-
amplified as previously described (268) using the PreAMP Master Mix Kit 
(Applied Biosystems) according to manufacturers’ instructions. Each 
preamplification reaction was prepared in a 0.2 ml tube mixing 25 µl of 
TaqMan PreAmp MasterMix (2✕), a mix of 90 nM forward and reverse primers 
and 120 ng cDNA in a final volume of 50 µl.  
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After mixing, samples were run in a PCR machine (Applied Biosystem 9700) for 
10 cycles by using the following thermal cycling conditions: 10 min at 95°C for 
15 sec and 60°C for 4 minutes. 
Preamplification products were diluted 1:5 in DNase-free H2O and analysed in 
duplicates by quantitative PCR assays using the ABI PRISM 7900HT machine 
(Applied Biosystems). Each PCR reaction was prepared in a final volume of 10 
l containing 2 l of pre-amplified cDNA in the presence of 5µM primers’ mix, 
hot-start DNA polymerase (Quiagen), 0.1X SYBR green (Sigma-Aldrich) and 0.2X 
ROX dye (Invitrogen). The thermal cycling conditions used were: 2 minutes at 
50°C to activate the UDG enzyme, 15 minutes at 96°C, 40 cycles at 96°C for 15 
sec and 60°C for 1 minute. 
 
 
3.4.8 Quantitative real-time evaluation of gene expression after selective 
preamplification in RA synovia and SS salivary glands 
 
RNA extracted from RA and OA synovia was pre-amplified and then analysed 
by quantitative RT-PCR assays as described above. The following target genes 
were evaluated: CD19, LMP2A, EBNA1, EBER, and GAPDH. The primers used 
were designed and previously tested in the laboratory of Dr. Eliana Coccia (ISS, 
Rome, Italy) and primers sequences are listed in table 3.4. PCR products 
derived from cDNA of EBV+ P3HR-1 cells and human primary B cells were 
included in each run as positive controls for EBV and CD19 gene expression 
respectively, together with a negative control (positive control in the absence 
of RT enzyme). Values were normalized to GAPDH and calculated using the 2-
ΔCt formula. The experiments in RA and OA tissues were performed during my 
stay in the laboratory of Dr. Eliana Coccia, ISS, Rome, Italy. 
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Conversely, detection of the same target genes in the salivary glands of SS and 
NSCS were performed in the EMR lab using the same technique and primers. 
RNA extracted from SS and NSCS salivary glands was pre-amplified and then 
analysed by quantitative RT-PCR assays as described above. The following 
target genes were evaluated: CD19, EBER1 and GAPDH. cDNA from HRCS57 
and Ramos cells line (a king gift of Dr. Emanuela Carlotti, Institute of cancer, 
QMUL) was used as a positive and negative control for EBV, respectively. cDNA 
from tonsil was used as positive control for CD19 expression.  
Relative quantification was assessed using the Comparative Ct Method 
calculated as described above. 
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Table 3.4 Primers used in real-time RT-PCR 
 
-From Applied Biosystem- 
Gene product RefSeq Gene Expression Assay  ID 
AID NM_020661 Hs00221068_m1 
CXCR13 NM_006410.1 Hs00757930_m1 
BLIMP NM_001198.3 Hs00153357_m1 
Human 18S XO3205.1 Hs99999901_s1 
Human β-actin NM_001101 Hs99999903_m1 
 
-Designed primers- 
Gene Forward primer Reverse primer 
LMP1 5’-CCC TTT GTA TAC TCC TAC TGA TGA TCA C-3’ 5’-ACC GAA GAT GAA CAG CAC  AAT-3’ 
LMP2A 5’-TTC TGG CTC TTC TGG GAA CA-3’ 5’-ATT GCC CCA ATC TGA GTC CT-3’ 
EBNA1 5’-GGA GCC TGA CCT GTG ATC GT-3’ 5`- TAG GCC ATT TCC AGG TCC TGT A-3’ 
CD19 5’-AGA ACC AGT ACG GGA ACG TG-3’ 5’-CTG CTC GGG TTT CCA TAA GA-3’ 
GAPDH 5’-ACA GTC CAT GCC ATC ACT GCC-3’ 5’-GCC TGC TTC ACC ACC TTC TTG-3’ 
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3.5 Identification of autoreactive plasma cells in RA synovia and 
SS salivary glands 
 
 
Autoreactive plasmacells can be identified on a tissue-section using a 
biotinylated self-antigen against which the plasma cells produce antibodies. 
The binding of the biotynilated antigen can be visualised either by IHC (using 
the Elite Vectastain ABC kit or the Dako EnVision System Polymeric Method) or 
by IF (using a fluorochrome-conjugated Streptavidin). In order to identify the 
autoreactive plasma cells in RA and SS tissues, double IF using a biotinylated 
antigen known to be associated with RA or SS was performed. After incubation 
of the biotinylated antigen, a fluorochrome-conjugated streptavidin was added 
and followed by incubation with an anti-CD138 antibody as marker of plasma 
cells. In this study biotinylated citrullinated fibrinogen or biotinylated Ro 52-Kd 
and La 48-Kd were used to identify the autoreactive plasma cells in RA synovia 
and SS salivary glands respectively. 
 
 
3.5.1 Identification of anti-citrullinated protein/peptide antibodies (ACPA)-
producing cells in RA synovia 
 
In order to identify the autoreactive plasma cells producing anti-citrullinated 
protein antibodies (ACPA) in the RA synovia we used a citrullinated 
biotinylated fibrinogen (CFb) using an in vitro method previously optimised by 
Dr M. Bombardieri at EMR (85). Plasminogen-depleted human Fb (Calbiochem: 
EMD BioSciences) was incubated at 0.86 mg/ml with 10 U/ml of rabbit skeletal 
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muscle peptidyl arginine deiminase (Sigma-Aldrich) in 0.1 M Tris-HCl (pH 7.4) 
(Appendix I), 10 mM CaCl2, and 5 mM DTT for 2 h at 50 °C. The enzyme was 
inactivated by adding 2% SDS and heating at 100 °C for 3 min and removed by 
serial spinning and washing with 0.01 M sterile bicarbonate buffer in a 100 kDa 
Amicon filter device (Millipore). CFb was then biotinylated using NHS-LC biotin 
(Pierce Biotechnology). In addition, an aliquot of unmodified Fb of the same 
concentration as the CFb was biotinylated to be used as a negative control. 
To detect and localize ACPA-producing cellsand study their relationship with 
EBV infection I used high-inflamed and EBV+ paraffin-embedded RA synovial 
tissue from ACPA+ RA patients. Three µm-thick, deparaffinised tissue sections 
underwent antigen retrieval with buffer citrate and protein block with the 
Dako Protein Block Solution. Sections were then incubated with the 
unconjugated primary antibodies (CD20, CD138 or BFRF1) followed by 
incubation with the specific secondary antibodies conjugated with ALEXA-488 
or -555. Biotinylated CFb was then added at 1:20 dilution, incubated for 1h and 
followed by incubation with streptavidin ALEXA-488 or -555. Sections were 
counterstained with DAPI. Biotinylated, unmodified fibrinogen was used as 
negative control for CFb. 
 
 
3.5.2 Analysis of anti-Ro 52-Kd and anti-La 48-Kd antibodies-producing cells 
in SS salivary glands by IHC 
 
Paraffin-embedded ELS+ and EBV+ SS salivary glands from Ro52/SSA+ and 
La/SSB+ SS patients were stained using the biotinylated Ro 52-Kd and La 48-Kd 
(a kind gift of Prof. Roland Jonsson at University of Bergen, Norway).  
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Three µm-thick, deparaffinised tissue sections underwent antigen retrieval 
with buffer citrate and endogenous peroxidase, avidin, and biotin activity was 
blocked as described above. After the protein block with the Dako Protein 
Block Solution, sections were incubated with the biotinylated Ro 52-Kd or La 
48-Kd (both diluted 1:20) for 1 hour RT, followed by incubation of biotinylated 
secondary antibodies and avidin-biotin peroxidase complex (Elite Vectastain 
ABC kit, Vector Laboratories, Burlingame, CA). The final reaction was visualized 
with diaminobenzidine and sections were counterstained with Mayer’s 
haematoxylin. 
For the identification of anti-Ro52 and/or anti La 48-Kd producing cells, 3 µm-
thick, deparaffinised tissue sections underwent antigen retrieval with buffer 
citrate and protein block with the Dako Protein Block Solution. Sections were 
then incubated with the unconjugated primary antibodies (CD20, CD138 or 
BFRF1) followed by incubation with the specific secondary antibodies 
conjugated with ALEXA-488 or -555. Biotinylated Ro 52-Kd or La 48-Kd  were 
then added at 1:20 dilution, incubated for 1h and followed by incubation with 
streptavidin ALEXA-488 or -555. Sections were counterstained with DAPI. 
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3.6 Serological studies 
 
 
3.6.1 Detection of ACPA (anti-CCP) antibodies 
 
ACPA were detected in both RA and OA sera and synovial fluid (diluted 1:100) 
and in sera of SCID mice transplanted with RA synovium (diluted 1:10) using a 
commercially available anti-cyclic-citrullinated antibody (anti-CCP2) ELISA kit 
(Axis Shield), following the manufacturer's instructions. Results are expressed 
as optical density (OD).  
 
 
3.6.2 Anti-unmodified EBV antibodies 
 
Human IgG antibodies against recombinant unmodified VCA, EBNA1 and EA 
were detected using commercially available ELISA kits (Serion, Würzburg, 
Germany), following the manufacturer’s instructions. All 3 antibodies were 
screenedin RA sera and synovial fluid (diluted 1:100) and in mouse sera 
(diluted 1:10). OA sera and synovial fluid (diluted 1:100) were screened only 
for anti-EBNA1 antibodies.All results are expressed as optical density (OD). The 
cut-off was calculated as described in the kits. 
 
 
3.6.3 Anti-citrullinated EBV antigens antibodies 
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All SCID mice sera found anti-CCP+ were further screened for the presence of 
anti-viral citrullinated peptide antibodies VCP1 or VCP2 by ELISA. This set of 
experiments was performed in the laboratory of Dr. Paola Migliorini (University 
of Pisa, Italy). Briefly, 10 µg/ml VCP1 or VCP2 was added to polystyrene plates 
(Nunc MaxiSorp F96; Nunc, Roskilde, Denmark) in PBS and incubated overnight 
at 4°C. Saturation was carried out with PBS containing 3% bovine serum 
albumin (BSA) for 45 min at room temperature. Sera diluted 1:50 in PBS 
containing 1% BSA and 0·05% Tween 20 were then incubated in duplicate for 
3h at RT. After washing with PBS 1% Tween and PBS, alkaline phosphatase 
conjugated anti-human IgG (Sigma-Aldrich, St Louis,MO, USA) was added and 
incubated for 2 h at RT. Alkaline phosphatase activity was revealed with p-
nitrophenyl phosphate in 50 mm Na2CO3 (pH 9·6). All results are expressed as 
optical density (OD). 
 
 
3.6.4 Anti-SSA/Ro and anti-SSB/La antibodies 
 
Anti-SSA/Ro and anti-SSB/La antibodies of IgG isotype were measured in mice 
serum (diluted 1:10) by commercial ELISA Kit (Euro Diagnostica). Cut-off was 
calculated as described in the Kits. Results are expressed as U/mL. 
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3.7 Statistical analysis 
 
Differences in quantitative variables were analysed by Mann Whitney U-test or 
Kruskal-Wallis with Dunn’s post-test when comparing two or multiple groups, 
respectively. Fisher’s exact test was used to evaluate associations of qualitative 
variables. All statistical analyses were performed using GraphPad Prism version 
3.03 (GraphPad Software, San Diego Ca, USA). A p value <0.05 was considered 
statistically significant. 
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CHAPTER 4 RESULTS 
Detection of EBV in RA synovia 
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In my PhD project, I first aimed to clarify the long-standing issue whether EBV 
protein and nucleic acids are expressed in the RA synovia, performing a 
comprehensive analysis of EBV antigens/RNA expression using different 
techniques (i.e. RT-PCR, ISH, IHC and IF) in a large cohort of RA patients.  
Importantly, each RA synovia was also analysed for the level of inflammation 
and the presence of ELS by IHC and/or RT-PCR. This is extremely relevant as RA 
synovitis is a highly heterogeneous inflammatory process in terms of degree of 
inflammation as well as lymphoid organization, and novel as no one so far 
attempted to correlate EBV presence with either the level of immune cell 
infiltration or the presence of GC-like structures. The latter is of pivotal 
important as it was recently suggested that ELS are preferential niches of EBV 
persistence and reactivation in chronic autoimmune diseases (72, 73).  
 
 
4.1 Histological characterization of RA synovial samples 
 
Fifty paraffin-embedded synovial tissue samples from 43 RA patients were first 
analysed for the global inflammation and synovitis scores determined as 
described in materials and methods. On the basis of the synovitis score, 2 RA 
synovia were classified with no synovitis (score 0-3), 18 with low-grade 
synovitis (4-6) and 30 with high-grade synovitis (7-9). Each sample was first 
analysed for the presence and size of lymphocytic aggregates (G1, G2, G3) 
using H&E staining as described in materials and methods.  Furthermore, in 
order to better characterise the degree of cellularity, the predominant 
infiltrating cell subsets and the presence of ELS, each sample was stained in 
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sequential sections, for CD20, CD3, CD138, CD68, and CD21 and the presence 
of each antigen was scored as described in materials and methodsand as 
shown in Fig 4.1. On this basis RA samples were further classified as follow; 12 
displayed perivascular synovitis with large B-cell aggregates containing CD21+ 
FDC networks (ectopic GC) and the typical segregation of B and T cell areas, 18 
showed B-cell enriched lymphocytic aggregates without FDC networks (these 2 
groups were collectively classified as ELS+), and 20 were characterised by 
diffuse synovitis with sparse or no B cells and dominant macrophage 
infiltration (Fig 4.2).  
Additionally, CD138+ plasma cells were significantly more abundant in ELS+ 
synovia compared to diffuse synovitis. Of relevance, while plasma cells mostly 
localized at the periphery of ectopic B-cell follicles suggesting local 
differentiation in ELS+ samples, they displayed prevalent perivascular 
accumulation in samples with diffuse synovitis, rather suggesting recent 
migration from the peripheral compartment.  
In order to enrich the variety of material used in this study (i.e. some EBV 
antigens cannot be detected on paraffin samples), we also characterised the 
level of inflammation in 9 RA synovial snap-frozen samples staining for CD20, 
CD3 and CD138. On the basis of the stainings 4 RA synovia were characterised 
as ELS+ and 5 as samples with diffuse inflammation devoid of B-cell aggregates. 
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Figure 4.1 
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CD68 sub-lining 
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Figure 4.1 RA synovitis score  
The atlas shows representative stainings of each antigen for each score. Each 
antigen was scored from 0 (no positive cells) to 4 according to the number of 
stained cells. CD68 scoring was analysed separately for the lining and sub-lining 
compartments.Bars: 50 µm in all panels. 
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Figure 4.2 
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Figure 4.2 Classification of RA synovial samples according to their synovial 
pathotype 
RA synovial sections were immunostained for CD20 (B cells), CD3 (T cells), 
CD138 (plasma cells), CD68 (macrophages) and CD21 (follicular dendritic cells) 
and classified as; i) ELS- with diffuse inflammation, mainly characterised by 
macrophage infiltration, with sparse or no B and plasma cells and negative for 
CD21. ii) ELS+ without FDC, characterised by variable number and dimension of 
B/T cell aggregates with surrounding plasma cells, variable macrophage 
infiltration but negative staining for CD21. iii) ELS+ with FDC networks 
characterised by numerous and large B/T cell aggregates with surrounding 
plasma cells, variable macrophages infiltration and positive for CD21. An 
example of each pathotype is shown.Bars: 50 µm in all panels. 
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4.2 EBV latent antigens are expressed by B cells and are strictly 
associated with ELS formation in the RA synovia 
 
Among the paraffin-embedded RA synovial samples characterised for the level 
of inflammation and presence of GC-like structures, 38 were selected for the 
IHC screening of EBV latent antigens (LMP1 and LMP2A) in single staining and 
in double immunofluorescence with B-cell specific marker (CD20 and CD79a) in 
order to identify whether infiltrating B cells express EBV latent antigens in the 
RA synovia. 11 OA were selected as disease control.The specificity of all anti-
EBV antibodies used in this study was previously tested in EBV+ and EBV- 
tissues and cell lines (72, 73). However, positive and negative control tissues 
were included in all cases. 
LMP2A expression was at first analysed by single IHC or IF in combination with 
single staining for CD20, CD3, CD138 and CD21 in sequential sections (Fig 4.3 
A-G). LMP2A expression mostly localised in the B cell area of B cell-follicles. By 
double IF for CD20/LMP2A (Fig 4.3 H) I could confirm that LMP2A was mainly 
expressed by B cells inside B cell aggregates. Rarely did I observe few LMP2A+ 
/CD20- cells, which were identified as plasma cells on the basis of their 
morphology (Fig 4.3 I). Quantitative analysis demonstrated that LMP2A was 
expressed inside B-cell aggregates in all RA synovial samples with ectopic GC (n 
= 10) and 7 out of 14 samples containing B-cell aggregates without FDC (Fig 4.3 
table). The percentage of CD20+ B cells expressing LMP2A varied among 
different B-cell aggregates, ranging from 8.2% to 54.7% (mean+SD, 
19.3+12.8%). Outside B-cell aggregates, a very small proportion of CD20+ B 
cells (3+6%) co-expressed LMP2A. All 14 RA samples containing diffuse 
immune infiltrates and sparse B cells were negative for LMP2A (Fig 4.3 J and 
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table). All OA sections stained as a negative control tissue also did not express 
LMP2A (Fig 4.3. K).  
In selected RA synovial samples with ectopic GC (n=4) I also performed 
immunostaining for LMP1, another viral membrane protein expressed during 
the growth and default programs of EBV latency (2). Similarly to LMP2A, LMP1 
immunoreactivity was mainly present inside B-cell aggregates. Double stainings 
for LMP1 and the B-cell marker CD79a confirmed that LMP1 was expressed in 
B cells (Fig. 4.3 L). 
I also analysed 9 snap-frozen samples for LMP2A and LMP1 expression by 
immunofluorescence. LMP2A was further analysed in double IF with CD20. As 
expected and as observed with paraffin-embedded RA synovia, the latent 
antigens of EBV were mostly expressed by B cells within B cell follicles of ELS+ 
RA synovia and virtually absent in RA synovia characterised by diffuse/no B cell 
inflammation. 
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Figure 4.3 
 
 
 
 
RA synovia  N LMP2A+ 
ELS+ FDC+ 10 100% 
ELS+ FDC- 14 50% 
diffuse 14 0% 
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Figure 4.3 Detection of the EBV latency proteins LMP2A and LMP1 in RA 
synovia 
Almost sequential RA synovial sections, stained in bright field for LMP2A and 
CD20, show LMP2A+ cells co-localising in the B cell area of B cell aggregates (A-
B). Sequential cut RA synovia sections stained for LMP2A in IF and for CD20, 
CD3, CD138 and CD21 in IF/IHC show that LMP2A expression co-localised in the 
B cell area of a GC-like structure characterised by B/T cell segregation, 
surrounding plasma cells and an FDC networks (C-G). Double IF CD20/LMP2A 
demonstrate that LMP2A is expressed by B cell of a B-cell follicle (H) and the 
inset in H highlight the typical membrane localization of LMP2A. RA synovia 
showing few LMP2A+/CD20- cells, identified as plasma blast on the basis of 
their morphology (I). RA synovia characterised by diffuse B cell infiltration and 
LMP2A negative (J). OA synovia LMP2A negative (K). Double IF CD20/LMP1 
show that LMP1 is expressed by B cells within a B cell follicle (L) and in the 
inset is highlighted the typical membrane localization of LMP1.  
The table shows the percentage of ELS+/FDC+, ELS+/FDC- and diffuse RA 
synovia LMP2A+.Bars: 50 µm in A,B, E, G, K; 10 µm in C, D, F, H, I, J,L. 
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4.3 EBER is mostly expressed by B cells in RA synovia and is 
positively associated with ELS formation 
 
Next I sought to visualize EBV infected cells using in situ hybridization for EBER, 
the gold standard technique for EBV detection in pathological tissues (269). 
Paraffin synovial samples from 19 RA patients (15 with aggregate and 4 with 
diffuse synovitis) and 8 OA cases were analysed. To check for RNA integrity, 
GAPDH ISH was performed. Fifteen of 19 RA synovial samples and all OA 
synovial samples displayed a suitable GAPDH signal (Fig 4.4 A). In sections of a 
tonsil from a case with infectious mononucleosis, which was used as positive 
control tissue, EBER signals were present at a very high frequency and were 
localized mainly outside B-cell follicles (Fig. 4.4 B). None of the 5 GAPDH- RA 
samples was EBER+ while 10 of the 15 GAPDH+ RA samples displayed EBER 
signals. Among the latter, the highest frequency of EBER+ cells was detected in 
those containing ELS with ectopic GC and FDC networks (6 EBER+ samples out 
of 7 analysed) (Fig 4.4 table). Analysis of RA ELS+ samples immunostained for 
CD20 in combination with EBER ISH revealed that EBER was expressed by B 
cells inside B cell-follicles as well as CD20- cells localising at the border of the 
follicles (Fig 4.4 C). It should be noted that the double staining CD20/EBER did 
not give a clear EBER signal, probably because the strong CD20 signal in dark 
red cover the blue EBER staining, especially within B cell follicles where many 
positive CD20 cells accumulate. I therefore preferred to analyse EBER 
localization in sequential sections. Immunostaining of adjacent sections for 
CD20, CD138, CD3 and EBER showed that EBER+ cells were located both inside 
and at the border of intrasynovial B-cell follicles (Fig. 4.4 D-G), around T-cell 
areas (Fig. 4.4 H, I) and in B-cell-rich perivascular aggregates (Fig. 4.4 J, K).  
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In RA samples with less organised B-cell aggregates (without FDC), fewer and 
mainly scattered EBER+ cells were detected in 4 out of 5 biopsies (Fig 4.4 L, M). 
Conversely, no EBER+ cells were detected in samples with diffuse synovitis 
(N=3), which generally lacked a substantial B-cell infiltrate (Fig 4.4 N). EBER 
signals had the expected nuclear localization in the large majority of EBV 
infected cells (Fig. 4.4 inset in M). No signal was detected in RA synovia using a 
non-specific probe (Fig. 4.4 O). EBER signals were not detected in any of the 8 
OA specimens analysed despite presence of infiltrating B cells and plasma cells 
in some samples (Fig. 4.4 P). 
In summary, the above experiments demonstrated the presence of EBV latency 
transcripts and virally infected cells in RA synovial samples characterized by 
well-preserved RNA and aggregated B-cell infiltrates, the highest frequency of 
EBER+ cells being associated with ectopic GC. 
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Figure 4.4 
 
 
 
 
 
 
 
RA synovia N EBER+ 
ELS+ FDC+ 7 86% 
ELS+ FDC- 5 80% 
diffuse 3 0% 
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Figure 4.4 Detection of EBER+ cells by ISH in the RA synovia 
GAPDH ISH on an ELS+ RA synovia shows a good RNA preservation (A). EBER 
ISH in a tonsil from a patient with infectious mononucleosis (B). RA synovial 
sample ELS+ immunostained for CD20 in combination with EBER ISH show 
several EBER+ cells inside and at the border of a B-cell aggregate. The EBER 
signal is mostly covered by the strong CD20 staining (C).CD20 immunostaining 
(D) and EBER ISH (E) in serial sections of a RA synovia with ectopic B-cell 
follicles show a high frequency of EBER+ cells both inside and at the border of 
B-cell follicles. EBER ISH (F) and CD138 immunostaining (G) performed in serial 
sections reveal a high frequency of EBER+ cells in an area enriched in plasma 
cells. CD3 immunostaining (H) and EBER ISH (I) performed in serial sections of a 
RA synovium with aggregate synovitis reveal that EBER+ cells accumulate 
around a T-cell aggregate (marked with an asterisk) which is EBER negative.  
Perivascular accumulation of CD20+ (J) and EBER+ (K) cells in serial sections of 
a RA synovia with lymphocytic aggregates. Presence of scattered CD20+ cells 
(L) and EBER+ cells (M) in an area of diffuse immune infiltration in a RA 
synovium with B-cell infiltration but without FDC. The typical nuclear 
localization of EBER+ cells (inset in M). Absence of EBER+ cells in a RA synovia 
characterised by diffuse infiltration (N). Negative control performed by ISH 
using a no sense probe on a RA synovia ELS+ (O). OA synovial samples 
immunostained for CD20 in combination with EBER ISH show some CD20+ cells 
EBER negative (P). 
The table shows the percentage of ELS+/FDC+, ELS+/FDC- and diffuse RA 
synovia EBER+. Bars: 10 µm in A, C, E-G, I-M, P; 50 µm in B, D, H, N, O 
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4.4 The presence of EBV latent transcripts is associated with the 
level of AID, CD19 and CXCL13 gene expression in RA synovia 
 
 
Search for EBV transcripts in RNA later-preserved RA synovial samples was 
performed using a highly sensitive and specific quantitative real time RT-PCR 
including a cDNA pre-amplification step that selectively enriches for the genes 
of interest (268). Thirteen RA synovial samples with optimal RNA quality were 
selected for this set of experiments. Of these, 9 samples were classified as ELS+ 
aggregate synovitis based on histological and immunohistochemical 
characterization, presence of AID RNA and higher frequency of CXCL13 and 
CD19 transcripts, and 4 samples were classified as diffuse synovitis, being 
devoid of lymphocytic aggregates, a detectable AID signal and substantial 
CXCL13 and CD19 gene expression (Fig. 4.5 A, B). Four synovial tissues from 
patients with established osteoarthritis (OA) were used as control. 
Three genes expressed during EBV latent infection (EBNA1, LMP2A, and EBER1) 
were analysed. The frequency of CXCL13, CD19, EBER1 and LMP2A transcripts 
was found to be significantly higher in RA samples with ELS than in those with 
diffuse synovitis (Fig. 4.5 A-D).  EBNA1 transcripts were not detected. The 4 OA 
samples were negative for CXCL13 and all EBV transcripts and CD19 was 
detected only in the most inflamed OA case (Fig. 1 A-D). These findings further 
confirm at mRNA level the association between the degree of B-cell infiltration, 
lymphoid organization and EBV infection in the RA synovium. 
 
 
 
  
160 
 
Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Detection of EBV transcripts in the RA synovia 
Quantitative real-time RT-PCR reveals a higher expression of the CXCL13 gene 
in ELS+/AID+ RA synovia compared to diffuse/AID- RA synovia or OA synovia 
(A). Pre-amplification of selected genes followed by real time RT-PCR shows 
that CD19 (B), EBER (C) and LMP2A (D) gene expression is significantly higher in 
ELS+AID+ than in diffuse/AID- RA samples. A low level of CD19 mRNA, but no 
latent viral transcripts, can be detected in OA synovia.  
*p<0.05, ** p<0.01 
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4.5 EBV reactivation occurs in plasma cells and is associated with 
ELS formation in the RA synovia 
 
 
To investigate whether EBV also reactivate in the RA synovia, I first stained 34 
RA synovial samples for BFRF1, an antigen associated with the early phase of 
the viral lytic cycle (270). In details, I performed both IHC staining on 
sequential sections for CD20, CD138 and BFRF1 and double IF for CD138/BFRF1 
on RA paraffin-embedded synovial tissues. All 7 RA synovia with ectopic GC 
contained cells were immunopositive for BFRF1 (Fig. 4.6 table). Differently 
from LMP2A+ and LMP1+ cells, BFRF1+ cells mainly localized at the periphery 
of B-cell follicles and in the interfollicular areas and were identified as CD138+ 
plasma cells (Fig 4.6 A-E). CD138-/BFRF1+ cells were rarely observed. The 
percentage of CD138+ plasma cells expressing BFRF1 in ELS+ RA cases with 
ectopic GC ranged between 3 and 23% in individual microscopic fields (mean 
10.1+7.3%, mean + SD). Only a few BFRF1+ plasma cells either isolated or in 
small clusters, were detected in 5 out of 14 RA samples with B-cell aggregates 
without FDC (Fig. 4.6 F and table). No BFRF1 immunoreactivity was detected in 
13 RA synovia with diffuse inflammation (Fig 4.6 G and table).  As expected, all 
OA synovia analysed were BFRF1 negative (Fig 4.6 H).  
In selected RA synovia with ectopic GC (n=6) I also analysed the expression of 
BMRF1, another viral lytic antigen. Performing double stainings CD138/BMRF1 
I found that BMRF1, similarly to BFRF1, was mainly expressed by peri-follicular 
plasma cells (Fig 4.6 I and inset). 
I also analysed 9 snap-frozen samples for BFRF1 expression performing double 
IF for BFRF1/CD138. As expected and as observed with paraffin-embedded RA 
synovia, BFRF1 was mostly expressed by plasma cells outside B cell follicles of 3 
162 
 
out of 4 ELS+ RA synovia and absent in all 5 RA synovia characterised by 
diffuse/no B cell inflammation. These observations strongly suggest that EBV 
reactivation in the RA synovium is associated with highly organised B-cell 
follicles and an ongoing GC reaction which allows the in situ differentiation of 
plasma cells. 
To understand whether EBV reactivation in the RA synovium could lead to 
production of mature viral particles, expression of the EBV structural proteins 
gp350/220 and p160 was analysed in 6 BFRF1+ RA samples with ectopic GC. 
Only two small clusters of gp350/220+ cells and p160+ cells were detected in 2 
different samples (Fig. 4.6 J, K). These findings suggest abortive EBV 
reactivation or rapid elimination of productively infected cells. 
 
163 
 
 
Figure 4.6 
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Figure 4.6 Detection of EBV lytic proteins BFRF1 and BMRF1 in RA synovia 
The table on top shows the percentage of BFRF1+ samples among ELS+/FDC+, 
ELS+/FDC- and diffuse RA synovia. Representative immunostainings for CD20 
(A), CD138 (B) and BFRF1 (C) performed in serial sections of a RA synovial 
sample with ectopic B-cell follicles reveals that both plasma cells and BFRF1+ 
cells localize at the B-cell follicle border. The inset in C highlights the typical 
cytoplasmic localization of BFRF1. Sequential sections show numerous plasma 
cells accumulating around a large B cell follicle (D) and many of them 
displaying reactivity against BFRF1 (E). A few CD138+/BFRF1+ cells are 
detected among scattered CD138+ plasma cells in a RA synovial sample with 
aggregates devoid of FDC (F). A RA synovia characterised by diffuse 
inflammation show no reactivity for BFRF1 (G). An OA samples BFRF1 negative 
is also shown (H). Double IF for CD138/BMRF1 performed on a RA synovia 
ELS+/FDC+ show several plasma cells displaying reactivity against BMRF1+ (I); 
those plasma cells localise just outside a B cell follicle, identified by sequential 
staining for CD20 (inset in I). Immunohistochemistry for the EBV late lytic 
proteins p160 (J) and gp350/220 (K) reveals two groups of productively 
infected cells in 2 different RA synovial samples with ectopic GC. The inset in K 
shows few gp350/220+ cell at high power magnification. Bars: 50 µm in A-D, H, 
K; 10 µm in E-G, I, J. 
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4.6 Ongoing cytotoxic activity at sites where EBV lytically infected 
cells accumulate in the RA synovia 
 
Since CD8+ T cells play a key role in the control of EBV by eliminating infected 
cells and respond vigorously to viral lytic antigens (271), I investigated the 
relationship between CD8+ T cells, B cells and EBV infected cells in 13 RA 
synovial samples (3 ELS+/FDC+, 2 ELS+/FDC- and 8 diffuse). As reported 
previously (272), CD8+ T cell infiltration was much more abundant in ELS+ RA 
synovia than in those lacking ELS (Fig 4.7 graph a). However, double 
immunofluorescence stainings for CD8 and CD20 revealed that in ELS+ RA 
samples CD8+ T cells were mostly excluded from B-cell follicles and infiltrated 
the surrounding plasma cell-rich area (Fig. 4.7 A, B). Conversely, in RA synovia 
with smaller B-cell aggregates or diffuse synovitis CD8+ T cells were 
intermingled with B cells (Fig. 4.7 C, D). To visualize possible interactions 
between intrasynovial CD8+ T cells and EBV lytically infected cells, I performed 
double immunofluorescence for CD8 and BFRF1. Only occasional contacts 
between CD8+ and BFRF1+ cells were observed (Fig. 4.7 E).  
In order to establish whether intrasynovial CD8+ T cells displayed cytotoxic 
activity, I analysed the expression of granzyme B, a serine protease whose 
expression is restricted to cytotoxic lymphocytes and correlates with functional 
cytolytic activity (273). As expected, a significantly higher number of granzyme 
B+ cells were found in ELS+ compared to ELS- RA samples (Fig 4.7 graph b). 
Although granzyme B+ cells were also present in perifollicular areas populated 
by BFRF1+ cells, physical contacts between EBV lytically infected cells and 
granzyme B+ cells were rarely observed (Fig. 4.7 F). 
By performing double immunofluorescence stainings for CD8 and granzyme B I 
observed that the lytic enzyme was expressed in both CD8+ and CD8- cells (Fig. 
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4.7 G and H). However, the percentage of CD8+ cells co-expressing granzyme B 
was more than 2-fold higher in EBV- diffuse synovitis than in EBV+/ELS+ RA 
samples (Fig 4.7 graph c). These findings indicate that the majority of CD8+ T 
cells infiltrating ELS+ synovia do not display cytotoxic activity, as previously 
suggested (274). Accordingly, the percentage of CD8+/granzyme B+ cells 
relatively to the total granzyme B+ cell population was significantly higher in 
ELS-/EBV- RA samples compared to ELS+/EBV+ RA samples (Fig. 4.7 G, H and 
graph d). Since granzyme B is expressed in the cytoplasmic granules of 
cytotoxic T cells and NK cells, I next investigated if the numerous CD8-
/GranzymeB+ cells in ELS+ RA synovia were NK CD56+ cells. Therefore I 
performed double staining for CD56/Granzyme B on selected (n=4) ELS+ RA 
synovia characterised by a high number of CD8-/GranzymeB+ cells. 
Surprisingly, only 3% of the total granzyme B + cells were CD56+ too (Fig 4.7 I).    
Since previous studies (275-278)observed that in chronic viral infections, 
including EBV and in some chronic inflammatory diseases, including RA, the 
CD4+ T cells can acquire lytic activity, I next analysed the level of inflammation 
and the lytic state of CD4+ T cells in ELS+ versus ELS- RA samples. I found that 
CD4+ T cell infiltration was more abundant in ELS+ RA synovia compared to 
those lacking ELS (Fig 4.7 graph e). Of relevance, the percentage of GrB+/CD4+ 
T cells among GrB+ cells was significantly higher in ELS+EBV+ RA samples 
compared to EBV- samples and samples with diffuse synovitis  (p<0.001) (Fig. 
4.7 J, K and graph f). These findings suggest that in EBV+/ELS+ RA synovia, but 
not in diffuse synovitis, a large subset of CD4+ T cells acquire cytolytic activity.  
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Figure 4.7 
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Figure 4.7 Distribution and frequency of cytotoxic cells relatively to EBV 
infected cells in the RA synovia 
CD8+ cells in ELS+ synovia do not enter large B-cell follicles and localize mainly 
in plasma cell areas (A,B). The distribution of CD138+ cells is shown in the inset 
of panel A. Conversely, in ELS- RA synovia CD8+ cells are found intermingled 
with B cells (C, D). BFRF1+ and CD8+ cells at the border of a B-cell follicle in 
ELS+ RA synovium. Only rarely, CD8+ cells were observed in direct contact with 
BFRF1+ cells (E and inset). Granzyme B+ cells in a perifollicular area where EBV 
lytically infected cells are also present (F). The inset in F shows cell-cell contact 
between a granzyme B+ cell and a BFRF1+ cell. CD8+ cells are mainly granzyme 
B negative in ELS+ RA synovium (G). Instead, in ELS- RA synovium a high 
percentage of CD8+ cells express granzyme B (H). In ELS+ RA synovia Granzyme 
B+ cells do not express CD56 (I). In ELS+ RA synovium many granzyme B+ cells 
are CD4+ (J and inset) whereas in ELS- RA synovium the majority of CD4+ cells 
are granzyme B-negative (K). Bars: 50 µm in A-C; 10 µm in D-K. 
The absolute number of CD8+ cells is significantly higher in ELS+ compared to 
ELS- RA synovium (graph a). The absolute number of Granzyme B+ cells is 
significantly higher in ELS+ than ELS- RA synovium (graph b).The percentage of 
CD8+/Granzyme B+ cells on the total CD8+ cells is significantly higher in ELS- 
than ELS+ RA synovium (graph c). The percentage of CD8+/Granzyme B+ cells 
on the total Granzyme B+ cells is significantly higher in ELS- than ELS+ RA 
synovium (graph d). The absolute number of CD4+ cells is significantly higher in 
ELS+ than ELS- RA synovium (graph e). The percentage of CD4+/Granzyme B+ 
cells on the total Granzyme B+ cells is significantly higher in ELS+ than ELS- RA 
synovium (graph f).*p<0.05, ** p<0.01, *** p<0.001 
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CHAPTER 5 RESULTS 
Detection of EBV in SS salivary glands 
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EBV has been previously associated with ELS in MS and MG (72, 73)and I 
confirmed a strong link between EBV and ELS in RA (Chapter 4). Thus, the 
concept emerging from these data is that EBV may not be associated to a 
specific autoimmune disease, but that a dysregulated EBV infection is a 
common feature of different autoimmune diseases characterised by B cell-
dysregulation and formation of ELS. 
To better validate this hypothesis I next extended the analysis of EBV infection 
to another chronic autoimmune disease characterised by ELS formation in the 
target organs, the salivary glands of Sjogren’s syndrome. For this purpose, 
similarly to RA, I performed a deep analysis of the level of 
inflammation/presence of ELS in each SS salivary glands analysed, both by IHC 
and RT-PCR and analysed the status of EBV latent and lytic infection by 
different techniques (i.e. IHC, IF, ISH and real-time RT-PCR), focusing on the 
relationship between EBV expression/reactivation and ELS formation. 
 
 
5.1 Histological characterization of SS salivary glands 
 
Salivary glands from 13 SS and 5 NSCS patients were stained for the presence 
of CD20, CD3, CD138 and CD21 and each antigen was scored as described in 
materials and methods. CD68 staining was not performed on SS salivary glands 
since it was previously observed in the RA synovia that macrophages 
infiltration was mostly unrelated with the status of EBV infection. 
Among the 13 SS salivary glands analysed, 6 (46.1%) were characterised by the 
presence of large B-cell enriched lymphocytic aggregates which displayed FDC 
networks, while 5 (38.4%) showed smaller lymphocytic aggregates without FDC 
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and 2 (15%) were characterised by diffuse inflammation with sparse or no B 
cells (Fig 5.1).  
Among 5 NSCS salivary glands analysed 2 showed small lymphocytic aggregates 
of less than 50 cells and 3 showed diffuse inflammation with no/sparse B cells. 
Notably none of the SS NSCS salivary glands analysed was FDC+. 
I observed a typical B/T cell segregation with surrounding plasma cells in most 
of the aggregates with FDC networks and in some of the FDC- ones. 
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Figure 5.1 
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Figure 5.1 Immunohistochemical characterization of the inflammatory 
infiltrates in SS salivary glands 
Sequential sections of SS salivary glands were stained for CD20, CD3, CD138 
and CD21 and samples were classified as: i) with diffuse inflammation with no 
or sparse B cells; ii) ELS+ FDC- (characterised by B/T cell aggregates, 
surrounding plasma cells without FDC network; iii) ELS+FDC+ (characterised by 
B/T cell aggregates, surrounding plasma cells and FDC network). An example of 
each pathotype is shown. Bars: 50 µm in all panels.  
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5.2 EBV latent antigens are mainly expressed by B cells in SS 
salivary glands and are strictly associated with ELS formation 
 
I next analysed the status of EBV latent infection in SS salivary glands by 
immunohistochemistry for LMP2A expression. Since EBV is mainly expressed 
by B cells and/or plasma cells, we first selected 4 SS salivary glands ELS+/FDC+ 
and stained serial sections for LMP2A and CD20. LMP2A+ cells were detected 
in all ELS+ samples and localised in the B cell-rich areas (Fig 5.2 A, B).  
Next I performed double staining for CD20/LMP2A in all 13 SS samples and 
confirmed that LMP2A was mainly expressed by B cells (Fig 5.2 C and D). 
LMP2A positive B cells were found in 100% of ELS+/FDC+ (Fig 5.2 C and table) 
and ELS+/FDC- (Fig 5.2 D and table) SS salivary glands, mostly in B cell-
aggregates. Conversely samples with sparse or no B cells did not display 
CD20+/LMP2A+ cells (Fig 5.2 E and table). Similarly, I did not detect 
CD20+/LMP2A+ cells in any NSCS salivary glands (Fig 5.2 F).  
A second pattern of LMP2A+ expression outside CD20+ B cell areas was also 
observed in both SS and NSCS salivary glands. In this context, LMP2A seemed 
to be mainly expressed by ductal/acinar epithelial cells; thus I performed 
double IF staining for a cytokeratin marker and LMP2A in all SS and NSCS 
samples. By these means I could observe LMP2A expression in all SS samples 
analysed and mostly in ductal epithelial cells, although with a rather low 
prevalence (<10 cells/sample) (Fig 5.2 G, H and table). Also 4 out of 5 NSCS 
samples displayed few LMP2A+/cytokeratin+ cells. 
In selected SS salivary glands with ectopic GC (n=4) I also performed 
immunostaining for LMP1, and as observed for LMP2A, this EBV latent antigen 
was mostly expressed by B cells inside B-cell aggregates but also by few 
ducts/acini cells. Double staining for LMP1 and the B-cell marker CD79a 
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confirmed that LMP1 was expressed by B cells mostly inside B-cell follicles (Fig 
5.2 I).  
Interestingly, the presence of either LMP1+ and/or LMP2A+ ductal epithelial 
cells was not associated with the formation of periductal inflammatory 
infiltrates. 
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Figure 5.2 
 
 
 
 
 
 
SS salivary glands N B cells LMP2A+ Epithelial cells LMP2A+ 
ELS+ FDC+ 6 100% 100% 
ELS+ FDC- 5 100% 100% 
diffuse 2 0% 100% 
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Figure 5.2 Detection of LMP2A+ and LMP1+ cells in SS salivary glands 
Sequential sections from ELS+ SS salivary glands stained for CD20 and LMP2A 
show LMP2A+ cells co-localising in the B cell area of a B–cell follicle (A, B). A 
representative B cell follicle, with CD21+/FDC networks as demonstrated by 
sequential staining (inset in C) is extensively LMP2A+ (C). Some B cells LMP2A+ 
in a B cell aggregate FDC- (D). In the inset in D a high power magnification of a 
CD20+/LMP2A+ cell is shown. A SS salivary gland characterised by diffuse 
inflammation is LMP2A negative (E).  A salivary gland from a NSCS patient is 
LMP2A negative (F). Few LMP2A+ epithelial cells in a SS (G) and a NSCS (H) 
salivary gland. Double IF for CD79a/LMP1 in an ELS+FDC+ SS salivary gland 
shows LMP1+ B cells in a small aggregate (I).   
The table shows the percentage of LMP2A+ SS salivary glands among samples 
with ELS+FDC+, ELS+FDC- and diffuse inflammation. Bars: 10 µm in all panels. 
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5.3 EBER is mainly expressed by plasma cells and B cells and is 
associated with ELS formation in SS salivary glands 
 
In order to confirm the presence of EBV latency in SS salivary gland, I next 
performed ISH for EBER transcripts. I first performed ISH for GAPDH on 9 SS (5 
ELS+/FDC+, 3 ELS+/FDC- and 1 with diffuse inflammation) and 5 NSCS salivary 
glands (2 with small aggregates and 3 with diffuse inflammation) in order to 
confirm good RNA preservation. All samples analysed showed a good GAPDH 
signal (Fig 5.3 A) and were therefore analysed for EBER expression by ISH. EBER 
was expressed in 8 out of 9 and in 1 out of 5 of the SS and NSCS salivary glands 
respectively (Fig 5.3 table). Of relevance, the only SS sample which was found 
EBER- was the one characterised by diffuse inflammation (Fig 5.3 B and table). 
Conversely, the only NSCS sample found EBER+ also displayed small B cell 
follicles. 
Staining sequential sections of ELS+ SS salivary glands for 
EBER/CD20/CD138/CD3 I observed that EBER+ cells mostly accumulate in the 
B/T/plasma cell-rich areas, with maximal enrichment around ectopic B cell 
follicles (Fig 5.3 C-F). Less frequently and less numerous EBER+ cells were 
observed in area of diffuse B/plasma cell infiltration in ELS+ samples (Fig 5.3 G-
I). In order to identify the cells expressing EBER I analysed 2 ELS+ SS samples, 
combining EBER in situ hybridization with immunohistochemistry for CD20 or 
CD138. Using this approach, I could observe that both CD138+ plasma cells (Fig 
5.3 J) and CD20+ B cells (Fig. 5.3 K and inset) expressed EBER. Interestingly, I 
could not detect any epithelial cells EBER+, despite LMP2A/LMP1 positivity (Fig 
5.3 L). This suggests that epithelial cells in the salivary glands express a 
different latent EBV programme compared to infiltrating B cells.  
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Finally, no EBER signal was detected in SS or NSCS salivary glands using a non-
specific probe (Fig. 5.3 M). 
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Figure 5.3 
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Figure 5.3 Detection of EBER+ cells in SS salivary glands 
GAPDH ISH on a representative SS salivary gland showing good RNA 
preservation and uniform signal (A). A representative SS salivary gland 
characterized by diffuse inflammation is EBER negative (B). Serial sections of 
ELS+FDC+ SS salivary gland stained for CD20 (C), CD21 (inset in C), CD3 (D), 
CD138 (E) and EBER (F) show an accumulation of EBER+ cells in an area with a 
B-cell follicle and FDC networks surrounded by numerous T cells and plasma 
cells. Serial sections of an ELS+ FDC- SS salivary gland stained for CD20 (G), 
CD138 (H) and EBER (I) show EBER+ cells accumulating in the same area where 
plasma cells accumulate.  A double staining for CD138/EBER on ELS+ SS salivary 
gland confirms that most EBER+ cells are plasma cells (J) while a minority 
display double EBER/CD20 staining demonstrating that a subset of B cells also 
expresses EBER (K). In the inset in K a large magnification of a CD20+/EBER+ 
cell is shown. Double staining for CD20/EBER show some EBER+ cells 
accumulating around a duct which is EBER negative (L). No signal was detected 
in SS salivary glands using a non-specific probe (M).  
The table shows the percentage of EBER+ salivary glands among SS samples 
with ELS+FDC+, ELS+FDC- and diffuse inflammation. Bars: 50 µm in all panels. 
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5.4 The expression of EBV latent transcripts correlates with the 
level of CD19, AID, and BLIMP mRNA in SS salivary glands 
 
I next aimed to confirm the presence of EBV latency in SS salivary glands at 
transcript level and its correlation with the B cell and plasma cell content. For 
this purpose I analysed the mRNA expression of EBV latent genes 
EBER1/EBER2, a gene marking B cell and plasma cells (CD19) as well as markers 
of functional B cell activation (AID), plasma blasts/cells differentiation (Blimp) 
and a master regulator of ELS formation (CXCL13). EBV latent genes and CD19 
expression were detected using a highly sensitive and specific quantitative real 
time RT-PCR which includes a cDNA pre-amplification step that selectively 
enriches for the selected genes. Conversely, conventional TaqMan RT-PCR with 
no pre-amplification step was used for AID, CXCL13 and Blimp quantitative 
mRNA assessment. 
Twenty-nine SS salivary glands with optimal RNA quality were selected for this 
analysis. RNA from 4 NSCS salivary glands was used as disease control. 
Furthermore, RNA from HRC57 and Ramos cell lines were used as positive and 
negative controls for EBER genes, respectively.  Finally, RNA from a human 
tonsil was used as positive control for AID, CXCL13 and BLIMP expression.   
Thirty-one out of 33 samples (27 SS and 4 NSCS) displayed a good GAPDH 
signal and were selected for further analysis. Variable level of CD19 expression 
was detected among the SS samples analysed (Fig 5.4 A). A significantly lower 
average level of CD19 expression was detected among the 4 NSCS samples 
analysed (Fig 5.4 A). As expected, I observed a significant positive correlation 
between the level of CD19 expression and AID positivity (Fig 5.4 B). Detectable 
levels of EBER were observed in 21 (77%) of the SS samples analysed 
respectively. EBER expression significantly correlates with the level of AID and 
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CD19 mRNA (Fig 5.4 C-D). EBER signal showed also a significant correlation 
with Blimp mRNA expression (Fig 5.4 E), a plasma cell marker, confirming the 
ISH data indicating predominant EBER expression within infiltrating 
perifollicular plasma cells. Finally the expression of EBER was positively 
associated with the level of CXCL13 expression (Fig 5.4 F), confirming that EBER 
expression is closely associated with the formation of ELS in SS salivary glands. 
Interestingly, only 1 out of 4 NSCS samples displayed barely detectable EBER 
positivityin the context of a low level of CD19 expression (Fig 5.4 A).  
A 1% agarose gel was used to confirm specificity of the EBER, CD19 and GAPDH 
amplificons (Fig 5.4 G). As expected, specific PCR products of 167 bp (EBER), 
115 bp (CD19) and 266 bp (GAPDH) were observed.  
Overall, these data confirmed that EBV latency in SS salivary glands is strictly 
associated with ELS formation, B cell infiltration and plasma cell differentiation. 
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Figure 5.4 
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Figure 5.4 Detection of EBER transcripts in SS salivary glands by quantitative 
TaqMan RT-PCR  
Significantly higher levels of CD19 mRNA are expressed in SS respect to NSCS 
salivary glands (A). CD19 (B) and EBER (C) gene expression positively correlate 
with the level of AID expression. EBER gene expression also significantly 
correlates with the level of CD19 (D) and BLIMP-1 (E). EBER expression was 
positively associated with the level of CXCL13 (F). 1% agarose gel showing 
EBER, CD19 and GAPDH PCR products confirms specificity of the PCR on ELS+ 
and ELS- SS salivary glands. Band of the correct size were observed for all the 
genes analysed. Higher level/frequency of CD19 and EBER but not GAPDH gene 
expression were detected in ELS+ compared to ELS- SS salivary glands (G). 
*** p<0.001; ** p<0.01; *p<0.05 
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5.5 EBV reactivation occurs in plasma cells and is associated with 
ELS formation in SS salivary glands 
 
I next analysed whether EBV also displays reactivation in the SS and NSCS 
salivary glands, performing double IF for CD138/BFRF1 on 13 SS and 4 NSCS 
salivary glands. I observed numerous BFRF1+ cells (>20+ cells/section) in all 
ELS+FDC+ SS samples (Fig 5.5 A and table) and few BFRF1+ cells (< 5 
cell/section) in 4 out of 5 ELS+FDC- SS samples (Fig .5.5 B and table). All SS 
samples with diffuse inflammation were BFRF1 negative (Fig 5.5 C and table). 
Among the 4 NSCS samples one displayed reactivity against BFRF1, although 
only rare positive cells were identified in the whole section (Fig 5.5 D). Notably, 
the only NSCS sample BFRF1+ was the one displaying some small B cell follicles, 
albeit this patient did not fulfil Chisholm and Mason criteria for histological 
diagnosis of SS.  
BFRF1+ cells were invariably identified as CD138+ plasma cells (Fig 5.5 A, B, D) 
and mostly localised at the periphery of B cell aggregates (Fig 5.5 E-F). 
In order to confirm the lytic reactivation of EBV in SS salivary glands I next 
investigated the expression of another early lytic EBV antigen, BMRF1, in 3 
selected ELS+FDC+ SS samples performing double IF for CD138/BMRF1. As 
expected, I observed BMRF1+ cells in all the samples analysed mostly localising 
at the border of B cell aggregates and co-localizing with CD138 (Fig. 5.5 G). 
Overall, these observations strongly suggest that EBV reactivation in the SS 
salivary glands is dependent of in situ plasma cell differentiation within highly 
organised B-cell follicles in an ongoing GC reaction. 
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Figure 5.5 
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Figure 5.5 Detection of BFRF1+ and BMRF1+ cells in SS salivary glands 
Numerous CD138+/BFRF1+ cells are observed in ELS+FDC+ SS salivary glands 
(A) compared to  ELS+/FDC- SS salivary glands (B). Rare plasma cells BFRF1 
negative are also observed in one SS sample lacking B cell follicles (C). One 
single sample of NSCS salivary glands displays 2 BFRF1+ plasma cells (D). Serial 
sections show BFRF1+ cells (E) accumulating around a B cell follicle (F) in an 
ELS+ SS salivary gland. Serial sections show BMRF1+/CD138+ cells (G) 
accumulating around a B cell follicle (inset in G) in a ELS+FDC+ SS salivary 
gland, confirming EBV reactivation. 
The table shows the percentage of BFRF1+ SS salivary glands among samples 
with ELS+FDC+, ELS+FDC- and with diffuse inflammation. Bars: 10 µm in all 
panels. 
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5.6 Ongoing cytotoxic activity in SS salivary glands preferentially 
occurs at sites where EBV lytically infected cells accumulate 
 
I next investigated the localization of cytotoxic CD8+ T cells and their possible 
association with EBV reactivation in SS salivary glands. Performing double 
immunofluorescence staining for CD8 and CD20 in 13 SS samples I observed 
that CD8+ T cells mostly localised outside B cell follicles in ELS+ samples (Fig 5.6 
A). CD8+ T cells were significantly more abundant in ELS+ compare to ELS- 
samples (Fig 5.6 graph a). Double IF for CD8/BFRF1 on ELS+/BFRF1+ SS salivary 
glands (n=10) demonstrated that CD8+ T cells can accumulate in BFRF1+ areas 
around B cell follicles with seldom direct cell-cell contact with  BFRF1+ cells (Fig 
5.5 B and inset).  
To assess whether CD8+ T cells in SS salivary glands display cytotoxicity I next 
performed double IF for CD8/Granzyme B on both ELS+ and ELS- SS salivary 
glands.  
Interestingly, I observed numerous Granzyme B+ cells in the same areas where 
BFRF1+ cells accumulate (Fig 5.6 C), revealing ongoing cytotoxic activity at sites 
of EBV lytic reactivation. Several cell contacts between BFRF1+ and Granzyme 
B+ cells were observed, suggesting that cytotoxic cells may be acting against 
EBV-reactivation (Fig 5.6 C inset). However, only a small proportion of CD8+ T 
cells also expressed granzyme B, and the percentage of cytotoxic double 
positive Granzyme B/CD8 T cells was significantly higher in ELS- compared to 
ELS+ samples (Fig 5.6 D-E and graph b).  
Conversely, double IF for CD4/Granzyme B on 3 ELS+ SS salivary glands 
revealed that around half of the infiltrating Granzyme B+ cells were CD4+ (Fig 
5.6 F). In order to investigate whether the Granzyme B+/CD4+/CD8- cells 
belonged to the recently described subset of activated T helper cells I next 
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performed on 2 selected SS samples double IF for PD1/Granzyme B and 
observed that over 90% of CD4+/Granzyme B+ cells were also PD1+ (Fig 5.6 G).  
On the basis of the above data it is possible to  speculate that in ELS+/EBV+ SS 
salivary glands, a defective cytotoxicity in the CD8+ T cell population is present 
which seems to be compensated by the acquisition of cytotoxic activity by a 
subset of activated Th cells.  
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Figure 5.6 
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Figure 5.6 Analysis of the link between cytotoxic T cells and EBV reactivation 
in SS salivary glands 
CD8+ cells accumulate out of a B cell follicle in an ELS+ FDC+ SS salivary gland 
(A). Just outside a B cell follicle, numerous CD8+ T cells accumulate in the same 
area of some BFRF1+ cells (B). In the inset in B a direct cell-cell contact 
between a BFRF1+ and CD8+ cell is shown. Many Granzyme B + cells just 
outside a B cell follicle, in an area where BFRF1+ cells accumulate (C). In the 
inset in C a contact between a BFRF1+ and a Granzyme B+ cell is shown. In a 
ELS+/FDC+ SS salivary gland most of the CD8+ T cells are non-cytotoxic (D), 
whilst most of the CD8+ cells are Granzyme B positive in SS salivary glands with 
diffuse inflammation (E). In the inset in E a double positive CD8/Granzyme B 
cells is shown. Most of the CD4+ T cells express Granzyme B in ELS+/FDC+ SS 
salivary glands (F) with the inset in F showing a high magnification of a double 
positive CD4/Granzyme B cell. Some Granzyme B+ cells co-express PD1 in an 
ELS+ SS salivary gland (G) with the inset in G shown a high magnification of a 
double positive PD1/Granzyme B cells. Bars: 50 µm in A; 10 µm in B-G. 
Graph: The absolute number of CD8+ T cells is significantly higher in ELS+FDC+ 
and in ELS+FDC- compared to ELS- SS salivary glands (a). The percentage of 
CD8+/Granzyme B+ cells on the total number of Granzyme B is significantly 
higher in ELS- compared to ELS+FDC+ SS salivary glands (b). 
*p<0.05, ** p<0.01 
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CHAPTER 6 RESULTS 
EBV reactivation, humoral autoimmunity and anti-EBV 
responses in patients with RA and SS 
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It has long been postulated that EBV may contribute to the development of 
autoimmunity via the rescue, survival and activation of autoreactive B cells 
which would be otherwise depleted in the periphery (82). However, this 
hyphotesis has never been formally tested.  
Thus, in the final part of my PhD project I investigated the relationship 
between EBV and autoimmunity in patients with RA and SS.  
First, I assessed the humoral response against EBV antigens in the serum and 
synovial fluid compartment of RA paients and analysed its correlation with 
immunoreactivity towards citrullinated antigens. Second, I took advantage of 
the human/mouse chimeric SCID model in order to investigate the direct 
production of native and/or translationally modified (i.e. citrullinated) human 
anti-EBV antibodies by human RA synovia or SS salivary glands engrafted into 
SCID mice and their association with either ACPA (RA) or anti-SSA/Ro, anti-
SSB/La antibodies (SS). As the only source of human antibodies in this system 
are those locally produced within the target organ, this experimental approach 
allowed me to directly investigate in situ production within ELS. 
Finally, I used RA and SS-specific recombinant autoantigens (citrullinated 
fibrinogen and Ro52, respectively) in order to investigate whether plasma cells 
infiltrating the RA synovium and SS salivary glands and showing evidence of 
EBV reactivation (see Chapters 4 and 5) were autoreactive and producing 
antibodies against disease-specific autoantigens. 
In Chapter 6 I present the results of this analysis in RA patients first, followed 
by a parallel investigation in SS. 
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6.1 Humoral anti-EBV response, ACPA and synovial EBV 
reactivation in RA patients 
 
I first analysed the production of anti-EBV antibodies in paired sera and 
synovial fluids from RA and OA patients. This analysis aimed first of all to clarify 
whether there is a differential anti-EBV response in RA vs OA patients. 
Secondly, comparing the titres of anti-EBV antibodies in paired serum and 
synovial fluid from the same patients, I aimed to investigate whether anti-EBV 
antibodies are enriched in the synovial fluid as an indirect indication of a local 
production within the RA synovia. 
Following this, I tested the hypothesis that anti-EBV antibodies may cross-react 
with self-antigens, potentially contributing to the local production of 
autoantibodies. I first investigated whether there was a correlation between 
the levels of anti-EBV antibodies with those of anti-CCP antibodies in the 
serum/synovial fluid of RA patients. Second, in order to directly analyse the 
local production of anti-CCP and anti-EBV antibodies in the RA synovia and its 
association with ELS formation I investigated the production of anti-EBV, anti-
citrullinated EBV and anti-CCP human IgG antibodies in the sera of SCID mice 
transplanted with ELS+ or ELS- RA synovia.  
Finally, I tested the hypothesis that EBV contributes to the survival of 
autoreactive plasma cells in the RA synovia, investigating whether ACPA-
producing plasma cells, identified by binding of biotinylated citrullinated 
fibrinogen (cFb)  were infected with EBV. 
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6.1.1 Analysis of anti-EBNA1, anti-VCA, anti-EA and anti-CCP antibodies in 
paired serum and synovial fluid from RA patients 
 
Paired serum and synovial fluid from 7 RA patients were screened by 
commercial ELISA in order to detect antibodies anti-EBNA1 IgG (marker of EBV 
past infection), anti-VCA IgG (marker of EBV primary and recent infection) and 
anti-EA IgG (marker of acute infection or recent reactivation).  
Detectable level of anti-EBNA1 (Fig 6.1 A) and anti-VCA IgG antibodies (Fig 6.1 
B) were found in all RA serum and synovial fluid analysed. Anti-EA IgG were 
detected in 2 out of 7 RA sera (28%) and in 3 out of 7 RA synovial fluids (42%) 
(Fig 6.1 C). Anti-VCA IgG antibodies production was the only that significantly 
correlated comparing serum and synovial fluid from RA patients (Fig 6.1 D). 
Interestingly, some synovial fluids displayed higher levels of anti-EBV 
antibodies compared to the serum (higher anti-VCA in 1 RA patient and higher 
anti-EBNA1 and anti-EA in 2 RA patients), suggesting that antibodies anti-EBV 
may be locally produced in the synovium in a subset of RA patients.   
Anti-CCP production in serum and synovial fluid of the 7 RA patients was 
significantly correlated (Fig 6.1 E). Remarkably, I demonstrated that the anti-
CCP level in the synovial fluid of RA patients significantly correlated with the 
synovial fluid levels of anti-VCA (Fig 6.1 F) and anti-EBNA1 (Fig 6.1 G) 
antibodies.  
As expected, analysis of paired synovial fluids and sera from 10 OA patients 
demonstrated detectable anti-EBNA1 in all cases (Fig 6.1 H), with no 
substantial difference between RA and OA anti-EBNA1 titres. Moreover, level 
of anti-EBNA1 antibodies wasnot significantly different in serum compared to 
synovial fluid from all OA patients (Fig 6.1 H), suggesting that anti-EBV 
antibodies are not locally produced in OA synovia.  
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Figure 6.1 
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Figure 6.1 Analysis of anti-EBV and anti-CCP antibodies in paired sera and 
synovial fluida from RA and OA patients  
All sera and synovial fluid from RA patients were anti-EBNA1 IgG (A) and anti-
VCA IgG (B) positive. Two out of 7 RA sera and 3 out of 7 RA synovial fluid 
displayed detectable level of anti-EA IgG antibodies (C). Anti-VCA IgG levels 
were significantly correlated in serum and synovial fluid from RA patients (p= 
0.02; R= 0.7) (D). Anti-CCP level were significantly correlated in serum and 
synovial fluid from RA patients (p= 0.001; R=0.9) (E). Level of anti-CCP were 
significantly correlated with anti-VCA (F) or anti-EBNA1 (G) IgG in the RA 
synovial fluid (both p= 0.02; R=0.6 and 0.7 respectively). Anti-EBNA1 level was 
not significantly differentin sera and synovial fluid from OA patients (H). 
The red line in graph A-C and H indicates the cut off for positivity. 
sf= synovial fluid 
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6.1.2 ELS+ RA synovia engrafted into SCID mice produce antibodies against 
unmodified EBV antigens 
 
I next examined in an in vivo model whether production of antibodies against 
unmodified EBV antigens takes place within isolated RA synovium and 
correlates with ACPA production. For this purpose, Hu-RA/SCID mice chimeras 
were generated by implanting fragments of RA synovial tissue (ELS+ or ELS-) 
into SCID mice (Figure 6.2 A, B). The presence of synovium-derived circulating 
human antibodies was analysed after 4 weeks. As previously observed(85) 
levels of human IgG ACPA were significantly higher in sera of mice transplanted 
with ELS+ compared to ELS- RA synovia (Figure 6.2 C). ELS+ RA synovial grafts 
also produced significantly higher levels of IgG antibodies directed against the 
EBV proteins EBNA1 and VCA compared to ELS- (Figure 6.2 D, E), while no 
production of  anti-EA antibodies was detected (Figure 6.2 F). Those findings 
directly demonstrate for the first time that antibodies against native EBV latent 
antigens are locally produced in the RA synovia in the presence of ELS and their 
production is significantly associated with ACPA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
200 
 
Figure 6.2 
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Figure 6.2 Unmodified anti-EBV antibodies are locally produced in RA synovia 
and correlate with ACPA production 
Synovial tissue from 4 RA patients was transplanted into 30 SCID mice (arrows 
depict site of transplants) (A). Transplanted RA synovial tissue in SCID mouse 
(B) (A-B are reproduced from Humby et al, PLoS Med, 2009). Four weeks after 
transplantation mouse sera were analysed by ELISA for the presence of human 
ACPA and anti-EBV IgG antibodies. ELS+ RA synovia engrafted into SCID mice 
produce significantly higher levels of ACPA (C), anti-EBNA1 (D) and anti-VCA (E) 
antibodies compared to ELS- synovia, while no production was observed for 
anti-EA antibodies (F).   
*** p<0.001; ns= statistically not significant 
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6.1.3 ELS+ RA synovia engrafted into SCID mice produce antibodies against 
citrullinated EBV antigens which closely correlate with local ACPA production 
 
Given the strong association between ACPA and anti-EBV antibody production, 
I next investigated whether the observed anti-EBV synovial humoral immune 
response could be directed against citrullinated EBV antigens derived from 
EBNA1 and EBNA2 (VCP1 and VCP2, respectively), as previously demonstrated 
in the sera of RA patients (66). For this purpose I analysed ELS+ HuRA/SCID 
sera, previously found positive for anti-CCP, anti-EBNA1 and anti-VCA 
antibodies (see Figure 6.2). As shown in Fig. 6.3 A and B ELS+ HuRA/SCID sera 
reacted with VCP1 and VCP2 and the binding to the citrullinated viral antigens 
positively correlated with the level of ACPA. These findings support the 
conclusion that citrullinated EBV proteins are antigenic targets of the humoral 
immune response generated in ectopic GC in the RA synovium. Moreover, 
since ACPA cross-react with citrullinated EBV antigens in RA (66, 246), this 
findings further suggest that local production of VCP1 and VCP2 in RA synovia 
could play a role in the induction of RA-specific antibodies. 
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Figure 6.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Citrullinated anti-EBV antibodies are locally produced in the RA 
synovia and correlate with ACPA production 
ACPA+/anti-EBNA1+/anti-VCA+ sera from Hu/RA SCID mice engrafted with 
ELS+ RA synovia were analysed for production of antibodies to citrullinated 
viral antigens VCP1 and VCP2. In vivo production of anti-citrullinated VCP2 EBV 
antibodies is closely associated with local ACPA production (A, B). 
** p<0.01, ns= statistically not significant 
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6.1.4 ACPA-producing synovial plasma cells are infected with EBV 
 
In order to understand whether EBV might contribute to RA pathology by 
supporting the survival and differentiation of pathogenic B-cell clones we 
asked whether synovial autoantibody-producing B cells were infected with 
EBV. ACPA-producing plasma cells in the RA synovium were identified by the 
binding of biotinylated citrullinated fibrinogen (CFb). This set of experiments 
was performed in 8 ACPA+ ELS+ RA synovial samples with ectopic GC and 
numerous EBV infected cells, and one ACPA+ RA sample with diffuse 
inflammation and no detectable EBER+ cells. Serial sections of these samples 
were double stained for CFb and CD138 (to identify ACPA-producing plasma 
cells), CD138 and BFRF1 (to identify EBV lytically infected plasma cells), and 
BFRF1 and CFb (to identify EBV lytically infected APCA-producing cells). As 
negative control, we used an excess of biotinylated non-citrullinated antigen. 
In addition, 2 ELS+ salivary glands of patients with Sjogren’s syndrome were 
used as controls for the specificity toward citrullinated antigens. 
In 6 out of 8 ELS+ RA synovia analysed around 30% of the CD138+ plasma cells 
at the periphery of FDC+ B-cell follicles bound CFb (Fig 6.4 A-C), but not non-
citrullinated Fb (Fig. 6.4 D). The same perifollicular areas were populated by 
lytically infected BFRF1+/CD138+ plasma cells (Fig. 6.4 E, F). When double 
staining for BFRF1 and CFb was performed, we observed that about 70% of 
ACPA-producing plasma cells at the periphery of ectopic GC co-expressed the 
EBV lytic antigen (Fig. 6.4 G-H). Neither ELS- RA synovia (Fig 6.4 I) nor SS 
salivary glands bind CFb (Fig 6.4 J). These findings clearly indicate that in GC-
containing RA synovia a subset of autoreactive plasma cells are infected with 
EBV.  
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Figure 6.4 
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Figure 6.4 Detection of the EBV early lytic protein BFRF1 in autoreactive 
plasma cells in ELS+ RA synovia. 
Double immunofluorescence staining for CD20 and CD138 shows a B-cell 
follicle surrounded by numerous plasma cells (A). At the border of the same B-
cell follicle (marked with an asterisk in B, D, E) many of the CD138+ plasma 
cells react with cytrullinated fibrinogen and express BFRF1, indicating that they 
produce APCA, and are EBV lytically infected. No binding of non-citrullinated 
Fb is detected in the same perifollicular area (D). Double immunofluorescence 
staining for CFb and BFRF1 indicates that a fraction of the ACPA-producing cells 
(CFb+) is positive for BFRF1 (G-H). Double immunostainings were performed on 
serial sections and the areas shown in G-H correspond to the areas 
immediately outside the B-cell follicle shown in A-E.No binding of CFb is 
detected in ELS- RA synovia (I) or in SS salivary gland (J). Bars: 50 µm in A, B, J; 
10 µm in C-I. 
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6.2 Local humoral anti-EBV response, autoimmunity and EBV 
reactivation in SS salivary glands 
 
Following the observation that EBV reactivation, local production of anti-EBV 
and of RA-associated antibodies are closely associated in the RA synovium with 
ELS, I next tested the hypothesis that i) anti-EBV antibodies are locally 
produced also in ELS+ SS salivary glands characterised by a dysregulated EBV 
infection; ii) their local production is associated with that of SS-associated 
autoantibodies and iii) EBV reactivation affects anti-Ro52/SSA and/or anti-
La/SSB autoreactive plasma cells in SS salivary glands   
 
 
6.2.1 SS salivary glands engrafted into SCID mice produce anti-Ro52/SSA, 
anti-La/SSB and anti-EBV antibodies 
 
Eight Hu-SS/SCID mice chimeras were generated by implanting fragments of SS 
salivary glands into SCID mice. The presence of salivary glands-derived 
circulating human antibodies was analysed by culling 2 mice at each time point 
at week 1, 2, 3 and 4 post-engraftment. I observed detectable levels of anti-
Ro52/SSA and anti-La/SSB antibodies at week 1 and 2 with a peak of 
production at week 2 (Fig 6.5 A, B). The same sera were next analysed for anti-
EBV antibodies production. As shown in Fig 6.5 C, D I found positive levels of 
anti-EBNA-1 and anti-VCA antibodies at week 1 and 2 with a peak of 
production at week 2. Conversely, I could not detect anti-EA antibodies at any 
time point (Fig 6.5 E). Interestingly, a significant positive correlation between 
the intra-glandular production of SS-associated autoantibodies (anti-La/SSB 
and anti-Ro/SSA) and anti-EBV antibodies (anti-EBNA1 and anti-VCA) was 
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observed (Fig 6.5 F-I). Since Ro52 and EBNA1 proteins share homology in the 
sequence (81), it is possible to speculate from this preliminary data that EBV 
infection might trigger an immune intra-glandular response via cross-reaction 
with self-antigens, thus contributing to autoimmunity in SS.  
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Figure 6.5 
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Figure 6.5 Anti-La/SSB, anti/Ro/SSA and anti-EBV antibodies are locally 
produced in SS salivary glands 
Detection of anti-La/SSB (A), anti-Ro/SSA (B), anti-EBNA1 (C), anti-VCA (D) and 
anti EA (E) antibodies in the serum of the Hu-SS/SCID after 1, 2, 3 and 4 weeks 
after transplantation. Levels of anti-La were significantly correlated with level 
of anti-EBNA1 (p=0.02; R=0.6) (F) and anti-VCA (p=0.002; R=0.8) (G) antibodies 
in the serum of Hu-SS/SCID mice. Level of anti-Ro were significantly correlated 
with level of anti-EBNA1 (p=0.004; R=0.9) (H) and anti-VCA (p=0.008; R=0.8) (I) 
antibodies in the serum of Hu-SS/SCID mice. 
The red line in graph A-E indicates the cut off. 
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6.2.2 Anti-Ro52 autoantibody-producing peri-follicular plasma cells in SS 
salivary glands display evidence of EBV reactivation 
 
In order to investigate whether EBV play a direct role in the survival and 
differentiation of autoreactive plasma cells in SS salivary glands, in the final 
part of my PhD project I investigated whether anti-Ro52/SSA and anti-La/SSB 
producing-plasma cells are EBV-lytically infected. For this purpose I analysed 5 
SS salivary glands biopsies; 3 ELS+ EBV+ and 2 ELS- EBV- from anti-Ro/SSA anti-
La/SSB positive SS patients.  
Autoreactive plasma cells were first identified by analysing immunoreactivity 
against biotinylated recombinant Ro-52Kd and La-48Kd antigens, generated as 
previously described (202) (a kind gift of Prof Roland Jonsson, University of 
Bergen).  
I first tested the suitability of Ro-52 and La-48 biotinylated antigens on ELS+ SS 
salivary glands. While biotinylated Ro-52 gave the predicted staining in large 
cells surrounding ectopic B cell follicle, La-48 failed to demonstrate a specific 
immunoreactivity and was not carried forward for further analysis. 
Serial sections of ELS+ SS salivary glands were then double stained for Ro-
52/CD138 (to identify autoreactive plasma cells), for CD138 and BFRF1 (to 
identify EBV lytically infected plasma cells), and for BFRF1/Ro-52 (to identify 
EBV lytically infected anti-Ro52 producing cells). In all ELS+ SS salivary glands 
analysed, I detected numerous cells localising just outside B cell follicles and 
binding Ro-52 (Fig 6.6 A). Performing double IF for CD138/Ro-52, CD138/BFRF1 
and Ro-52/BFRF1 on sequential sections I were able toidentify that a sizeable 
subset of Ro52-producing autoreactive CD138+plasma cells display EBV 
reactivation (Fig 6.6 B-D). As expected, I did not detect any immunoreactivity 
against Ro52 in ELS- EBV- salivary glands (Fig 6.6 E). Finally, staining with 
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biotinylated Ro-52 on ELS+/EBV+ RA synovia failed to demonstrated any anti-
Ro52 immunoreactivity in synovial plasma cells (Fig. 6.6 F). 
These data strengthen that EBV-infected locally-differentiated plasma cells 
maintain specific autoreactivity against target autoantigens which are specific 
for each autoimmune disease, being selectively expressed within the local 
inflammatory milieu. 
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Figure 6.6 
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Figure 6.6 EBV infects autoreactive plasma cells in SS salivary glands 
Ro52+ cells localised just outside a B cell follicle in an ELS+ SS salivary glands 
(A). Serial sections stained for CD138/BFRF1 (B), CD138-Ro52 (C), and Ro-
52/BFRF1 (D) reveal that i) all Ro52+ cells are plasma cells. ii) In the same area 
some EBV lytically infected plasma cells accumulate. iii) A subset of the EBV-
lytically infected cells displays reactivity against Ro52. Either ELS- SS salivary 
gland (E) or RA synovia (F) show reactivity for Ro52. 
Bars: 50 µm in A; 10 µm in B-F.
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7.1 Significance of Epstein-Barr virus infection in the Rheumatoid 
Arthritis (RA) synovium 
 
Epstein-Barr virus is able to promiscuously and efficiently infect any resting B 
cells in culture, leading to cellular activation, proliferation, and the outgrowth 
of transformed lymphoblastoid cell lines(2). Not surprisingly, the virus is 
pathogenically associated with important human malignancies that include B 
cell-lymphomas (Burkitt’s, Hodgkin’s and immunoblastic lymphomas in the 
immunosuppressed) and carcinomas (nasopharyngeal and gastric)(2, 18). EBV 
has long been suspected also in the pathogenesis of various autoimmune 
diseases, including RA. Perturbed EBV infection is present in patients with RA 
(50)as demonstrated by i) serological data (227, 230, 279), showing an 
increased prevalence of anti-viral antibodies in RA patients; ii) a higher EBV 
blood viral load (56, 231); iii) molecular mimicry between self-antigens and EBV 
antigens (63, 66, 238, 239) and iv) clonal expansion of CD8+ T cells reacting 
against the virus in the joints of RA patients (244). However, EBV dysregulation 
in the RA synovium has remained a point of contention and whether EBV 
proteins/RNA are expressed in the inflamed joints of RA patients is still highly 
controversial. In fact, some works failed to detect EBV proteins or RNA 
expression in the RA synovia (71, 250, 251), whereas others reported a 
significant number of EBV+ cells (69, 70).  
A likely explanation for these controversies is that none of the previous works 
has attempted to investigate the presence of EBV in the context of the degree 
of synovial B cell infiltration and, more importantly, the formation of ELS. This 
is extremely relevant since the group of Francesca Aloisi at the ISS in Rome 
recently demonstrated a close link between EBV infection and ELS formation in 
the menynges of patients with MS (73) and in the thymus of patients with MG 
217 
 
(72), two autoimmune diseases characterised by ELS formation in their 
respective target organs.  
These high impact publications demonstrated EBV persistence and reactivation 
in the brain of MS and the thymus of MG patients mainly restricted to ectopic 
lymphoid follicles where they also observed signs of an ongoing anti-viral 
immune response. Thus, previous work suggested that a response towards EBV 
in the context of ELS could contribute to exacerbate the local inflammation. 
Moreover, the presence of EBV in ectopic B cell follicles, would strongly 
support the “GC model”, the most robust explanation currently available to 
elucidate the mechanisms by which EBV gains access to the memory B cell 
compartment (18). This model assumes that the virus uses the growth latency 
program to drive newly infected resting B cells into the cell cycle so that they 
can differentiate into resting memory state (where EBV can persist for life-
time) via a germinal centre reaction. As a result, the potential intersection of 
EBV and the GC reaction, both of which can drive B-cell growth and 
differentiation by delivering anti-apoptotic and proliferative signals, may 
provide a powerful combinatorial risk factor for the development of B-cell 
related autoimmune diseases (82).  
Moreover, the observation that ELS represent preferential niches for EBV 
persistence and reactivation suggested that EBV-containing ELS might be 
considered a signature of organ-specific autoimmune diseases where ectopic 
lymphoid neogenesis develops.  
Starting from this overall hypothesis and the previous investigations linking 
EBV with RA pathogenesis, in the first part of my PhD project I aimed to 
investigate whether a perturbed EBV infection was also present in the RA 
synovia characterised by the presence of ELS.   
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My group and others have previously described ELS in the joints of around 50% 
of patients with RA; these structures not only recapitulate the most important 
morphological features of the secondary lymphoid organs (SLO), such as T/B 
cell segregation, HEV differentiation and expression of lymphoid chemokines 
CXCL13 and CCL21(84, 126, 143), but also retain the functionality typical of SLO 
as demonstrated by the presence of network of follicular dendritic cells and 
the expression of AID (the enzyme required for SHM and CSR). Furthermore, 
recent evidences from my group also demonstrated a direct link between ELS 
and the in situ differentiation of autoreactive plasma cells reactive against 
citrullinated self-proteins (85, 280). 
Thus, my first aim was therefore to settle the longstanding issue of whether 
EBV proteins/RNA are expressed in the RA synovia. As discussed before, 
previous studies are highly controversial and the observed discrepancies are 
likely to a combination of i) technical reasons, i.e. sub-optimal sensibility of the 
techniques used, lack of a comprehensive approach, questionable preservation 
of the synovial tissue, and ii) the lack of stratification of RA synovia on the basis 
of the B cell infiltration and ELS formation.  
In order to perform a more exhaustive and clear-cut analysis of EBV expression 
in the RA synovia I used a large variety of techniques (such as IHC, IF, ISH and 
quantitative real-time PCR) on a large number of RA synovial tissues accurately 
quality-controlled for a good preservation of the tissue. In addition, I deeply 
characterised the level of inflammation and the presence of ELS in all RA 
synovial specimens, staining sequential sections for CD20, CD138, CD3, CD68 
and CD21 allowing the classification of the samples in 3 main subgroups, 
ELS+FDC+, ELS+FDC- and sample with diffuse synovitis. As expected from 
previous published data on synovial hystophathology, around half of the RA 
synovia showed diffuse inflammation, characterised mainly by macrophages 
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infiltration and synovial fibroblast proliferation with diffuse T cells and few/no 
B cells, with the remaining half presenting ELS, characterised by the presence 
of B cell follicles with common segregation of B and T cells in separate areas 
and surrounding CD138+ plasma cells. Among the ELS+ samples, I further 
characterised them as those displaying clear evidence of CD21+ FDC+ networks 
(40%) and those lacking FDC (60%).  
Once the synovial pathotype of the RA samples was assessed and the samples 
carefully selected, I then moved to the investigation of whether EBV latent 
antigens (LMP2A and LMP1) were expressed in the RA synovia and were linked 
to the presence of synovial ELS. By using double IF CD20/LMP2A and staining 
sequential sections for CD20, CD3, CD138, CD21 and LMP2A as well as staining 
for LMP1, I clearly demonstrated a strong association between LMP1 and 
LMP2A expression, the presence of ELS and the differentiation of FDC 
networks.  
According to the GC model of EBV persistence, EBV employs four sequentially 
expressed, virally-encoded latency transcription programs which drive infected 
naive B cells to become proliferating blasts and participate in GC reactions 
(where both LMP1 and LMP2A are expressed) in secondary lymphoid tissues, 
and finally enter the memory B-cell compartment where the virus establishes 
persistent infection. LMP1 and LMP2A possess the signalling properties of 
CD40 and the B-cell receptor, respectively, and have the capacity to promote 
the development of infected B cells in the absence of cognate antigen by 
providing pro-survival signals (281). Thus, my data are consistent with the GC 
model, whereby both LMP1 and LMP2A are expressed in EBV infected B cells 
transiting ectopic GC in the RA synovium, suggesting that these viral proteins 
may be involved in the abnormal expansion and survival of EBV infected B cells 
observed in the pathological tissue sustaining local B-cell activation and 
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differentiation. Moreover, these results provide a clear explanation for the 
high variability in the frequency of EBV infected cells in RA synovial tissues 
reported in previous studies and strengthen the concept that stratification 
upon synovial B-cell infiltration is essential to reliably assess the presence of 
EBV infection in the RA joints.  
I also confirmed the presence of EBV latency in the RA synovia at mRNA level 
by using two different techniques, ISH and RT-PCR. Performing ISH for EBERs 
which are EBV-encoded non-translated small RNAs combined with IHC for 
CD20 CD3, CD138 on sequential sections, I clearly demonstrated that the 
highest frequency of EBER+ cells was associated with ectopic GC. EBER+ cells 
were detected both inside and at the border of intrasynovial B-cell follicles, 
around T-cell areas and in B-cell-rich perivascular aggregates. Conversely, EBER 
was virtually absent in RA samples with diffuse inflammation. Overall, these 
findings confirmed the histological data allowing to conclude that the latent 
phase of EBV is strongly associated with ELS in the RA synovia and it is mainly 
expressed by B cells.  
The observation of EBER in plasma cells in the absence of LMP2A/LMP1 
expression is likely related to a relative higher expression of EBER within the 
cells, thus allowing greater sensitivity compared to immunostaining of LMP2A 
and LMP1. Notably, 33% of the RA synovia analysed were excluded due to 
suboptimal RNA preservation, as assessed by GAPDH ISH. Therefore, a poor 
tissue preservation may explain the failure of previous works to detect EBER+ 
cells (282).  
The presence of EBV RNA and its association with ELS in RA synovia was further 
confirmed by TaqMan real time RT-PCR, a very sensitive method which also 
allows quantitative assessment of gene expression. The analysis was 
performed only on samples that showed an optimal RNA integrity, assessed by 
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resolving total RNA on an agarose gel. Moreover, to avoid false negative 
results due to low target expression, I also performed an additional pre-
amplification step of target genes, which amplifies the starting material and 
increase the sensitivity of the technique. This technique has been optimised 
and used by our collaborators in previous work(268). EBV-infected B cells 
represent only a small fraction of the total resident and infiltrating synovial 
cellular compartment and the sensitivity of conventional real-time PCR 
techniques might not be sufficient to detect EBV RNA even in highly infiltrated 
tissue samples.  
Consistent with the results obtained by IHC, IF and ISH, EBV latent transcripts 
(LMP2A, LMP1 and EBER) were  strongly associated with the expression of 
several genes closely related to the formation and function of ELS such as 
CXCL13, a B cell chemoattrant and AID, the enzyme responsible for IgH V gene 
somatic hypermutation and Ig class-switching in B cells.  
Only one EBV latent-expressed gene was consistently undetectable in the RA 
synovium irrespectively from the presence of ELS, EBNA-1. This gene product 
acts as a transcriptional activator and is essential for the replication and 
persistence of EBV as an episome in infected B cells (2). In the absence of a 
clear explanation for the lack of synovial EBNA-1 expression, it is possible to 
speculate that the negative EBNA1 findings could be due to a low level of RNA 
expression in the RA synovium below the detectability of the method. 
After this comprehensive assessment of EBV latency, I next investigated 
whether EBV merely persists in its latent phase in the RA synovia or also 
undergo reactivation. For this purpose I analysed the synovial expression of 
BFRF1 and BMRF1, which are antigens associated with the early lytic cycle of 
EBV infection (283, 284). By double staining and sequential section analysis, I 
clearly demonstrated that BFRF1 is expressed almost invariably by plasma cells 
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and is strictly associated with ELS and FDC formation being, detected in 100%, 
36% and 0% of ELS+/FDC+, ELS+/FDC- and diffuse RA samples respectively. 
Typical BFRF1+/CD138+ plasma cells were observed at the periphery of B-cell 
follicles and in the interfollicular areas but always in association with ELS+ 
samples, strongly suggesting local differentiation within GC-like structures. 
Thus, in this scenario viral reactivation is initiated as a consequence of the 
differentiation of EBV infected B cells in ELS whereby the local inflammatory 
milieu induces the switch from the latent to the lytic EBV gene programme 
during local plasma cell differentiation. In contrast, EBV structural proteins, like 
p160 and gp350/220, were rarely detected in synovial ELS suggesting abortive 
viral replication or very efficient elimination of cells expressing EBV late lytic 
antigens. 
Because EBV has been shown to break tolerance mechanisms and induce 
autoreactive B-cell activation when LMP2A is constitutively expressed in 
transgenic mice (285), EBV infection has been discussed as a biologically 
plausible mechanism allowing potentially pathogenic autoreactive B-cell clones 
to escape deletion and cause autoimmunity. Thus, a fundamental question 
that was not addressed previously in RA or in any other autoimmune disease is 
whether EBV infection in ELS is directly linked to humoral autoimmunity. Since 
EBV delivers growth and survival signals to the infected B cell, it has been 
proposed that EBV transformation promotes the survival of autoreactive B 
cells (82). The RA synovium represents an ideal experimental setting to test 
this hypothesis since synovial ELS support a GC response leading to in situ 
differentiation of plasma cells that produce ACPA (85, 280). 
Here, I showed for the first time that a remarkable proportion (about 70%) of 
ACPA-producing plasma cells at the periphery of ectopic GC are infected with 
EBV and that about 60% of EBV lytically infected cells in the same areas are 
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ACPA-producing plasma cells. Persistence of ACPA-producing, EBV infected 
plasma cells in the RA synovium implies that completion of the EBV lytic cycle 
is somewhat impaired and is consistent with intrasynovial production of potent 
plasma cell survival signals, such as CXCL12 and APRIL, which normally support 
long-lived plasma cells in the bone marrow (286, 287). Therefore, the evidence 
that EBV infects a subset of autoreactive plasma cells in the RA synovia, 
support the hypothesis that EBV, with its unique ability to immortalise B cells, 
play a role in the survival of auto-antibody producing plasma cells, that directly 
contribute to RA pathogenesis.These findings raise the possibility that EBV 
infection favours the survival of pathogenic autoreactive B cells that 
participate in the formation of ectopic GC in the RA synovium. These structures 
and the local availability of self-antigens likely provide the appropriate 
environment that allows EBV infected autoreactive B cells to selectively 
expand, undergo affinity maturation and differentiate into autoantibody-
producing plasma cells. The recent finding that EBV persists in self-reactive 
memory B cells (288)lends support to the idea that EBV may contribute to the 
survival of self-reactive B cells that home to the RA synovium.  
As previously discussed the induction of anti-viral humoral immune responses 
cross-reactive with self-antigens is another possible mechanism through which 
EBV may contribute to autoimmunity (289, 290). In a normal adult, latent EBV 
infection is associated with moderate, stable and highly correlated levels of IgG 
antibodies against VCA, EBNA-1, and EA-R, with very low or undetectable levels 
of antibodies against EBNA-2 and EA-D(291-293). In situations of decreased 
cellular immunity, however, EBV reactivation, or the transition from latent to 
lytic infection, can occur. Anti-VCA IgG antibodies, anti-EBNA-2 antibodies, and 
anti-EA antibodies are often elevated in these situations, which is consistent 
with EBV reactivation. Latent EBV can replicate and spread despite the 
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presence of antibodies, and antibody titers correlate with viral activity rather 
than with the degree of protection afforded (293). In many diseases strongly 
associated with EBV, such as nasopharyngeal carcinoma and Burkitt's 
lymphoma, anti-EBV serology is abnormal many years before the onset of 
disease.  
Different studies revealed that anti-EBV titres are higher in patients with RA 
than in controls (228-230, 279)but very few attempts have been made to 
compare immune response to EBV in RA sera vs synovial fluids yielding 
contrasting results results (228, 233). In particular, although anti-EBV 
antibodies can be detected in the synovial fluid of RA patients, it is still not 
clear if those antibodies are locally produced in the RA synovia or merely 
reflect the systemic production. I therefore aimed to evaluate if a perturbed 
EBV infection in RA patients can cause a systemic and/or local synovial 
humoral anti-EBV immune response, eventually capable to interfere with self-
antigens and exacerbate the pathological immune response. For that purpose I 
first analysed paired sera and synovial fluids from RA patients and found a 
significant correlation between the levels of anti-EBV antibodies in the two 
compartments with few cases in which anti-EBV antibodies were higher in 
synovial fluid compared to the serum, suggesting that a humoral anti-EBV 
response can be triggered directly into the joint of a subset of RA patients. 
Anti-EBNA1 antibodies have been shown to cross-react with different 
autoantigens in RA, including denatured collagen and keratin (294), leading to 
the hypotheis that anti-EBNA1 immunoreactivity may fuel breach of self 
tolerance in the RA synovia, via molecular mimicry. This would result in local 
production of anti-EBV antibodies, possibly cross-reacting with self-antigen and 
therefore contributing to the RA pathogenesis via autoantibody production.  
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In support of this hypothesis, I first observed a significant positive correlation 
between the synovial fluid production of anti-EBNA1 and anti-CCP antibodies, 
a highly specific marker of RA. Anti-CCP production also significantly correlated 
with the level of anti-VCA antibodies in the RA synovial fluid. Following this in 
vitro evidence, I moved to in vivo studies in the Hu-RA SCID mice chimera, 
which is generated by engrafting fragments of RA synovial tissues in 
immunodeficient recipient mice. This model allows detection of circulating 
human antibodies into the mice circulation which are by definition locally 
produced in the RA synovia, as this is the only possible source of human 
antibodies in this model. Using this approach I confirmed that ELS+ but not 
ELS- RA synovia implanted in SCID mice release detectable level of human 
ACPA in the mouse circulation, supporting the notion that lymphoid structures 
within the rheumatoid arthritis synovia have a direct contribution to RA 
pathogenesis via ACPA production (85). By using the Hu-RA SCID mice I was 
also able to provide the first and direct evidence that anti-EBV antibodies (anti-
EBNA1 and anti-VCA IgG) are locally produced in the RA synovia characterised 
by a perturbed EBV infection and ELS formation and correlate with ACPA 
production. The latter evidence is of particular interest as it was recently 
demonstrated that circulating ACPA in the blood of RA patients recognize 
citrullinated EBNA-1 antigenic peptides VCP1 and VCP2(66). Thus, I furher 
analysed the sera of SCID mice engrafted with ELS+ RA synovia, and observed 
detectable level of antibodies against the citrullinated EBNA1 antigens VCP1 
and VCP2 that positively correlate with the level of ACPA. This observation 
demonstrates that cross-reactive antibodies are actively manufactured by GC 
in the RA synovium, likely contributing to local inflammation and tissue 
destruction. It is conceivable that the enzyme peptidyl-arginine deaminase, 
which is abundantly expressed within the inflamed RA synovium (295) might 
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be involved in the generation of citrullinated viral and self-antigens. Overall, 
this data provide the first direct link in the RA synovia between ectopic 
lymphoid neogenesis, EBV infection, humoral response to the virus and local 
production of ACPA, one of the most specific markers of RA. 
Finally, since latent and lytic EBV proteins are the targets of a cytotoxic 
immune response, the presence of EBV in RA synovia prompted me to 
investigate whether EBV might contribute to local inflammation through 
stimulation of a cytotoxic T cell response.  I first observedthat in ELS+ RA 
synovia CD8+ T cells were largely excluded from EBV+ ectopic GC, which 
suggests that these structures represent immune privileged niches for EBV 
persistence. Furthermore, the majority of granzyme B+ cells infiltrating ELS+ 
synovia were CD4+ rather than CD8+ whilst granzyme B+/CD8+ T cells 
predominated in ELS- RA synovia. These observations are in keeping with the 
reported preferential accumulation of non-cytotoxic, IFNɣ-producing CD8+ T 
cells in ELS+ RA synovia (274)and impaired cytotoxic function of EBV-specific 
circulating CD8+ T cells in RA patients, suggesting defective control of EBV 
infection (235).Accumulation of granzyme B+ CD4 T cells in ELS+ synovia is also 
consistent with previous studies showing that an uncommon subset of 
circulating cytotoxic CD4+ T cells is present in chronic viral infections (including 
EBV) as well as in RA patients (275-278). Taken together, these findings can be 
interpreted as an attempt of CD4+ T cells to compensate a possible defect of 
CD8+ T cells in controlling increased EBV loads in RA. Moreover, since I 
detected a massive accumulation of both CD8+, CD4+ and Granzyme B+ cells in 
sites where EBV reactivates, it is possible to speculate that viral reactivation in 
locally differentiated plasma cells contribute to the local chronic inflammation 
via the recruitment and activation of  cytotoxic T cell cells, resulting in an 
immunopathological process. In support of this hypothesis previous studies 
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detected CD8+ T cell clones directed against EBV lytic antigens directly into the 
joints of RA patients (244).  
In summary, in this first part of my PhD project aimed at the identification of 
EBV infection in the RA synoviaum, I consistently demonstrated that i) EBV 
perturbation is strongly linked with the latent infection of infiltrating B cells 
within ELS, ii) EBV reactivation takes place during in situ differentiation of 
plasma cells within GC-like structures, iii) EBV support the development of 
autoimmunity either by infecting autoreactive plasma cells or by favouring the 
generation of cross-reactive  self-antigens such as citrullinated EBV proteins 
and iv) Cytotoxic T cell activity in the RA synovium is defective at sites of EBV 
infection and may favour EBV persistence. 
 
The results obtained in this part of my PhD significantly advance our 
understanding of the interplay between EBV infection, loss of immunological 
self-tolerance and establishment of humoral autoimmunity in RA, and will 
stimulate further studies on the role of altered EBV-host interactions in RA 
etiopathogenesis.  
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7.2 Significance of Epstein-Barr virus infection in Sjogren’s 
syndrome (SS) salivaryglands 
 
Following the demonstration of EBV infection and reactivation in the RA 
synovia, in the second part of my PhD I moved to a parallel investigation in the 
salivary glands of SS patients. This investigation was fuelled by several lines of 
evidence which candidates EBV as an important player in SS pathogenesis.  
SS is a complex, multifactorial autoimmune rheumatic disease characterised by 
mononuclear cell infiltration of the exocrine glands and the presence of 
circulating autoantibodies such as anti-Ro/SSA and anti-La/SSB. A viral 
involvement in SS etiology has long been suggested, with implication of several 
pathogens including EBV, HTLV-1 and Cocksackie viruses.  Additionally, GC-like 
structures can be identified in 30-40% of SS salivary gland samples and the 
presence of ectopic B cell follicles correlates with elevated titres of rheumatoid 
factors and anti-Ro/La, increased circulating IgG, more severe disease and 
MALT lymphoma development (296, 297).  
Clearly, the main common denominator which prompted this investigation was 
to test the hypothesis that the presence of ELS in SS salivary glands could 
identify preferential niches of EBV persistence and reactivation as observed in 
RA patients in my PhD studies as well as in the target organs of patients with 
MS (73) and MG (72). 
Thus, the overarching hypothesis was that EBV latency and reactivation is a 
common factor in different autoimmune diseases which shared B-cell 
dysregulation and ELS formation as hallmarks. In addition, the evidence that 
EBV has its normal site of latency in salivary and lacrimal glands identified SS as 
a unique platform to investigate the complex interactions between infection of 
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epithelial cells and development of local inflammatory foci which have a typical 
periductal distribution in SS lesions.  
Previous investigations strongly support a role for EBV in SS pathogenesis. 
First, antibodies against EBV antigens are higher in serum of SS compared to 
healthy patients (238, 298, 299). Also, several examples of molecular 
resemblances between self-antigens in SS and EBV antigens have been 
identified; anti-La autoantibodies precipitate proteins that are complexed with 
EBV-encoded small RNAs (EBER1 and EBER2) (33). Moreover, serum from SS, 
but not from other autoimmune diseases or from healthy controls, cross-
reacted with lipocardin (a protein highly expressed in tear and saliva and 
recently suggested as a novel auto-antigen in SS), α-fodrin (a cytoskeleton 
protein considerate an important auto-antigen in SS) and EBV proteins (254). It 
has also been recently demonstrated that the saliva of patients with SS can 
activate EBV (256), reinforcing the pathological link between the virus and the 
disease.  
Furthermore, a more functional link between EBV and the pathogenesis of SS 
was proved by Miyasaka et al with an in vivo study on humanized mice 
whereby they transferred B cell lines generated from SS patients into SCID 
mice and observed an induced monoclonal lymphoproliferative disorder 
resembling those arising in SS (255). 
Despite the above observations, similar to RA, it is still somewhat controversial 
whether EBV proteins and nucleic acids are detected more frequently and at 
higher level in salivary and lacrimal glands from SS compare to healthy patients 
and whether the accumulation of EBV in the salivary glands is simply an 
epiphenomenon of the chronic inflammatory process or plays an active role in 
the pathogenesis (74, 257-259, 300). Moreover, the majority of the studies 
identified EBV proteins, RNA and DNA in epithelial cells of SS salivary and 
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lacrimal glands while only one study reported EBV+ lymphocytes infiltrating 
the SS salivary glands (74). Notably, similarly to RA, no attempt has been made 
to correlate the presence of EBV with the degree of B cell infiltration, 
functional activation and the formation of ELS in the salivary glands. 
With these limitations in mind, in the second part of my PhD project I 
therefore aimed to clarify whether; i) EBV proteins/nucleic acids are expressed 
in SS salivary glands, ii)  there is a correlation between EBV expression and ELS 
formation and iii) EBV is associated with the development of autoimmunity to 
SS-specific antigens.  
For this purpose I first assessed in a semiquantivative score the degree of 
infiltration of B, T and plasma cells as well as the presence of CD21+ FDC 
networks in SS and NSCS (as disease control) salivary glands. By these means I 
was able to precisely characterise SS samples as ELS+FDC+, ELS+FDC- or with 
diffuse inflammation. Then, I analysed EBV latent and lytic expression using the 
same experimental strategy and array of techniques optimised in the RA study, 
i.e. IHC, IF, ISH and real-time RT-PCR.  
Using this approach I could demonstrate without any reasonable doubt that 
ectopic B cell follicles forming in the salivary glands of SS patients are a main 
site of EBV persistence and reactivation.  
Using IHC and IF I clearly demonstrated that EBV latent antigens (i.e. LMP2A 
and LMP1) are expressed by B cells only within ELS and preferentially in the 
context of highly organised follicles with FDC network differentiation. 
Conversely B cells in SS samples with diffuse inflammation or NSCS salivary 
glands were EBV-. The evidence of EBV latency in SS salivary glands and its 
close association with ELS formation was further confirmed by ISH for EBER. I 
detected EBER+ cells only in ELS+ SS salivary glands and exclusively in the B cell 
and plasma cell compartment of the inflammatory infiltrate. Similarly to RA, it 
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appears that B cell and plasma cells in SS display a different latency 
programme whereby B cells express both LMP1/LMP2A and EBER whilst 
plasma cells express EBERs but not LMP1/LMP2A. As argued before, this 
discrepancy may however be dependent on differences in the sensibility of the 
two techniques linked with diverse level of expression of EBV proteins and RNA 
in the two cell types examined. Selective EBER expression in ELS+ SS salivary 
glands was also confirmed by quantitative RT-PCR analysis which 
demonstrated a close association of EBER with the degree of B cell infiltration 
(CD19), functional activation (AID) and differentiation (BLIMP-1). Overall, these 
data allowed me to conclude that EBV latency is mainly expressed by activated 
B cells in SS salivary glands and significantly correlate with ELS formation, 
substantiating a direct link between EBV infection and B cell dysregulation in 
SS.  
An interesting observation which I reported in these studies is that only rare 
ductal epithelial cells displayed EBV latent infection in SS but also in NSCS 
samples as demonstrated by LMP2A/LMP1 expression. EBV latency was 
independent from the presence of periductal inflammation, suggesting that 
latent EBV infection in ductal epithelial cells may not be directly related to the 
generation of an autoimmune response in the salivary glands. However, it may 
also be possible that occasional reactivation (which however I was unable to 
detect) within the epithelial compartment might trigger a local immune 
response contributing to the chronicity of the inflammatory process.  
Since EBV reactivation in SS salivary glands can have important pathogenic 
consequence, i.e. can provoke an attack from the immune system contributing 
to local inflammation, I also analysed whether evidence of EBV reactivation 
could be observed in SS salivary glands. Similarly to what I observed in the RA 
synovia, BFRF1 and BMRF1, two EBV lytic antigens, were almost exclusively 
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expressed by plasma cells in ELS+ SS salivary glands. BFRF1+ and BMRF1+ 
plasma cells mostly localised at the border of B-cell follicles, again suggesting 
that EBV reactivated in locally differentiated plasma cells. Thus, in this 
scenario, on one side ELS provide B cell niches for EBV latent persistence and 
on the other side they allow the reactivation of the virus in the context of a 
functional germinal centre response giving rise to locally differentiated plasma 
cells.  
A crucial discovery of my PhD work is that these locally differentiated EBV+ 
plasma cells are not only frequently autoreactive, but they display 
immunoreactivity towards autoantigens specifically associated with the 
autoimmune disease in question. Thus, a large subset of CD138+/BFRF1+ 
plasma cells in SS were found to be reactive with Ro52, a major autoantigen in 
SS, but not citrullinated proteins (and viceversa in RA), strongly suggesting that 
different local autoantigenic triggers fuel the autoimmune process in the 
different target organs. Several studies have demonstrated an increased 
humoral response to EBV in the blood of SS patients compared to healthy 
controls (238, 298, 299), but none investigated local production of anti-EBV 
antibodies in the SS salivary glands. Here, using SCID mice engrafted with SS 
salivary glands, I demonstrated that anti-VCA and anti-EBNA1 antibodies can 
be locally produced in the SS salivary glands and significantly correlate with the 
production of SS-associated autoantibodies, such as anti-Ro52/SSA and anti-
La48/SSB. These findings strongly suggest that EBV can contribute to stimulate 
the intra-glandular humoral immune response in SS patients. Additionally, it is 
conceivable that this phenomenon may contribute to breach of self tolerance 
and trigger/contribute to the development/maintenance of autoimmunity in 
SS via molecula mimicry and epitope spreading. In particular, EBNA1 shares 
antigenic epitopes with the human autoantigen Ro52 (81, 301) which might 
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explain the observed association between the production of anti-Ro52 and 
anti-EBNA1 antibodies in the SS salivary glands engrafted into SCID mice. Thus, 
although I do not provide a direct evidence of such cross-reactivity in this 
study, my data further support the possibility that EBV can contribute to 
humoral autoimmunity in SS salivary glands.  
In the final part of my PhD I investigated the relationship between cytotoxic 
cells and EBV reactivation in SS salivary glands. CD8+ T-cell-mediated 
immunopathology is one of the major determinants of tissue destruction in 
EBV-associated diseases and it has long been suggested to contribute to tissue 
damage and exocrine dysfunction in SS patients.  
By analysing the infiltration of Granzyme B+ cytotoxic cells and their 
characterization with common T cell markers I was able to demonstrate that a 
significant accumulation of cytotoxic cells was preferentially associated with 
areas of EBV reactivation, mostly in association with peri-follicular BFRF1+ 
plasma cells suggesting that EBV reactivation might contribute to chronic 
inflammation via recruitment and activation of cytotoxic cells. Interestingly, as 
observed in the RA synovia, in ELS+ SS salivary glands the majority of the CD8+ 
cells did not display evidence of cytotoxicity whilst the majority of granzyme B+ 
T cell were characterised as activated Th cells and possibly T follicular helper 
cells as demonstrated by expression of PD1+, although further characterization 
is needed in order to substantiate this finding. 
Nevertheless, it is possible to speculate that in ELS+ EBV+ SS salivary glands, 
EBV latently infected cells may be allowed to accumulate within B cell-follicles 
due to the follicular exclusion of CD8+ T cells which might not be fully 
compensated by the acquisition of a cytotoxic phenotype within the CD4 Th 
compartment.  
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In conclusion, results obtained in the study of EBV in SS salivary glands support 
a complex role for EBV in the SS pathogenesis through its ability to establish a 
persistent infection in ELS+ salivary glands, promote local differentiation of 
autoreactive plasma cells and stimulate production of SS-associated 
autoantibodies.  
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CHAPTER 8 
Scientific questions to be addressed and future plans 
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8.1 Scientific questions to be addressed and future plan 
 
 
In the present work, I clearly demonstrated that a perturbed EBV infection is a 
common feature of RA synovia and SS salivary glands characterised by ELS 
formation. In addition, the results obtained during my PhD project strongly 
support a pivotal role of EBV in promoting autoimmunity either by directly 
providing proliferative advantage to infiltrating autoreactive B cell/plasma cells 
or via molecular mimicry and the induction of cross-reactive autoantibodies. 
Although the above evidence is extremely compelling, there are several 
unknowns which should be addressed and would prompt for further 
investigation into the factual pathogenic role of EBV in RA, SS and more in 
general, the formation of ectopic lymphoid neogenesis.  
First of all, it should be noted that a mechanistic evidence of a direct role of 
EBV in the pathogenesis of RA or SS is extremely difficult to obtain because of 
the absence of a suitable animal models. EBV fails to infect murine B cells or 
epithelials cells and a murine equivalent of EBV is not available, thus in vivo 
studies of EBV pathogenesis have been very limited. Whereas Old World 
primates have been found to be refractory to EBV infection, New World 
species, including the common marmoset (Callithrix jacchus) and the cottontop 
tamarin (Sanguinus oedipus oedipus) (302), have been found to be susceptible 
to infection by EBV. Common marmosets have been infected by direct 
intramuscular or intraperitoneal injection. Persistent EBV infections can be 
detected in this model, but EBV-associated lymphomas do not develop (303). 
Cottontop tamarins that are injected with EBV develop multifocal large-cell 
lymphomas. Despite their usefulness as in vivo models of EBV infection, New 
World primates represent endangered species and can only be used in small 
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numbers because they are rare and costly. An alternative model that has been 
used to study EBV-associated B-cell lymphoproliferative disease is the SCID 
mouse (304, 305). SCID mice lack functional B and T cells due to a deficiency in 
double-stranded DNA break repair activity involved in the proper joining of 
V(D)J coding sequences of B- and T-cell antigen receptors during lymphocyte 
maturation (306). Because of their lack of T and B cells, SCID mice are not 
capable of rejecting human cells. SCID mice can be reconstituted with human 
cells transplanting human hematopoietic stem cells (HSC) into preconditioned 
mice (307). The fact that the majority of human cells in recipient SCID mice are 
B cells makes them ideal targets for infection with EBV. Unfortunately, the 
transplantation of human HSC into SCID mice results in relatively low levels of 
reconstitution with human cells. In contrast, non-obese diabetic SCID 
(NOD/SCID) mice also support the growth and differentiation of human HSC 
and result in significantly higher levels of engraftment and reconstitution with 
human cells.  
Therefore in order to study the direct involvement of EBV in the RA 
pathogenesis I am planning to use a humanised mouse model by transplanting 
SCID mice with cord blood derived CD34+ stem cells and with ELS+ RA synovia 
or SS salivary glands. In this context, gain of function experiments with the 
inoculation of high doses of EBV (308)together with loss of function 
approaches with antiviral therapies (i.e. acyclovir or Cydofovir or Acyclovir, 
Ganciclovir alone or in combination with gemcitabine or doxorubicin) (309-
311) would allow to clarify the direct role of EBV in synovial/salivary gland 
inflammation, B cell activation, ELS function and development of 
autoimmunity. 
A second objective of my future plan of investigation is to provide direct 
evidence in in vitro studies that EBV promotes the preferential survival of 
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autoreactive cells in SS and RA blood circulation.  Previously, Shimaoka et al 
(312) observed that after 4-weeks of culture of RA PBMC, surviving B cells were 
invariable EBV infected. Starting from this finding I aim to investigate if RA and 
SS B cells that resist to apoptosis after a long culture are not only EBV infected 
but also display an autoreactive phenotype. For this purpose I am planning to 
isolate B cells from the blood and tissues of RA and SS patients and culture 
them for up to 4 weeks. At the end of the experiments, lymphoblastoid cells 
will be collected, in order to investigate the expression of EBV latent/lytic 
genes together with the assessment of the production of autoreactive 
antibodies (anti-CCP/RF in RA and anti-Ro/SSA and anti-La/SSB in SS).   
 
The third long term aim which spans directly from this project is to investigate 
the persistence of EBV infection in the RA synovium and/or SS salivary glands 
of patients undergoing B cell depletion with the monoclonal antibody 
Rituximab. On the basis of the data obtained during my PhD, one would 
predict that local B cell depletion should result in a strong reduction/abolition 
of EBV signals with disappearance of EBV+ B cells. However, there is increasing 
evidence that ELS in RA synovium or SS salivary glands might escape depletion 
at target tissue level due to their ability to rescue B cells from apoptosis via the 
release of B cell trophic factors. In this context, EBV may play a further role 
through the provision of strong survival signals delivered by the activation of 
the latent viral programme (i.e. LMPs and EBNAs). Patients with RA undergoing 
Rituximab treatment (and possibly also SS patients) and US-guided synovial 
biopsies before and after treatment will be made available in my Institution 
providing a unique platform to test thus hypothesis. 
Finally, another extremely interesting and surprising aspect which has emerged 
from my work is the evidence that Th cell subsets acquire cytotoxic capacity in 
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the context of EBV+ ELS in both the RA synovia and SS salivary glands. 
Preliminary work in SS salivary glands suggests that these cells may represent a 
unique subset of T follicular helper (Tfh) cells. However, because no single 
marker is sufficient to characterise Tfh, a short-term objective of my future 
work is to combine staining with Granzyme B/perforins together with Tfh 
markers such as CD4, CD3, PD1, ICOS, CXCR5, CD45Ro and IL-21  using 
multicolour confocal microscopy as well as FACS analysis. Once I identify the 
cytotoxic cells, the next step would be to characterise their functional 
properties in controlling EBV infection in in vitro experimental settings.  
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APPENDIX I 
 
Immunohistochemistry 
 
4 % paraformaldehyde 
 
4g of paraformaldehyde were added to 100 ml of TBS .The solution was 
warmed up and stirred until the paraformaldehyde was dissolved. 
 
10X Tris (hydroxymethil)methylamine-buffer saline (TBS) 
 
61 g of Trizma Base (0.5 M) and 90g of NaCl (9%) were dissolved into distilled 
H2O. To adjust the PH to 7.6, 1M HCl was added until needed. Solution was 
stored at room temperature and diluted 1:10 with distilled water before use. 
 
Acid Alcohol 
Add 1ml of concentrated Hydrochloric Acid to 99 ml of 70% Alcohol. 
 
Tris-HCl  
24.22 g of Trizma base were diluted in 800 ml of distilled water and adjusted to 
pH 8.2 within 3N HCl. Distilled water was added up to 1000 ml and solution 
was stored at room temperature. 
 
HRP Avidin-Biotin Complex (DAKO) 
10 µl of Solution were added to 1 ml of TBS pH 7.6, and mixed well. Another 10 
µl of solution 2 were added and mix well. The ABC complex was prepared at 
least 30’ before use. 
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APPENDIX II 
 
Molecular Biology Buffers and Reagents 
 
Ethylenediaminetetraacetic acid (EDTA 9.5 M pH 8.0): 
18.6 g of EDTA were dissolved in 80 mL H2O. NaOH was used to adjust the pH. 
Distilled water was added to the final volume of 100 ml. The solution was 
stored at room temperature. 
 
Tris Borate EDTA (TBE buffer 5x): 
27g of Tris base, 13.75 g of boric acid and 10 ml of EDTA 0.5 M (pH 8.0) were 
dissolved in 400 ml of distilled water. Distilled water was added to the final 
volume of 500 ml and the solution was stored at RT. 
 
Tris Acetic acid EDTA (TAE buffer 5x): 
12.1 g of Tris base, 2.86 ml of acetic acid and 5 ml of EDTA 0.5 M (pH 8.0) were 
dissolved in 50 ml of distilled water. Distilled water was added to the final 
volume of 55 ml and the solution was stored at RT. 
 
Loading dye (Bromophenol-blu dye 6X): 
300 ml of 30% glycerol and 400 ml of EDTA 0.5 M (pH 8.0) were added to 300 
ml of deionised H20 and mixed well. 2 mg of bromophenol-blue were added to 
the solution and dissolved by inversion. Solution was stored at -20°C and 
diluted to working solution at the time of use. 
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This work has also been presented as oral or poster presentation at several 
meetings: 
 
1. Poster presentation. 2010 BSI, Liverpool  
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8. Oral presentation, 2012, WHRI Annual Research Review 
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